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1 Zusammenfassung 
Darmkrebs, insbesondere das kolorektale Karzinom, ist weltweit eine der 
häufigsten Krebstodesursachen und wird vorwiegend im fortgeschrittenen Alter 
diagnostiziert. Die nicht erblich bedingte Form von Darmkrebs entsteht meist aus 
anfangs gutartigen Darmpolypen (Adenomen). Diese entwickeln sich durch molekulare 
Veränderungen im Darmepithelgewebe, die vorwiegend den Wnt-APC-β-catenin 
Signalweg betreffen. Adenome gelten als Vorstufe von Krebs und können sich durch 
zusätzliche genetische und epigenetische Veränderungen zu einem bösartigen 
Adenokarzinom entwickeln. Eine frühzeitige Entdeckung und Entfernung dieser 
Krebsvorstufen gilt daher nach wie vor als beste Vorbeugung von Darmkrebs. 
Screening-Verfahren anhand gastroenterologischer Endoskopie gelten als sehr 
effizient, sind jedoch invasiv, kosten- und zeitaufwändig (für Personal und Patienten). 
Nicht zuletzt deswegen stossen endoskopische Verfahren auf wenig Zustimmung 
seitens der Patienten. Die häufiger verwendeten Tests mittels Stuhlproben sind 
kostengünstiger und einfacher zu handhaben, haben jedoch im Vergleich zu 
endoskopischen Untersuchungen eine weit geringere Aussagekraft. Daher ist die 
Entwicklung einer nichtinvasiven und sensitiven Diagnostikmethode für die Detektion 
verdächtiger Adenome und früher Adenokarzinome anhand von spezifischen 
Biomarkern ein grosses Bedürfnis. 
Im Zusammenhang mit kolorektalen Adenomen sind zahlreiche genetische und 
epigenetische Veränderungen dokumentiert worden, jedoch wurden deren funktionelle 
Auswirkungen auf Proteinebene noch nicht umfassend untersucht. Auf 
Massenspektrometrie (MS) basierende Studien sind zu einem Eckpfeiler der 
Krebsproteomforschung geworden und Fortschritte in dieser Technologie haben zu 
einer deutlichen Verbesserung der Sensitivität und der Reproduzierbarkeit geführt und 
erlauben eine weitaus umfassendere Proteinanalyse. Bis heute haben sich die meisten 
Proteomstudien im Zusammenhang mit Darmkrebs auf Veränderungen zwischen 
Adenokarzinom und Normalgewebe konzentriert; nur wenige Untersuchungen zum 
Proteinprofil von präinvasiven Adenomen existieren. 
Um ein grösseres Verständnis zur Biologie von kolorektalen Adenomen zu 
erhalten, und um potentielle Marker für die Erkennung früher Darmkrebsstadien zu 
identifizieren, haben wir umfassende Proteomanalysen von Adenomen mittels 
quantitativer Shotgun-Massenspektrometrie durchgeführt (Siehe Appendix I). Mittels 
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iTRAQ 8-plex labelling, OFFGEL Elektrophorese und HPLC- gekoppelter Tandem-
Massenspektrometrie haben wir das Proteom von 30 kolorektalen Adenomen und 
gepaarter Normalschleimhaut untersucht (beide Gewebsproben wurden während einer 
Koloskopie entnommen). Zusätzlich wurde das Proteom von normalen Epithelzellen 
(HCEC) und kanzerösen Darmepithelzelllinien (SW480, SW620, CACO2, HT29, CX1) 
untersucht. Die Resultate aus diesen Analysen zeigen neue Aspekte von klinischer 
Bedeutung in Bezug auf die untersuchten Krebsvorstufen auf. Insbesondere konnten 
wir mittels multivariater Analysen zeigen, dass das Proteom der Adenome sich deutlich 
vom Normalgewebe abgrenzen lässt. Ebenso lassen sich die Krebszelllinien von den 
HCEC Zellen unterscheiden. Wir haben 212 Proteine identifiziert, die in den Adenomen 
im Vergleich zum Normalgewebe entweder signifikant hoch- (76) oder herunterreguliert 
(136) waren. Die meisten identifizierten Änderungen auf Proteinebene entsprachen 
den Veränderungen auf Transkriptomebene, die wir in unserer Gruppe in bereits in 
früheren Studien identifizieren konnten. 51 dieser Veränderungen sind sehr 
wahrscheinlich auf das Epithel der Adenome zurückzuführen, da diese sowohl in den 
Zelllinien (Krebszellen vs. HCEC) als auch in den Biopsieproben (Adenoma versus 
Normalgewebe) beobachtet wurden und jeweils ähnliche Veränderungsmuster zeigten. 
Auf der Suche nach potentiellen Biomarkern für die Diagnose von Darmkrebs im 
Frühstadium haben wir die Liste der hochregulierten Proteine in Adenomen mit den 
verfügbaren Daten der „Human Protein Atlas Database“ verglichen. Diese Datenbank 
enthält Informationen über Proteinexpression in Krebs- und Normalgewebe. Wir 
entdeckten, dass bereits Adenome die Proteinveränderungen aufweisen, die in 
früheren Studien für fortgeschrittene Darmkrebsproben dokumentiert wurden. 
Ausserdem waren bereits 16 der von uns entdeckten 76 hochregulierten Proteine in 
dieser Datenbank als Biomarkerkandidaten für Darmkrebs eingetragen. 
Eine der herausragendensten Veränderungen auf Ebene der Proteinexpression, 
die wir in Adenomen gefunden haben, betraf die Hochregulierung der Sorbitol 
dehydrogenase (SORD), einem Schlüsselenzym im Polyol-Stoffwechselweg. Über die 
mögliche Rolle von SORD während der Tumorgenese ist in der Literatur nur sehr 
wenig bekannt. Unsere Validierungsstudien zeigten eine deutlich erhöhte 
Konzentrationen und Aktivität von SORD in Adenomen und in den Krebszelllinien. 
Zusätzlich waren Expressionsänderungen anderer Enzyme im gleichen (Aldose 
Reduktase, AKR1B1) sowie verwandten (Ketohexokinase, KHK) Stoffwechselwegen in 
Adenomen deutlich dereguliert. Die Nutzung des Polyol-Stoffwechselweges durch 
Adenomazellen könnte möglicherweise einen Selektionsvorteil gegenüber normalen 
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Zellen darstellen. Zusätzlich zur Glykolyse und dem Pentosephosphatweg, die beide in 
Tumoren erhöht sind, könnte der Polyol-Stoffwechsel einen weiteren Weg zur 
Glukosenutzung in Tumoren darstellen. 
Die meisten Proteomanalysestudien über Darmkrebs führten keine systematische 
Überprüfung und Validierung der gefundenen potentiellen Biomarker in Hinblick auf 
eine klinische Anwendung durch. Dies ist hauptsächlich dadurch zu erklären, dass 
robuste Methoden für den genauen und reproduzierbaren Nachweis von gleichzeitig 
mehreren Tumormarkern und für eine grosse Anzahl von Patientenproben fehlen. 
Jedoch können neue Methoden auf dem Gebiet der gezielten Proteomanalyse genutzt 
werden, um konventionelle, immunologische Methoden zu ergänzen und die 
Validierung möglicher Biomarker zu beschleunigen.  
Im zweiten Teil dieser Studie demonstrieren wir die Anwendung von „selected 
reaction monitoring“ (SRM), einer Technologie zur gezielten Proteomanalyse, um eine 
Auswahl an möglichen Darmkrebs-Biomarkern in Proben einer grösseren 
Patientenkohorte zu detektieren und zu quantifizieren. Mit dem Ansatz, diese 
Untersuchung sowohl in Adenomen wie auch in Karzinomen durchzuführen, 
demonstrierten wir eine robuste Methode um Veränderungen auf Proteinebene 
aufzuspüren, die einerseits schon früh in der Darmkrebsentstehung vorhanden sind 
und andererseits identifizierten wir auch solche, die während der Transformation von 
Adenomen zu Karzinomen bestehen bleiben. 
Proteinbiomarker, die in dieser Arbeit als Kandidaten validiert wurden, 
entstammen aus unserer vorangegangenen quantitativen (iTRAQ 8plex) „Shotgun-
Discovery“-Studie über humane Darmkrebsvorstufen. Die Probenvorbereitung und 
Analyseprotokolle wurden optimiert, um die Reproduzierbarkeit und Analysepräzision 
der SRM Messungen sicherzustellen. Verschiedene Softwarepakete für die SRM 
Assay Entwicklung (Skyline), die automatische Peakgruppenidentifizierung (mProphet) 
und für Proteinstatistik (MSstats) wurden in einen Arbeitsschritt zusammengefasst. Die 
SRM Experimente wurden in mehreren Schritten optimiert: Zunächst wurden SRM 
Koordinaten anhand der Fragmentspektren von Schwerisotop-markierten 
Referenzpeptiden ermittelt und anschließend durch Messung dieser Referenzpeptide 
und endogener proteotypischer Peptide in programmierten SRM Sequenzen verfeinert. 
Zusätzlich zeigten wir, dass unsere SRM Untersuchungen die reproduzierbare 
Detektion und die Quantifizierung ausgewählter Proteinmarker in menschlichen 
Darmproben ermöglichen. Diese Untersuchungen wurden an 72 Gewebeproben (19 
Adenomen und 17 Adenokarzinomen mit jeweils benachbartem Normalgewebe) mit 25 
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ausgewählten Markern durchgeführt. Wir haben eine signifikante Hochregulierung von 
zehn Proteinen in Darmkrebsvorstufen sowie in Darmkrebs bestätigt (SORD, SPB5, 
ANXA3, REG4, S10AB, NUCL, NGAL, LDHA, G6PD, AN32A). Gemäss Literatur ist 
bisher keines dieser Proteine in klinischen Biomarkerstudien validiert worden, obwohl 
einige der Proteine bereits mit Entstehung von Darmkrebs in Verbindung gebracht 
worden waren. Alle von uns verifizierten Tumormarker sind potentielle diagnostische 
Marker für Darmkrebs. Der Workflow mittels SRM bereitet ausserdem eine wertvolle 
Grundlage für weiterführende Studien, um Darmkrebsbiomarker in anderen 
Gewebeproben zu verifizieren. Im Moment wenden wir die optimierten SRM 
Untersuchungen an, um eine Auswahl von Biomarker in den Blutproben einer 
umfangreichen Kohorte von Darmkrebspatienten zu validieren. 
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2 Summary 
 Colorectal cancer is common in elderly individuals and is a major cause of 
cancer-related deaths worldwide. In the non-hereditary forms, tumorigenesis proceeds 
along the adenoma-adenocarcinoma pathway. As a result of molecular alterations 
involving (for the most part) the Wnt-APC-β-catenin signalling pathway, adenomatous 
tumors arise from the epithelium of the large bowel. These lesions are non-cancerous, 
but the accumulation over time of additional genetic and epigenetic alterations can 
transform them into malignant adenocarcinomas. Prompt identification and resection of 
precancerous lesions is therefore the most effective way to reduce the incidence of 
colorectal cancer.  
Endoscopic screening for these lesions is undeniably effective, but it is also 
invasive, expensive, and time consuming (for patients and operators). Consequently, a 
low patient compliance with colorectal cancer screening regulations has been reported 
worldwide. Faecal-based tests are cheaper and easier to use, but they have lower 
diagnostic accuracy than colonoscopy-based techniques. There is consequently a vital 
need for non-invasive, diagnostic tests based on biomarkers with high sensitivity and 
specificity for high-risk adenomas and early-stage adenocarcinomas. 
A multitude of genomic and epigenomic changes have been documented in 
colorectal adenomas, but their impact on the protein effectors of biological function has 
not been comprehensively explored. Mass spectrometry (MS) has become the 
cornerstone of most proteomic studies on cancer development, and ongoing technical 
advances have markedly improved the sensitivity, reproducibility, and proteome 
coverage of MS-based studies. Thus far, however, proteomic analyses of human 
colorectal tissue samples have focused mainly on alterations found in 
adenocarcinomas, as compared with the normal mucosa. Much less is known about 
the proteome profile of preinvasive colorectal adenomas.  
In an attempt to fill this knowledge gap and to identify promising candidate 
biomarkers of early-stage colorectal tumorigenesis, we performed a comprehensive 
proteomic analysis of colorectal adenomas based on quantitative shotgun mass 
spectrometry (see Appendix I). Using iTRAQ 8-plex labelling, OFFGEL electrophoresis, 
and HPLC-coupled tandem mass spectrometry, we investigated protein expression in 
30 colorectal adenomas and paired samples of normal mucosa (prospectively collected 
!!! 8!
during colonoscopy) and in normal (HCEC) and cancerous (SW480, SW620, CACO2, 
HT29, CX1) colon epithelial cell lines.  
The results revealed several novel aspects of these precancerous lesions with 
important clinical implications. First of all, in multivariate analysis, the proteomes of 
adenomas were clearly distinguished from that of normal mucosa, and equally clear 
distinction emerged between the proteomes of cancer cell lines and HCEC cells. We 
identified 212 proteins with significantly dysregulated expression in adenomas 
(upregulated in 76 cases, downregulated in 136) relative to normal mucosal expression. 
Most of the adenoma-related changes were similar to those previously identified by our 
group at the transcriptome level. Fifty-one of the changes appear to be specific to the 
epithelial (rather than stromal) component of adenomas since the proteins in question 
were all expressed in the colorectal epithelial cell lines, and their altered expression 
levels in colorectal cancer cells (vs. HCEC cells) were directionally similar to those 
observed in the adenomas (vs. normal mucosa samples).  
Second, to identify potential biomarkers for early-stage colorectal tumorigenesis, 
we compared the list of proteins exhibiting adenoma-related upregulation with data on 
protein expression in cancer and normal tissues available in the Human Protein Atlas 
Database. We discovered that adenomas already exhibit protein expression changes 
that have been documented in advanced colorectal cancers. Moreover, 16 of the 76 
proteins that were upregulated in our adenomas have already been designated as 
candidate biomarkers for colorectal cancer in this database.  
One of the most striking protein expression changes we observed in adenomas 
involved sorbitol dehydrogenase (SORD), a key enzyme in the polyol pathway whose 
possible roles in tumorigenesis are largely unexplored. Our validation studies revealed 
that SORD concentrations and activity are dramatically increased in both colorectal 
adenomas and cancer cell lines. Other enzymes in the same (aldose reductase, 
AKR1B1) and related (ketohexokinase, KHK) pathways were also obviously 
dysregulated in adenomas. Exploitation of the polyol pathway could provide 
adenomatous cells with a selective advantage over normal cells. Furthermore, the 
polyol pathway might be another means of tumor-related glucose consumption in 
addition to the well-known glycolytic and pentose phosphate pathways.  
A major shortcoming of most untargeted proteomic studies on cancer is the lack 
of systematic verification and validation of the identified markers —a fundamental step 
on the road to their clinical application. Unfortunately, robust methods are lacking for 
accurate, reproducible verification of multiple tumor markers in a large group of patient 
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tissue / body fluid samples. However, targeted proteomics methods are now emerging 
that can complement conventional immunoassay-based techniques and accelerate this 
verification process. 
One example is the method known as selected reaction monitoring (SRM), which 
we used in the second phase of our study to detect and quantify the abundance of 
putative colorectal cancer biomarkers in a large cohort of patient tissue samples. Our 
approach to perform this investigation in both adenomas and adenocarcinomas 
provided a consistent means to detect protein changes that occur early in colorectal 
tumorigenesis and those that are likely to persist during the transformation of 
adenomas to cancerous lesions.  
Candidate protein markers verified in this work were previously reported in our 
quantitative (iTRAQ 8plex) shotgun discovery study on human colorectal precancerous 
tissues. The sample preparation and analytical protocols were optimized to ensure the 
reproducibility and analytical precision of all SRM measurements. Software tools for 
SRM assay development (Skyline), automated peak group identification (mProphet), 
and protein significance analysis (MSstats) were combined in our comprehensive 
workflow. Using heavy isotope-labelled reference peptides, we confirmed peptide SRM 
transitions and refined all transition parameters for SRM measurements.  
The SRM assays we developed facilitated the reproducible detection and 
quantification of candidate biomarker proteins in human colorectal tissues. These 
assays were applied to monitor 25 proteins in 72 tissues samples comprising 
neoplastic and adjacent normal mucosa lesions (19 adenoma and normal mucosa 
pairs; 17 adenocarcinoma and normal mucosa pairs). We confirmed the statistically 
significant upregulation of ten proteins (SORD, SPB5, ANXA3, REG4, S10AB, NUCL, 
NGAL, LDHA, G6PD, AN32A) in both precancerous and cancerous colorectal 
neoplasms (relative to their expression in normal mucosa samples). A review of the 
literature found that a number of these proteins have been associated/implicated in 
colorectal tumorigenesis, but none appear to have been validated in clinical biomarker 
studies. The tumor markers we verified are all potential diagnostic markers for 
colorectal cancer. Our SRM protocol will be a valuable tool for use in future studies 
aimed at verifying colorectal biomarkers in other human tissues. We are already 
exploiting the optimized SRM assays to verify a selected set of putative biomarkers in 
blood samples from a large number of patients with colorectal cancer. 
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3 Introduction 
The human gastrointestinal (GI) or digestive system is responsible for the 
breakdown and absorption of nutrients from ingested food/fluids. It consists of 
specialized organs, beginning from the oral cavity in the mouth, through the stomach 
and intestines and terminating at the anus, where digested food is passed out as 
faeces.  
The different segments of the GI tract differ in morpholgy, muscular vasculature, 
enzyme composition and therefore function. Major functions of the GI system include 
ingestion, digestion (mechanical and chemical), propulsion (peristalsis and 
segmentation), secretion, absorption and waste elimination. In addition to the main GI 
organs, accessory organs such as the teeth, salivary glands, tongue, liver, pancreas 
and gall bladder play specialized roles to maintain the gastrointestinal flora and 
functions. This is very important as a range of gastrointestinal problems and diseases 
may occur due to malfunctions in the GI system.  
3.1 Anatomy and physiology of the gastrointestinal system (1) 
The upper GI tract includes digestive organs of the upper abdomen and chest. It 
comprises of the oral cavity, oesophagus, stomach. The lower GI tract includes the 
small intestine, the large intestine and anus.  
The segments of the GI tract are shown in Figure 3.1 (below). The mouth is the 
entrance to the GI tract. It is bounded anteriorly by the teeth and lips, and posteriorly by 
the oropharynx. The interior surface of the mouth contains the tongue and mylohyoid 
muscle covered with mucosa. Following the ingestion of food/fluids, enzymes 
contained in saliva trigger chemical digestion, where as mechanical digestion occurs 
with the aid of the teeth via mastication.  
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Figure 3.1 The Human Gastrointestinal System 
The location of main and accessory organs of the GI tract, with specialized roles for food digestion and 
nutrient absorption are depicted. Adapted from (2). 
Through the action of swallowing, masticated food proceeds through the pharynx 
to the oesophagus also know as the gullet. This muscular tube is lined with mucus 
membranes and facilitates the passage of ingested food from the mouth to the 
stomach by the process of peristalsis. A sphincter at the end of the oesophagus 
controls the delivery of food into the stomach and prevents food in the stomach from 
returning into the oesophagus.  
The J-shaped bag at the terminal end of the oesophagus is the stomach. It 
stretches and expands with the entry of food contents from the oesophagus. Ingested 
food is stored for a short period in the stomach. Churning and mixing motions aid the 
mechanical breakdown of food. Gastric glands located in the stomach secrete digestive 
juice and enzymes to enable chemical digestion. Also, stomach acids maintain an 
acidic environment that is unfavourable to bugs and germs.  
The small intestine extends from the pylorus of the stomach to the cecum. It is a 
coiled, approximately 20 feet, thin-walled tube, which is compressed into many folds 
and occupies a large proportion of the abdominal cavity. The small intestine is 
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composed of the duodenum, jejunum and ileum. The duodenum originates from the 
pyloric sphincter and forms the first part of the small intestine. Digestive enzymes 
secreted by the pancreas are delivered into the duodenum as pancreatic juice. A 
network of thin ducts carry bile produced in the liver and stored in the gall bladder to 
the duodenum. Bile is a greenish fluid, which aids chemical digestion by breaking down 
fats into small droplets. These digestive secretions are mixed with partly digested food 
ejected from the stomach. Chemical digestion and nutrient absorption occurs primarily 
in the middle segment of the small intestine, also known as the jejunum. Nutrients from 
digested material are absorbed through the wall of the small intestine into the blood 
stream and lymph. The ileum is the last and longest segment of the small intestine. It 
terminates at the ileocecal valve, a sphincter that monitors the entry of digested 
materials into the large intestine. Cells in the mucosa of the small intestine have 
specific functions including mucous secretion, absorption, immune defence, and 
secretion of digestive enzymes. The hepatic portal system channels blood containing 
digestive products from the small intestine to the liver.  
The large intestine has a length of about 5 feet and a diameter of 2.5 inches. It 
consists of the cecum, colon, rectum and anal canal. Digestive material (chyme) from 
the ileum is delivered to the cecum, a largely peritoneal pouch. It is separated from the 
ileum by the ileocecal valve and from the colon by the cecocolic junction. Hence, the 
cecum is often considered as the beginning of the large intestine with direct connection 
to the first part of the colon. The mammalian colon consists of four sections. The 
ascending colon is the first section of the large intestine. It travels up the right side of 
the abdomen from the cecum. After extraction of water and important nutrients, the 
digested material is moved upwards to the transverse colon by peristalsis. This section 
of the large intestine runs across the abdomen and is the longest and most flexible part 
of the colon. Waste material reaching the downward travelling descending colon, 
located at the left abdomen is stored as faeces. The short curving sigmoid colon is 
between the descending colon and the rectum. The contraction of its muscular walls 
helps deliver faeces to the rectum. The proximal colon comprises the cecum, 
ascending colon and transverse colon. And the lower or distal colon is made up of the 
descending colon and sigmoid colon. The human rectum is about 4.7 inches long. It 
begins at the end of the sigmoid colon and faeces released from the sigmoid colon is 
briefly stored in the rectum. When this occurs, stretch receptors of the nervous system 
in the rectal walls are stimulated, creating the urge to defaecate. The rectum is 
followed by the anal canal, which terminates at the anus. Faeces passes through the 
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anal canal and is excreted from the anus. Although a fairly low amount of nutrient is 
absorbed from the digested material that reaches the large intestine, the remaining 
water and electrolytes are absorbed. A host of beneficial microbial species thrive in the 
large intestine. 
3.2 Histology of the gastrointestinal tract (3-7) 
There is a level of consistency in the architectural walls of the digestive tract. As 
illustrated in Figure 3.2 (below), the walls of the GI tract are made up of four major 
layers: the serosa, the muscularis, the submucosa and the mucosa. 
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Figure 3.2. Sectional views of layers of the GI tract 
The four main layers of the GI tract are depicted, as well as some structural differences in the GI wall in 
the oesophagus, stomach, small and large intestine. 
The serosa is the outermost layer of the GI wall. It is made up of a thin layer of 
loose connective tissue, covered by a type of squamous epithelium referred to as the 
mesothelium. In the oesophagus, it is termed the adventitia. Serous fluid, produced by 
the serosa lubricates the lining of the GI wall. 
The muscular coat that lies between the inner submucosa and the outer 
adventititia or serosa is the muscularis. Along the GI tract, the muscularis usually 
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consists of an outer longitudinal layer of smooth muscle and an inner circular layer. 
However, the stomach muscularis contains an additional middle oblique layer. 
Networks of unmyelinated nerve fibers, called the myenteric plexus, are situated in the 
muscularis. They control peristalsis, mixing, relaxation of the pyloric and ileocecal 
spinchters, and smooth muscle tone. 
Situated beneath the mucosa is the submucosa. It comprises a layer of loose to 
dense connective tissue containing blood and lymphatic vessels. Another important 
component of the submucosa is the submucosal plexus, which provides nervous 
control to the mucosa. 
Lining the lumen is the mucosa. It differs in structure and function along the length 
of the GI tract. Epithelial cells cover the mucosa and are in direct contact with the 
lumen. Different specialized cells dominate the epithelium of the oesophagus, stomach, 
small and large intestine respectively, contributing to the specialized function of each of 
these organs. A layer of loose connective tissue (the lamina propria) exists beneath the 
epithelium, and consists of a network of blood vessels and lyphatic nodules beneficial 
to the immune roles of the GI tract. Dynamic movement of the mucosa is achieved with 
the lamina muscularis mucosae, a thin layer of smooth muscle found after the lamina 
propria. 
Each region of the GI tract has its characteristic histological features (Figure 3.3). 
Some of the main distinguishing features would be described next. 
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Figure 3.3. Microscopic view of sections of the gastrointestinal tract 
Distinctive differences in architecture of the surface epithelium (top region) in the oesophagus, stomach, 
small and large intestine are depicted. While stratified squamous cells form the epithelial surface of the 
oesophagus, columnar cells form gastric pits (P) in the stomach. Villi dominate the epithelial surface of 
the small intestine but is absent in the large intestine which has mucosal folds formed by muscle 
contractions. Adapted from (8). 
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The oesophagus has a stratified squamous epithelial lining that limits abrasion 
during swallowing (Figure 3.3), and is rapidly turned over. In the oesophagus, the 
lamina propria is sparse. And mucous secreted from mucous secreting glands 
(papillae) in the submucosa aid the passage of food. The muscularis propria consists 
of layers of smooth and striated muscles that surround the lumen of the oesophagus. 
These muscle layers control the movement of food down the oesophagus to the 
stomach by peristalsis. 
The stomach epithelium form deep-folded pits, and contains different types of 
cells, especially goblet cells. The epithelium is structured to act as a protective lining, to 
limit autodigestion, and to secrete compounds to facilitate digestion. Unlike other GI 
organs, the muscularis of the stomach comprises three muscle layers rather than two. 
These are the inner oblique muscle, circular muscle, and outer longitudinal muscle.  
The lining of the small intestine contains numerous permanent folds called 
plicae circulares and goblet cells. The epithelial surface of each plica is further folded 
to form numerous villi, and the surface of each villus is covered by epithelium with 
projecting microvilli. These maximise the total surface area available for the absorption 
of water, electrolytes, and nutrients. Large numbers of capillaries present in the villi aid 
the transfer of digestion products to the hepatic portal vein and the liver. Vessels in the 
submucosa control blood supply to the villi.  
Unlike the small intestine, the mucosa of the large intestine lacks villi. It is 
specifically structured to reduce abrasion during defecation, and invasion by intestinal 
microorganisms. The epithelial surface of the colon consists of a single sheet of 
columnar epithelial cells that form finger-like invaginations at regular intervals, called 
crypts (See Figure 3.4). Crypts have essential roles in maintaining homeostatic 
conditions in the large intestine. Alterations in crypt architecture and biology are the 
underlying causes of most diseases associated with the large bowel. 
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Figure 3.4. Intestinal crypt(s) of the normal colon mucosa. 
The normal colon epithelium consists of vertically, closely aligned crypts that extend down the 
muscularis mucosae at regular intervals. Crypt architecture is displayed in the histological stained 
section. A representative view of one crypt highlights the location of stem cells, proliferating cells, 
differentiating cells, and apoptotic cells along the crypt. Adapted from (9). 
Intestinal crypts occupy most of the volume of the mucosa, extending vertically 
from immediately above the muscularis mucosae to open on the mucosal surface. 
Each crypt contains a range of 500 to 200 epithelial cells, depending on its location in 
the colorectum (10-13). Mitotically active proliferating cells confined to the lower portion 
of the crypts are stimulated by growth factors involving the Wnt pathway. Epithelial 
stem cells lie in the base of the proliferative compartment. Committed progenitor cells 
undergo limited proliferation. As they migrate upward in an ordered fashion, these cells 
change into differentiated cells and replace the older, dying, apoptotic cells. Apoptotic 
cells are shed into the lumen, and the colon epithelium is kept under continuous 
renewal (10, 12, 14).  
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Figure 3.5 Schematic view of the differentiating cells of the colonic 
epithelium. 
Proliferating precursors produced by stem cells migrate towards the crypt top and differentiate into 
enterocytes (absorptive cells), enteroendocrine cells (hormone secreting cells), goblet cells (mucus 
secreting cells) or Paneth cells (secrete antimicrobial toxins). Adapted from (14). 
As illustrated in Figure 3.5, there are four major types of differentiated cells: the 
enterocytes or absorptive cells, the mucus-secreting goblet cells, peptide hormone 
secreting enteroendocrine cells and Paneth cells, which occasionally exist in the 
ascending colon and in certain disease states (13-15). Paneth cells, secrete 
antimicrobial toxins, migrate downward and are located at the crypt bottom.  
3.3 Diseases of the GI tract (16, 17)  
Gastrointestinal diseases constitute a huge burden on health resources worldwide. 
In the United States, gastrointestinal diseases affect an estimated 60 - 70 million 
individuals annually (3, 12, 13, 16, 18). Furthermore, a substantial rate of morbidity and 
mortality from human diseases has been attributed to diseases that affect the organs of 
the GI tract. The scenario in the United States would most likely be similar in other 
western countries. 
Recent epidemiological reports have identified colorectal cancer (CRC) as the 
major cause of patient deaths associated with gastrointestinal diseases. Colorectal 
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cancer accounted for more than half of all GI cancers in the United States and United 
Kingdom, and is the leading cause of GI-related mortality in most Western countries (3, 
5-7). More emphasis would therefore be placed on the biological abnormalities 
associated with the occurrence of CRC, factors that increase its incidence, and 
diagnostic tools for the early detection CRC. 
3.3.1 Colorectal Cancer 
3.3.1.1 Biology*of*colorectal*cancer*
Most sections of the GI tract are prone to precancerous lesions or adenomas. 
These lesions occur as a result of disruptions in processes regulating normal cell 
proliferation, cell differentiation, and renewal of the surface epithelium. Precancerous 
lesions with a characteristic epithelial alteration known as dysplasia are associated with 
an increased risk of cancer. Dysplasia is a histopathological abnormality characterized 
by cytological atypia, aberrant differentiation and disorganized architecture (12, 13, 19, 
20). Diagnosis and assessment of dysplasia is based mainly on haematoxylin and 
eosin stained paraffin sections. 
In the initial stages of colorectal cancer, the normal epithelium of the large bowel 
is transformed, forming benign (adenomatuos) lesions (21). Precancerous lesions or 
adenomas display early morphological changes in discrete clusters of epithelial crypts 
(12). These neoplastic lesions show some degree of dysplasia, and formation of 
aberrant crypt foci (ACFs) (10, 12, 13). ACFs are microscopic clusters of few abnormal 
crypts believed to precede the development of most neoplastic lesions, and are 
identified by high-magnification-chromoscopic-clonoscopy (15). They are usually larger 
than normal crypts, have thicker epithelial linings as well as slit-like openings that are 
raised slightly above the adjacent mucosa (Figure 3.6A) (10, 12). It should be noted 
that only a small proportion of ACFs progress to neoplastic lesions. Dysplastic ACFs 
associated with a mutation of the APC gene are associated with the occurrence of 
sporadic colorectal cancer through the adenoma-adenocarcinoma pathway (16). 
Non-dysplastic ACFs occur in the normal colon and are not regarded as precancerous 
lesions. However, non-dysplastic ACFs with features of hyperplastic polyps and a 
number of genetic mutations can also lead to colorectal cancer via the less frequented 
serrated pathway (12, 13, 16). Colorectal adenomas resulting from dysplastic ACFs 
lack invasive capabilities, and most have acquired alterations in the canonical Wnt-
APC-βcatenin pathway (13, 19, 20), epigenetic gene silencing, and some degree of 
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genomic instability (10, 13, 22-24). Over a number of years (5 - 10 years), subsequent 
accumulation of additional mutations in oncogenes and tumor suppressor genes 
transforms a minority of these lesions to adenocarcinomas (21). Cattaneo et al., (12) 
describes a conventional pathway by which this progression is postulated to occur 
based on consistent scientific findings (Figure 3.6A). In mucosal biopsies stained with 
methylene blue (Figure 3.6A), ACFs appear darker, larger, and slightly raised above 
the normal adjacent mucosa. With increasing dysplasia and mutations, a small 
percentage of ACFs progress to a neoplastic lesion. In sections from the 
adenocarcinoma (Figure 3.6A), high level of dysplasia, loss of glandular architecture, 
accumulation of goblet cells and a host of other architectural malformations are 
noticeable. 
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Figure 3.6. Pathway for the transformation of dysplastic adenomas to 
adenocarcinomas and schematic representation of type 0 neoplastic lesions. 
Histological features of the four stages of the adenoma-adenocarcinoma pathway to colorectal cancer - 
the normal mucosa, aberrant crypt foci (larger crypts in central region), a tubulovillous adenoma with 
epithelial dysplasia, and an invasive adenocarcinoma (A). Schematic representation of the main forms of 
!!! 20!
type 0 neoplastic superficial lesions defined according to the Paris classification (B). The endoscopic 
appearances of polypoid (pedunculated) and nonpolypoid (slighlty elevated) are shown in (C) and the 
distinctive characteristics of type 0 lesions are described in (D). Adapted from (12, 25). 
Colorectal adenoma variants (adenomas are hereafter used to describe 
neoplastic precancerous lesions) are grouped based on endoscopic appearance 
according to a defined terminology - the Paris endoscopic classification (25), (Figure 
3.6B). There are two main groups of the type 0 neoplastic tumors: polypoid and non-
polypoid lesions (Figure 3.6 B, C and D). Polypoid lesions protrude above the 
surrounding mucosal surface and could be either pedunculated, with a narrow base 
(Ip) or sessile (Is), wherein the base and the top of the lesions have a similar diameter 
(25). The non-polypoid or non-protruding neoplastic lesions are usually either slightly 
elevated (IIa), flat (IIb) or depressed (IIc) (25). Other types of growth patterns exist. 
Standard colonoscopy is usually performed to detect and resect these lesions, as they 
are believed to sometimes progress to invasive adenocarcinomas. Superficial invasive 
lesions (cancers) are commonly grouped according to the Tumor-Node-Metastasis 
(TNM) classification (26) (discussed later).  
Advanced colorectal adenomas with greater chances of malignancy are often 
identified based on size (≥ 1 cm), degree of dysplasia, and/or villous histology (16, 27). 
Distinguishing villous structures from elongated separated tubules could be challenging. 
Tubular adenomas (TA) usually contain <20% of villous change. Lesions with 20% - 
80% villosity have both villous and tubular structures and are referred to as 
tubulovillous adenomas (TVA). While villous adenomas (VA) lack the tubular growth 
pattern. Adenomas are more often diagnosed with the TVA pattern. However, the 
presence of villous changes in adenomas has been linked to increased malignant 
potential of these tumors, specifically called sessile adenomas (27, 28). 
Colorectal cancers could be either of a sporadic form (described above) or 
familial / inherited form (29). Inherited large-bowel cancers occur in patients with a 
family history of the disease and are of two major groups: the polyposis syndromes and 
nonpolyposis syndromes.  
Polyposis syndromes (28-33): This includes familial adenomatuos polyposis, 
Peutz-Jeghers syndrome and juvenile polyposis. Familial adenomatous polyposis 
(FAP) is the most frequent, and it accounts for less than 1% of the total CRC burden. It 
is a rare condition and patients are plagued with numerous amounts of adenomas in 
the large bowel. Tumors in FAP, are frequent in the distal colon and rectum, more 
aggressive, and are more likely to have aneuploid DNA. FAP is transmitted though an 
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autosomal dominant trait. It is associated with a deletion in the long arm of 
chromosome 5 (which contains the adenomatuous polyposis gene, APC), in both 
neoplastic and normal cells. Allelic loss of this genetic material and mutations in p53, 
and KRAS lead to a lack of tumor-suppressor genes and proteins that inhibit tumor 
growth. Upon confirmation of the disease with molecular genetic testing, patients are 
recommended for routine CRC screening between ages 20 - 55. FAP defects could 
also result in Gardner's syndrome and Turcot's syndrome.  
Nonpolyposis syndrome (28-31, 34, 35): Hereditary nonpolyposis colon cancer 
(HNPCC), also referred to as Lynch syndrome, is an autosomal dominant trait, 
characterized by a pertinent family history of CRC. About 1-6% of all colorectal cancers 
result from HNPCC. For HNPCC patients, a pattern of primary cancers (CRC inclusive) 
would have been clinically diagnosed before the age of 50 in three or more relatives 
spanning at least two generations. Also, at least one of the affected family members 
would be a first-degree relative of the other two. Germ-line mutations of various genes 
occur in HNPCC. The most predominant are the mismatch repair genes, in particular 
hMLH1 on chromosome 3, hMSH2 on chromosome 2, as well as hPMS1 and hPMS2. 
These mutations lead to microsatellite instability, greatly comprise cellular DNA 
replication and DNA mismatch repair mechanisms, and leads to errors that promote 
tumor cell growth, proliferation and differentiation. Unlike FAP, HNPCC patients 
present a high frequency of less-aggressive cancers arising in the proximal colon. 
Furthermore, these patients have adenocarcinomas early in life compared to those with 
sporadic cancers, and usually undergo routine colonoscopy beginning at 25 years. 
3.3.2 Colorectal cancer incidence and staging 
According to global statistics on cancer incidence and mortality, colorectal cancer 
still impacts a huge problem on humans and health care systems (36-41). Worldwide, It 
is the third most commonly diagnosed cancer in males and the second in females (38). 
While about 80% of the total number of CRC cases are sporadic, the remaining 20% 
are familial or inherited forms (29). A worrisome fact on the incidence of sporadic CRC 
is its increase in many historically low risk areas such as Eastern Asia (38) and Africa 
(42, 43). Although global CRC death rates remain among the top four cancers, it has 
decreased in recent years in some Western Countries due to increased awareness, 
early detection and improved treatment (38). The situation is unfortunately different in 
many countries with limited resources and health infrastructure, where CRC incidence 
continues to increase. As observed with most cancers, the survival rate for CRC is 
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highest in individuals diagnosed with the early stage of the disease (37, 44) (Figure 
3.7). Irrespective of race, the 5-year survival rate for localized CRC at diagnosis is 
greater than 90% (36, 37). With regional diagnosis, this drops to 63% (36, 37). Patients 
diagnosed with distant metastasis have the worst prognosis, with a 5-year survival rate 
of less than 10%. CRCs spread to the regional lymph nodes and other organs through 
the portal venous circulation. In most CRC cases, the liver is often the initial organ for 
distant metastasis. 
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Figure 3.7 TNM stages for colorectal cancer and patient prognosis. 
The grading of colorectal cancer based on the TNM system is depicted along with patient prognosis at 
each stage, and a visual description of stages based on the degree of tumor penetration of the 
epithelium, lymph node and liver metastasis. Adapted from (28). 
The staging of CRC is important as a benchmark for describing CRC occurence, 
and is useful for clinical, pathological and research purposes. CRC staging is most 
commonly done using a global standard staging system, known as the TNM system 
(26). The TNM classification of carcinomas of the colon and rectum is based on the 
extent of the tumor (T), the degree of spread to the lymph nodes (N), and the presence 
of metastasis (M). This is illustrated in (Figure 3.7B).  
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Figure 3.8 TNM classification of colorectal cancer stages. 
Description of the TNM grading system for colorectal cancer (A) and colorectal cancer stages classified 
according to the TNM scheme (B). Adapted from (25). 
Depending on the TNM classification of colorectal cancer, an overall stage of 0, I, 
II, III, IV can be assigned to an adenocarcinoma (Figure 3.8). These stages could also 
be subdivided using letters like IIA and IIB. Stage I colorectal cancers are the least 
advanced, and very often have a better prognosis compared to the more advanced 
stages (Figure 3.7 and Figure 3.8). 
3.3.3 Risk factors for colorectal cancer 
A variety of factors contribute to the risk of colorectal adenomas progressing to 
malignant tumors. This includes lifestyle, diet type, age, exposure to certain diseases, 
and family history.  
Healthy living and adequate physical activity promote fitness of body and mind.  
The majority of evidence indicates that CRC is a tobacco-associated disease (45-48). 
High body mass index (BMI) and obesity also increase the risk of colorectal cancer. 
Studies have also linked high physical activity to reduced risks for CRC (49-55).   
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Certain dietary habits have also been reported to have an inverse relationship 
with CRC risk. For example, high alcohol intake predisposes individuals to CRC (56). 
More so, populations consuming food high in meat and fat, but low in starch, fibre, fruit 
and vegetables, show higher rates of cancer of the colon and rectum (57-59). The 
intake of certain chemopreventive agents such as aspirin, calcium, vitamin D and folate 
have been suggested to avert adenoma formation (45). However more conclusive 
studies are required to substantiate these claims. 
The diagnosis of sporadic CRC is unusual before the age of 40, although its 
incidence increases exponentially with age (44), with majority of the cases occurring in 
older individuals over 60 years (36). This is not the case in individuals highly 
predisposed to CRC due to family history, genetic disposition or certain ailments. For 
this group of people, CRC risk could be elevated in the late teenage years. 
Patients with persistent inflammatory bowel diseases (ulcerative colitis or Crohns' 
disease) or a long family history of CRC have a higher predisposition to CRC. 
Furthermore, individuals with some types of inherited gene defects are at risk of 
developing CRC at a young age. For example, persons with familial adenomatous 
polyposis (FAP) syndrome have a germline mutation of the major Wnt signalling 
pathway component, APC (60). As a result, they develop numerous adenomas at an 
early age and a few of these lesions may progress to cancer (61). An inherited defect 
in the DNA mismatch repair genes (hMLH1, hMSH2, hPMS1, hPMS2) causes Lynch 
syndrome, or Hereditary non-polyposis colon cancer (HNPCC) (62). The lifetime risk 
for CRC in such individuals could be as high as 80%. A positive association has also 
been demonstrated between the occurrence of Type II diabetes and CRC, due to an 
overlap of risk factors pertaining to age, physical activity and body mass index (BMI) 
(44).  
3.3.4 Colorectal cancer screening 
Health guidelines on CRC recommend screening for individuals, beginning at the 
age of 50. Of course, high-risk persons should be screened earlier and more often. The 
reduction in CRC incidence reported in a number of Western countries has been 
attributed largely to the early detection of CRC: that is at the adenoma or early 
carcinoma stage (36, 37, 63). For example, in the UK, a one-time flexible 
sigmoidoscopy screening between 55 and 64 years of age reduced CRC incidence by 
33% and mortality by 43% (64). The main screening techniques employed in CRC 
detection would be further described (45, 63, 65-67). 
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Screening tests that can detect both colorectal adenomas and cancers are 
frequently recommended to patients. This category of tests is described below.  
Flexible sigmoidoscopy involves an examination of the rectum and parts of the 
colon (the distal colon) with the aid of a sigmoidoscope. Tumors detected in the distal 
colon and rectum examined can be removed.  
With colonoscopy, the entire length of the colon and rectum can be visually 
examined. This more detailed procedure improves the detection and removal of 
adenomas in the proximal colon.  
The double-contrast barium enema (DCBE) test is a type of x-ray test performed 
with a chalky liquid called barium sulfate. X-ray pictures of the lining of the colon are 
taken to search for adenomas or cancers. A positive DCBE is usually followed up with 
a colonoscopy test for resection of the lesion.  
CT colonography or virtual colonoscopy is an advanced type of computed 
tomography scan of the colon and rectum. This technique is more sensitive than DCBE, 
as computerized images with both two- and three dimensional- views of the inside of 
the colorectum can be observed for neoplastic lesions. If positive, a colonoscopy would 
most probably be needed to remove the tumor.  
One major pitfall with the tests described so far is that they are invasive, 
expensive, time-consuming, and individuals are exposed to small amounts of radiation. 
A more worrisome fact is that studies consistently report that patient compliance is low, 
and almost 70% of individuals who undergo colonoscopy have no colorectal neoplasia 
(45, 68-70).  
This highlights the need for a better diagnostic approach to estimate the absolute 
risk for individuals who undergo these screening techniques, and to more efficiently 
target those with late adenomas or early adenocarcinomas. 
The other types of screening tests available to the population detect mainly 
cancerous lesions. These tests involve assessing faeces (stool) samples for signs of 
cancer.  
Fecal occult blood test (FOBT) detects blood in faeces using a guaiac test for the 
peroxidase activity of haem in haemoglobin. It is the most commonly used CRC 
screening test. The blood is assumed to be from blood vessels on the surface of large 
tumors damaged during defaecation. FOBT lacks adequate specificity and sensitivity to 
detect early, small-sized colorectal tumors. The false positive rate is high as faecal 
blood could also be from other causes such as ulcers, IBDs, or certain dietary 
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components. Moreover, not all tumors bleed. When positive, further tests such as 
colonoscopy have to be performed.  
Immunochemical faecal occult blood test (iFOBT) or faecal immunochemical test 
(FIT) is used to screen faecal samples for a part of the human haemoglobin protein 
that is found in red blood cells. It uses antibodies against the globin component of 
human haemoglobin. Like FOBT, FIT may produce false-positive results (albeit less 
than FOBT) and needs to be followed up with a colonoscopy.  
Lastly, Stool DNA tests can detect certain aberrant genetic markers such as DNA, 
released from tumor cells (71-73). A possible drawback for this test is the degradation 
of long DNA (a marker for non-apoptotic cellss) shed from neoplastic cells by faecal 
bacterial endonucleases. Despite the improved sensitivity and sensitivity recently 
reported for this test (68), its performance is generally graded as equal to or lower than 
the less expensive FIT, and inferior to colonoscopy (74). All three tests are less 
invasive, and easier to perform compared to the more invasive CRC screening tests. 
However, early stage tumors are frequently missed (68).  
This again emphasizes the necessity for a more sensitive diagnostic method to 
detect early lesions in colorectal tumorigenesis.   
3.4 Somatic alterations in precancerous lesions of the adenoma-
carcinoma pathway. 
  To gain insight on molecular alterations that promote the development of CRC, 
the biology of adenomatous as well as cancerous lesions must be scrutinized. 
Numerous gene and mRNA expression studies on these lesions (adenomas and 
adenocarcinomas) have provided knowledge of molecular alterations that play valuable 
roles in the development of progressive tumors from normal epithelial cells. In addition 
to this, non-genetic mutations, especially in DNA methylation have also been 
discovered from epigenetic studies. Research on these lesions is also driven by the 
need for biomarkers to aid early detection, diagnosis and monitoring of colorectal 
tumorigenesis. Tumor-marker-driven studies have targeted extracts from human 
colorectal tissues, blood and faeces.  
3.4.1 Molecular alterations in the genome of adenomas 
Contributions to genomic instability in tumor cells are mainly from microsatellite 
instability (MIN) or chromosomal instability (CIN).  
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MIN is common in MMR deficient neoplastic lesions from individuals with HNPCC. 
MIN is observed in about 10-15% of sporadic cancers with acquired transcriptional 
silencing of hMLH1 due to the hypermethylation of its promoter region (75-78).  
A number of chromosomal abnormalities (CIN) occur in the early stages of 
colorectal tumorigenesis. Stages involved in the transformation of benign hyperplastic 
lesions to advanced adenomas and then adenocarcinomas are depicted in Figure 3.9. 
The loss of chromosome 17p is infrequent in adenomas of any stage (5 - 30%) 
whereas more than 75% of colorectal carcinomas contain a loss in a large portion of 
chromosome 17p (79). More importantly, patients with the 17p allelic losses were 
associated with a high risk of tumor progression from a benign to a malignant state (33). 
Interestingly, the common region of loss on chromosome 17p in colorectal tumors has 
been identified to contain p53, a tumor suppressor gene frequently switched off in 
colorectal cancers (21, 80). Another region of allelic loss in colorectal tumors, 
chromosome 18q, is found in almost 50% of advanced adenomas, and 73% of 
adenocarcinomas (32). This region has also been mapped, and the candidate tumor 
suppressor gene identified as DCC (21). It encodes a cell adhesion protein believed to 
be involved in maintaining normal cell adhesion matrix. Gains in chromosomes 8q, 13q 
and 20q, as well as losses in chromosomes 8p and 15q are also strongly associated 
with advanced adenomas (81). 
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Figure 3.9 Mutations in sporadic colorectal tumorigenesis 
Stages involved in the transformation of hyperplastic polyps to early adenomas, advanced adenomas 
(preinvasive, dysplastic lesions), and adenocarcinomas (invasive lesions). Adapted from (82). 
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3.4.2 Molecular alterations in the transcriptome of adenomas 
Remarkable differences identified in the transcriptome of adenomas when 
compared to the normal mucosa have revealed evidence of broad-scale transcriptome 
remodelling in precancerous neoplasms. 
The most common gene expression change characteristic of early adenomas is 
mutations in the APC tumor suppressor gene leading to activation in the Wnt signalling 
pathway. This mutation promotes chromosomal instability and is prevalent in almost 
80% of adenomas and 93% of carcinomas (83). The APC tumor suppressor protein 
regulates intracellular β-catenin levels by facilitating its ubiquitination and subsequent 
degradation. In the absence of APC, β-catenin is abundant in the cytoplasm, increased 
amounts are abnormally translocated to the nucleus, where it drives the transcription of 
various genes involved in tumor growth and invasion (83). 
 Activating mutation in KRAS is another key modification identified in tumor cells. 
About 50% of colorectal adenomas greater then 1 cm in size were found to have KRAS 
gene mutations (32). While only 9% of sporadic adenomas less than 1 cm showed 
KRAS mutations, approximately 50% of colorectal carcinomas were also found to 
display this mutation (32, 79, 84, 85). KRAS gene mutations could be a necessary 
feature for small adenomas to progress to an advanced stage, either as an initiating 
event or through the clonal expansion of mutated cells (79). KRAS mutation is 
predominant in DNA mismatch repair (MMR) proficient tumors and is associated with 
the promoter methylation of MGMT (86).  Activating mutations in EGFR, and BRAF 
also occur in some adenomas and are suggested to aid a constitutively active RAS 
signalling pathway.  
COX-2, the inducible isoform of COX, is expressed in response to mitogens, 
growth factors and inflammatory stimuli (87). Increased COX-2 expression has been 
consistently associated with early tumorigenesis (88, 89). While COX-2 mRNA levels 
were detected at high levels in adenoma and adenocarcinomas than in the normal 
mucosa, no overexpression was found in hyperplastic polyps (89). 
In one study, significant expression changes in 78 genes involved in the Wnt 
signalling cascade was confirmed (90). Also, noteworthy candidates in the list of 
overexpressed mRNAs in adenomas include four members of the REG family of genes 
(involved in tissue mitogen expression), CDH1 (important in epithelial-mesenchymal 
transition), CDH3 (associated with early transformation events), RTEL1 (facilitates 
telomere elongation) and KIA1199 (a novel Wnt target). 
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Additionally, tumor-associated genetic pathways altered at the different stages of 
adenoma-carcinoma transformation have been identified in comprehensive 
transcriptomic studies on colorectal adenomas (91). Pathways significantly altered in 
early colorectal lesions in one of such study are depicted in Figure 3.10. 
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Figure 3.10 Molecular pathways dysregulated during adenoma 
transformation 
An overview of tumor-related pathways identified from transciptomic studies to be dysregulated at 
different stages (SPL = early adenomas, LPL = advanced adenomas) of colorectal tumorigenesis. 
Arrows indicate upregulation (up) and downregulation (down). Adapted from (91). 
The expression level of transcription factor genes also change during 
tumorigenesis (92). For example, unlike carcinomas and normal mucosa, adenomas 
overexpress DACH1, which controls the transcription of several genes involved in cell 
proliferation and differentiation. Downregulation of TGFB1 in adenomas could also 
reflect a decline in the function of this proapoptotic gene, which maintains homeostasis 
in the normal epithelium. Furthermore, the transcription factor genes BIRC5, NR3C1, 
and MYB, were reported to show significant changes in expression pattern in 
precancerous lesions.  
These gene expression changes represent just a few of the many genetic 
alterations linked to early precancerous colorectal lesions (93). 
3.4.3 Epigenetic alterations in colorectal adenomas 
DNA methylation plays crucial roles in the regulation of gene expression. 
Neoplastic cells have an altered developmental program, and studies have revealed 
methylation patterns in these cells often deviates from that observed in normal cells.  
Goelz et al, showed that total DNA hypomethylation occurs in small, benign 
colorectal neoplasms, suggesting that an alteration in DNA methylation pathway could 
be an early event in the initiation of neoplasia (94). Preinvasive lesions also contain 
more precise hypomethylation patterns. Reduction in genomic 5-methylcytosine 
observed in adenomas and adenocarcinomas was significantly different from the 
normal colon mucosa even though the level of hypomethylation was similar in both 
neoplasms (95). Epigenetic changes such as hypomethylation could also contribute to 
instability in the cell genome and alter the rate at which genetic alterations occur in 
tumor cells (79). 
Despite global hypomethylation reported for colorectal neoplasms, several genes 
on the short arm of chromosome 11, including the calcitonin gene are extensively 
hypermethylated in benign colonic lesions prior to malignant transformation (96). 
Furthermore, silencing of SFRP (the gene encoding secreted frizzled-related proteins) 
by promoter hypermethylation occurs early in colorectal tumorigenesis and facilitates 
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constitutive Wnt signalling (97). Increased gene methylation could be of particular 
importance in the reduction of gene expression. 
3.4.4 Metabolic alterations in colorectal adenomas. 
Distinctive features in the metabolome of cancer cells were first described in the 
Warburg effect (98). Today, it is widely accepted that cancer cells undergo a 
comprehensive metabolome reprograming, influenced by oncogenes, tumor 
suppressor genes and tumor-associated signalling pathways (93, 99-101). This 
reprograming is channelled towards increased nutrient uptake and biosynthesis of 
macromolecules. For example, mutation in p53 promotes the pentose phosphate 
pathway and oxidative phosphorylation (99). Likewise, tumor-associated mutations in 
metabolic enzymes such as isocitrate dehydrogenase and pyruvate kinase 2 
isoenzyme are advantageous to cancer cells (100, 101). 
Literature on metabolic profile changes in colorectal adenomas is limited. A urine-
based diagnostic test comprising butyrate, serine, methanol, β-alanine, p-
methylhistidine, 3-hydroxybutyrate, asparagine, trigonelline, 3-hydroxyphenylacetate, 
histidine, acetone, 2-oxoglutarate, ethanolm adipate, 3-hydroxymandelate, tyrosine and 
benzoate, identified patients with adenomatous polyps with a greater level of sensitivity 
(83%) than commercially available faecal-based tests (102). Also, differential 
separation in the metabolomic profile of adenoma and nonadenoma controls was 
observed with a panel of 23 metabolites (103). Remarkable findings in this study 
include an increase in prostaglandin E2 in adenomas, and a decrease in anti-oxidant-
related metabolites 5-oxoproline and diketogulonic acid (103). The overproduction of 
protaglandin E2 (PGE2) is believed to promote the induction of COX-2 (87, 104). High 
levels of PGE-M (a major urinary metabolite of protaglandin E2) has also been linked to 
increased risk for multiple or advanced adenomas (104). 
3.4.5 Proteome alterations in colorectal adenomas 
The explanation of an observed phenotype related to a disease should not be 
based only on genetic and epigenetic changes. Moreover, the environment plays a 
crucial role in defining phenotype variations. Therefore, proteins associated with these 
genetic changes need to be unravelled to proffer conclusive relationships between 
genetic and phenotypic changes.  
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3.4.5.1 Proteomic*studies*on*colorectal*adenomas:**
Phenotypic variations in the digestive-tract mucosa, as displayed in endoscopy, 
occasionally define the different stages associated with colorectal cancer (see Figure 
3.7 and Figure 3.9A).  
The early diagnosis of colorectal tumors has been greatly facilitated by screening 
methods based on fecal analysis or colonoscopy, but both approaches have limitations 
(see Section 3.3.3). Promising results for the detection and validation of potential 
cancer biomarkers are emerging from proteomic studies on cancer development (105). 
In one of the earliest studies on the proteome of colorectal lesions, Stulik et al, 
(106) analysed protein extracts from normal and adenocarcinoma human tissue 
specimens using two-dimensional gel electrophoresis (2DE). Subsequent reports 
introduced a one dimensional electrophoresis step based on iso-electric focusing prior 
to 2DE or modifications in 2DE, such as two dimensional differential gel 
electrophoresis (2D-DIGE) (107-112). These reports have primarily evaluated the 
protein profiles of normal and adenocarcinoma biopsies, with the exclusion of 
precancerous adenomas. Proteins and pathways differentially regulated in adenoma 
compared to normal tissues could be conventional biomarker targets for the early 
detection of colorectal tumors in contrast to those up- or down-regulated in 
carcinoma/normal tissue. In the first reported study targeting a relatively large number 
of adenomatuous and matched normal mucosa lesions, the high abundance proteins 
ANXA3, S100A11, EIF-5A1, and S100P, were significantly overexpressed in benign 
lesions (113). Despite the use of a 2DE-based approach, useful insights were gained 
on the proteome of precancerous lesions.  
In line with technological advances in the field of proteomics, high-throughput 
proteomic methods could be applied in colon cancer study. Mass spectrometry (MS) 
based studies has become the hallmark of most proteomic investigations and 
advancements in MS techniques has greatly improved the depth of proteome coverage, 
reproducibility and sensitivity of MS based approaches (105, 114-118). Compared with 
the gel electrophoresis-based approaches used in the past, MS-based proteomic 
techniques are more sensitive, robust, and reproducible (119). They also offer broader 
proteome coverage, which also comprises less abundantly expressed cellular proteins 
(116, 118, 120, 121).  
Thus far, human colorectal adenomas have been the focus of only few MS-based 
proteomics studies (122, 123). Apart from the study by Lam et al., using a 2-DE 
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approach (113), no comprehensive MS-based study targeting a relatively large series 
of precancerous lesions has been reported. This highlights the need for further 
research applying improved MS-based techniques to investigate precancerous lesions.  
In addition to improving present knowledge on the biology of this tumor phenotype, 
putative tumor markers in the early stages of colorectal cancer development could be 
identified. 
3.4.6 Mass spectrometry-based proteomic techniques for biomarker studies 
(114, 115, 124-126). 
As illustrated in Figure 3.11, there are two major forms of MS-based proteomic 
techniques employed in conventional biomarker-centred studies: shotgun (discovery) 
MS and targeted MS. Each method can be further classified based on the desired 
approach for the study and the type of mass spectrometer involved. More importantly, 
the type of biological sample and problem(s) to be investigated strongly determines 
which MS method to implement in a biomarker study. 
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Figure 3.11 Methods applied in mass spectrometry based proteomics 
3.4.6.1 Shotgun*mass*spectrometry*(Shotgun*MS)*
This technique aids global protein identification in the target sample. A typical 
proteomic workflow for shotgun analysis is shown in Figure 3.12. For a defined 
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biological research question, the appropriate sample (such as plasma, tissue, or urine) 
to be analysed is selected.  
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Figure 3.12 A representative proteomics workflow 
 
Sample preparatory steps involve protein extraction, tryptic digestion, and peptide 
fractionation, to obtain suitable analytes (tryptic peptides) for MS analysis. The peptide 
fractionation process is crucial for improved proteome coverage as it reduces sample 
complexity and facilitates the detection of low abundance proteins (127). Coupling a 
chromatographic apparatus to a mass spectrometer permits direct MS analysis of 
peptides as they elute from the chromatographic column. Peptides are ionized prior to 
the first MS phase (MS1) and each charged peptide has a defined mass-to-charge 
ratio (m/z). In MS1, the m/z and relative abundance of peptides (precursor ions) eluting 
from the column at defined times are measured and reflected in a mass spectra. 
Thereafter, the peptide is fragmented and in the second MS phase (MS2), the relative 
abundance and m/z ratio of fragments ions are measured and documented in the 
resulting spectra. This type of analysis is called tandem MS or MSMS and results in a 
number of chromatographic peaks. Peptide spectra features serve as coordinates for 
peptide detection. Peptide spectra are queried against databases, and matched to the 
corresponding peptide and proteins, using defined algorithms. The selection of peptide 
precursors for MS2 is usually restricted to the most intense MS1 peaks (data 
dependent acquisition, DDA). A variety of mass spectrometers can be used for shotgun 
proteomics, but data generated from these instruments must be acquired in a data 
dependent mode. Rather than just identify proteins, quantitative information about all 
proteins in a sample can be investigated.  
To differentiate peptide/protein abundance in different samples, a quantitative 
dimension could be incorporated (illustrated in Figure 3.11). First of all, with label-free 
quantification, precursor signal intensity or spectral counting (number of spectra for a 
given peptide) is used as indicators to measure and compare peptide intensity in 
different samples. Computational tools like Absolute Protein Expression (APEX), 
exponentially modified protein abundance index (emPAI), Top 3 Protein Quantification 
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(T3PQ), Progenesis or SuperHirn could be used to quantify protein abundance in 
samples (128-131) (Figure 3.11). The second approach involves the use of stable 
isotope labelling (Figure 3.11). Isotopic labels attached to protein cross-linkers cause a 
known mass shift in the mass spectrum of labelled peptides. Samples tagged with 
different labels are usually pooled and analysed. Differences in the peak intensity of 
isotope labels reflect differences in protein abundance for the samples analysed. 
Examples of stable isotopes employed for shotgun proteomics are stable isotope 
labelling by amino acids in cell culture (SILAC), isobaric tag for relative and absolute 
quantification (iTRAQ), and isotope-coded affinity tags (ICAT) (132-134) (Figure 3.11). 
SILAC is a metabolic label that can be incorporated into in vivo samples. iTRAQ and 
iCAT are chemical labels better suited to in vitro experiments, such as with human 
samples. The type of labelling preferences applicable to a research study strongly 
depends on the biological questions to be addressed and the type of biological sample 
to be investigated.  
Drawbacks with the shotgun technique include under-sampling, mainly from the 
stochastic selection of peptide precursors in MS1 for fragmentation. And secondly by 
random sampling from dynamic exclusion filtering of precursors for fragmentation in the 
second MS phase. These factors undermine the sensitivity and reproducibility of 
shotgun experiments.  
3.4.6.2 Targeted*mass*spectrometry*(124,*135D138)*
 The hallmark of targeted MS is the reproducible detection and quantification of a 
predetermined set of proteins with high reproducibility and sensitivity, in multiple 
samples. A similar workflow shown in Figure 3.12 is applicable in targeted MS. 
However, LC-MSMS is performed in a different type of instrument, and sample 
fractionation is not recommended as it results in decreased sample throughput and 
could be a potential source of measurement bias/variability. Unlike discovery MS, data 
acquisition in targeted MS is performed in a triple quadrupole instrument in a data 
independent mode (DIA). This means that precursor ions selected for fragmentation, 
as well as fragment ions for detection are pre-set. No time is spent on the acquisition of 
unwanted spectra. Selected Reaction Monitoring (SRM) is a targeted technique that 
has been standardized for high accuracy mass measurements in a large series 
samples. Furthermore, emerging techniques such as Parallel Reaction Monitoring 
(PRM) and SWATH have also been applied in targeted proteomics and both have 
favourable future prospects for targeted proteomics (Figure 3.11).  
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Figure 3.13 SRM analysis in a triple quadrupole instrument 
Triple quadrupole (QQQ) instruments are capable of selectively isolating and 
monitoring specific precursor and corresponding fragment ions - collectively called 
SRM transitions. SRM transitions identify a specific peptide and its corresponding 
protein. The use of proteotypic peptides, unique to a protein, increases the specificity 
of SRM measurements. In a typical SRM experiment (see Figure 3.13), a selected 
precursor ion m/z is detected and isolated in the first quadrupole (Q1). Precursor 
fragmentation by collision induced dissociation (CID) in the second quadrupole (Q2) 
creates fragment ions. A set of fragment ions that is selective for the chosen precursor 
ion is sequentially detected in the third quadrupole (Q3). SRM transitions are monitored 
over time. The resulting intensity peak and specified elution time (retention time) serve 
as coordinates to quantify peptide abundance. To obtain an accurate quantification of 
peptide concentration, defined amounts of synthetic peptide standards (heavy isotope-
labelled peptides) could be spiked into samples and monitored along with the 
analogous endogeneous peptides in the same SRM experiment. At the defined 
chromatographic elution time, peak intensities for endogenous and labelled peptides 
are extracted (Figure 3.13) for precise quantitative measurement.  
3.4.7 Protein biomarkers for colorectal cancer 
At the moment, only two protein-based markers are currently in clinical use for the 
detection of colorectal cancer. Firstly, faecal occult blood test, which aids the detection 
of carcinomas albeit with low diagnostic accuracy (discussed in Section 3.3.3). 
Secondly, carcinoembryonic antigen (CEA) levels are important in evaluating disease 
prognosis, detecting recurrence, and monitoring therapy in patients with colorectal 
cancer. Both assays are unsuitable for the detection of adenomas and early stage 
adenocarcinomas, when disease prognosis is above 90% for patients.  
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The improved reproducibility, selectivity, sensitivity and dynamic range achieved 
with high-throughput SRM measurements makes it an ideal technique for the validation 
of putative biomarker candidates. Literature is vast with potential colorectal cancer 
biomarkers but very few have progressed to clinical use (93, 123). One reason for this 
is the harsh terrain that governs the pipeline from biomarker discovery to clinical 
application. Another major reason is the lack of an appropriate technique for large-
scale verification, optimization and validation of biomarker candidates. Presently, the 
most commonly used validation technique is enzyme linked immunosorbent assay 
(ELISA). Although it is a quantitative technique, the limitations of ELISA include 
availability of a suitable antibody, high cost of antibodies, low reproducibility, and small 
analytical size. If fully optimized, targeted MS methods such as SRM, has the potential 
to overcome these setbacks. This technique can also be applied for large-scale 
biomarker verification, and validation in multiple samples. 
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4 Aims of Study 
Phenotypic variations in the mucosa of the large bowel, as displayed in 
endoscopy, define the different stages associated with colorectal cancer. Colorectal 
cancer is prevalent in advance-aged individuals and is one of the major causes of 
cancer-related deaths worldwide. The early identification and resection of 
precancerous lesions detected during endoscopic screening remains the most effective 
way to reduce the incidence of the disease. Molecular research on colorectal tumors 
has contributed immensely to present day knowledge on the development of various 
cancers. More recently, the application of new techniques in the field of proteomics, 
transcriptomics, and metabolomics, has helped unravel novel gene interactions and 
pathways involved in colorectal tumorigenesis. Limited information exists on global 
proteome alterations pertinent to precancerous lesions of the large bowel.  Research 
on colorectal precancerous lesions is important to shed more light on the biology of 
these benign tumors and the molecular mechanisms that control their transformation to 
malignant lesions. Furthermore, protein markers for these lesions could be putative 
biomarkers for the early detection of colorectal carcinogenesis. 
The first aim of my study was to optimize a quantitative shotgun proteomics 
workflow to identify and relatively quantify protein expression in a large series of 
human colorectal adenomas and matched normal mucosa samples (discovery phase). 
And in particular, to apply this quantitative approach to identify proteins and biological 
processes altered in adenomas compared to the normal mucosa. The proteome of 6 
human colon epithelial cell lines (five cancerous and one non-cancerous cell line) was 
also investigated by quantitative proteomics. Since colorectal tumorigenesis originates 
on the epithelial mucosa, and human biopsies contain epithelial and stromal cells, 
proteome similarity between cell lines and tissues was hypothesized to be indicative of 
protein alterations specific to the colon epithelium. An iTRAQ-8plex shotgun workflow 
was optimized to achieve this. Additionally, we investigated the correlation of proteome 
and gene expression data from studies on human colorectal precancerous lesions 
using statistical tools. For this, proteomic data from my shotgun study was compared 
with transcriptomic data from studies (139) earlier reported on a different series of 
adenoma and adjacent normal mucosa tissues. 
The final goal of my study was to apply a targeted proteomic approach to validate 
putative tumor markers for colorectal adenomas in a large number of adenoma and 
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adenocarcinoma tissues (with normal mucosa pairs). High-throughput SRM assays 
were developed and optimized to detect and reproducibly quantify selected proteins 
candidates. These protein candidates selected from my shotgun study and from the 
transcriptomic study of Cattaneo et al., (139) were potential tumor biomarkers for the 
early stages of colorectal tumorigenesis. 
 
 
 
5 Results 
5.1 Quantitative shotgun proteomics reveals early markers of colorectal 
carcinogenesis 
The first aim of my study was to optimize a quantitative shotgun proteomics 
workflow to comprehensively investigate protein expression changes that arise during 
the formation of colorectal adenomas and to identify putative tumor markers for these 
lesions.  
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5.1.1 INTRODUCTION 
Colorectal cancer ranks third among the world’s high-incidence cancers and is a 
leading cause of cancer-related death among older adults (1, 2). In the United States 
alone, projections for 2013 include 102,480 new cases and 50,830 deaths (2). 
Cancerogenesis in the large bowel begins with the transformation of the epithelial cell 
lining of the gut. Molecular alterations, mainly involving the WNT signaling pathway, 
render these cells hyperproliferative, and they form benign adenomatous tumors. The 
neoplasms are initially noninvasive (3, 4), and the vast majority remain that way. But as 
genetic and epigenetic anomalies continue to accumulate, the tumor cells’ capacity for 
invasion and destruction of surrounding tissues increases. At some point, this process 
drives certain adenomas into the realm of frank malignancy, transforming them into 
adenocarcinomas.  
Early diagnosis of colorectal tumors has been greatly facilitated by screening 
methods based on fecal analysis or colonoscopy, but both approaches have limitations 
(5-9). Better understanding of the molecular mechanisms underlying large bowel 
tumorigenesis could improve our chances of detecting these lesions in the 
adenomatous or localized adenocarcinomatous stage, when the chances of successful 
treatment are greater. Promising results for the detection and validation of potential 
cancer biomarkers are emerging from proteomic studies of cancer development (10). 
Compared with older gel electrophoresis-based approaches, shotgun proteomic 
methods, particularly those that include pre-MS OFFGEL electrophoretic peptide 
fractionation (11), enhance the sensitivity, robustness, and reproducibility of these 
studies (12) and expand the proteome coverage to include proteins that are less 
abundantly expressed (13-16). Furthermore, with the aid of isobaric-tag peptide 
labeling strategies, MS can also be used for relative quantification of protein 
expression levels within a series of multiple human tissue samples (12, 17-19).  
Thus far, only a few MS-based proteomic studies have examined human 
colorectal adenomas (reviewed in refs. (9, 20)). We therefore decided to explore the 
proteome of a relatively large series of these precancerous lesions (each with a paired 
sample of normal colon mucosa) using quantitative shotgun MS with the widely used 
iTRAQ (isobaric tags for relative and absolute quantitation) peptide labeling technique 
(21, 22) and OFFGEL fractionation. Adenoma-related protein expression variations 
specific to the epithelial compartment of these lesions were identified with a novel 
approach, which involved comparing the human tissue proteome with that of colon 
epithelial cell lines. The results of these studies revealed several protein expression 
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changes previously documented only in advanced colorectal cancers. They also 
disclosed several novel changes with potentially important roles in early-stage large 
bowel tumorigenesis, including the marked upregulation of a key enzyme in the polyol 
pathway.  !
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5.1.2 EXPERIMENTAL PROCEDURES 
5.1.2.1 Human*tissue*samples*and*cell*lines*
Human colorectal tissues were prospectively collected from patients undergoing 
colonoscopy in the Istituti Ospitalieri of Cremona, Italy. Local ethics committee 
approval was obtained, and tissues were used in accordance with the Declaration of 
Helsinki. Each donor provided written informed consent to sample collection, data 
analysis, and publication of the findings. Progressive numbers were assigned to each 
patient to protect human confidentiality. The series comprised 30 colorectal adenomas, 
each with a paired sample of normal mucosa from the same colon segment, >2 cm 
from the lesion. Tissues were collected endoscopically, promptly frozen in liquid 
nitrogen, and stored at -80 oC. 
Five colorectal cancer cell lines (HT29, Caco2, CX1, SW480, SW620) were 
obtained from the Zurich Cancer Network's Cell Line Repository. All had been recently 
purchased from the American Tissue Culture Collection (Teddington, UK) and were 
certified to be mycoplasma infection-free. Caco2 and CX1 cells were cultured in 
Dulbecco's Modified Eagle Medium, HT29 cells in McCoy's medium, and SW480 and 
SW620 cells in RPMI 1640 medium supplemented with 10% fetal bovine serum, L-
glutamine, and 1% penicillin-streptomycin (Sigma, St Louis, Missouri, USA). The 
recently established line of immortalized human colon epithelial cells (HCEC) was 
obtained from J. W. Shay and grown as described elsewhere (23). 
5.1.2.2 Protein*extraction*from*tissues*and*cell*lines*
For MS studies, frozen tissue samples were quickly weighed and homogenized 
on ice (1 min grinding, 1 min on ice, 1 min grinding) in a Wheaton glass borosilicate 
grinder containing a solution of 100 mM triethylammonium bicarbonate (Sigma, St 
Louis, MO, USA), 1X Complete EDTA-free Protease Inhibitor Cocktail (Roche, 
Mannheim, Germany), 1 M urea, 5 mM β-glycerophosphate disodium salt hydrate, 1 
mM sodium orthovanadate, and 5 mM sodium fluoride (Sigma). The efficiency of cell 
lysis was microscopically confirmed. The homogenates were then sonicated with a 
Bioruptor (Diagenode, Denville, NJ, USA) (high power, five 10''/10'' ON/OFF cycles) 
and centrifuged (16,000g for 5 min at 4 oC). The supernatant containing the proteins 
was collected and stored at -80 oC.   
Cells (grown to >80% confluence in 15 cm2 dishes) were washed in PBS, covered 
with 250 µL of the buffer used for tissue sample homogenization (see above), detached 
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from the dish with a cell scraper, and homogenized (25 passages through a 25G 
needle). The efficiency of cell lysis was microscopically confirmed. Sonication and 
centrifugation were repeated, as described above, and the protein concentration was 
determined by Bradford assay. Prior to MS analysis, a 5-µg sample of each protein 
extract was subjected to 1-dimensional gel electrophoresis on a 12% bisacrylamide gel 
to assess protein integrity and extraction protocol reproducibility. The entire proteomic 
workflow, from tissue/cell processing to statistical analysis, is summarized in Figure 1 
and described in detail in the next five sections of Experimental procedures. 
For sorbitol dehydrogenase (SORD) assays (see below), >80% confluent cells 
were washed in PBS and covered with a solution consisting of 100 mM triethanolamine 
(Sigma) and 1X Complete EDTA-free Protease Inhibitor Cocktail (Roche). (A simple 
buffer was used to reduce the risk of introducing anti-enzymatic substances into our 
extract.) Cells were then scraped and homogenized with 25 passages through a 25G 
needle. Tissue samples were weighed and homogenized in a Wheaton glass 
borosilicate grinder containing the buffer described above. After centrifugation (16,000 
g, 4 oC, 5 min), the supernatant was aliquoted and stored at -80 oC. Protein 
concentration was measured by Bradford assay. 
5.1.2.3 Protein*digestion*and*iTRAQ*8Dplex*labeling*
iTRAQ 8-plex experiments were performed to analyze tissue extracts (10 
experiments) and cell-line extracts (1 experiment) (Figure 1). Labeling efficiency and 
relative quantitation accuracy were assessed with the aid of two reference protein 
extract mixtures: one for tissue samples (pooled extracts from 3 normal tissues and 3 
adenomas) and one for cell lines (pooled aliquots of each of the six cell line extracts). 
Fifty micrograms of protein per sample were used for each iTRAQ channel. Tryptic 
digestion (10% w/w, sequencing-grade modified trypsin; Promega, Madison, WI, USA) 
and iTRAQ 8-plex labeling (AB Sciex, Framingham, MA, USA) were performed 
according to manufacturers’ instructions (2.5-hour incubation of samples with iTRAQ 
labels). For tissue experiments, two iTRAQ labels, 113 and 114, were chosen for the 
reference mixture, while labels 115/116, 117/118, and 119/121 were used for the 3 
pairs of normal/adenomatous tissues included in each experiment. For the cell line 
experiment, labels 113 and114 were used for the reference mixture, and labels 115-
121 represented HCEC, HT29, Caco2, CX1, SW480, and SW620 cells, respectively 
(Figure 1). After iTRAQ labeling, the samples (for each experiment) were combined, 
desalted on 500 mg SepPak C18 columns (Millipore, Billerica, MA, USA), dried in a 
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SpeedVac concentrator (Thermo Scientific, NC, USA), and subjected to peptide 
fractionation. 
5.1.2.4 OFFGEL*electrophoresis*
Peptide fractionation was performed according to the manufacturer’s protocols 
with an Agilent 3100 OFFGEL fractionator and 12-well OFFGEL kit (both from Agilent 
Technologies, Santa Clara, CA, USA). Briefly, samples were resolubilized in 1.8 mL of 
1x OFFGEL peptide stock solution containing carrier ampholytes (pH range 3–10), 
loaded into the wells (150 µL per well), and focused until 20 kV/h was reached with a 
maximum current of 50 µA. For each experiment, 12 fractions were collected. A 15-µL 
aliquot of each fraction was acidified with 1.5 µL of a 50% acetonitrile / 1% 
trifluoroacetic acid solution, desalted using ZipTip C18 (Millipore, Billerica, MA, USA), 
dried, resolubilized in 15 µL of a 0.1% formic acid / 3% acetonitrile solution, and 
analyzed with MS.  
5.1.2.5 Liquid*Chromatography*and*Mass*Spectrometry**
Peptide samples (4 µL) were analyzed on an LTQ-Orbitrap Velos mass 
spectrometer (Thermo Fischer Scientific, Bremen, Germany) coupled to a nano-HPLC 
system (Eksigent Technologies, Dublin, CA, USA). The solvent compositions were 
0.2% formic acid and 1% acetonitrile for channel A and 0.2% formic acid and 80% 
acetonitrile for channel B. Peptides were loaded onto an in-house-made tip column (75 
µm × 80 mm) packed with reverse-phase C18 material (AQ, 3 µm 200 Å, Bischoff 
GmbH, Leonberg, Germany) and eluted (flow rate, 250 nL/min; solvent B gradient: 
from 3% to 30% in 62 min, from 30% to 45% in 70 min, and 45% to 97% in 75 min).  
Full-scan MS spectra (300−1700 m/z) were acquired at a resolution setting of 30 
000 at 400 m/z after accumulation to a target value of 1 x 106. For the eight most 
intense signals per cycle above a threshold of 1000, both CID (collision-induced 
dissociation) and HCD (higher-energy collisional dissociation) spectra were acquired in 
a data-dependent manner (Figure 1). CID scans were recorded in the ion-trap 
(settings: normalized collision energy, 35; maximum injection time, 50 ms; automatic 
gain control [AGC], 1 x 104 ions). For the HCD scans, spectra were recorded at a 
resolution setting of 7500 at 400m/z (normalized collision energy, 52; maximum 
injection time, 125 ms; AGC, 5 x 104 ions). Charge state screening was enabled, and 
singly charged states were rejected. Precursor masses previously selected for MS/MS 
were excluded from further selection for 60 s, and the exclusion window was set at 10 
ppm. The maximum number of entries in the exclusion list was set at 500.  All samples 
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were analyzed in duplicate, and precursors selected in the first run were excluded from 
fragmentation in the second run. The exclusion list was set on a time window of 4 
minutes and mass width of 10 ppm. Spectra were acquired using internal lock mass 
calibration on m/z 429.088735 and 445.120025. 
5.1.2.6 Peak*list*generation*and*database*search*
As depicted in Figure 1, Mascot Distiller 2.4.3.3 (Matrix Science, Boston, MA, 
USA) was used to generate Mascot generic format (MGF) peak lists. De-isotoping and 
peak picking were not performed between 112.5 and 121.5 m/z (the range containing 
iTRAQ reporter ions), and the HCD and CID spectra were merged by summing. For 
each of the 11 experiments, the corresponding 24 MGF peak lists were concatenated 
and searched, with the aid of the Mascot Server 2.3.02 (Matrix Science), against a 
forward UniProtKB/Swiss-Prot database for human proteins concatenated to a 
reversed decoyed FASTA database. The concatenated database contained a total of 
147,438 proteins with accessions in Gene Ontology-compatible format and 260 
common MS contaminants (NCBI taxonomy ID 9606, release date 2011-12-13). 
Methylthio (C), iTRAQ 8-plex labeling at N-terminal and lysine were set as fixed 
modifications, while variable modifications consisted of methionine oxidation and 
iTRAQ 8-plex labeling of tyrosine. We used the iTRAQ 8-plex-vs114 (Applied 
Biosystems) quantitation method. The isotope and impurity correction factors used for 
each iTRAQ label were those provided by the manufacturer. Precursor and fragment 
tolerances were set at 10 ppm and 0.8 Da, respectively. Enzyme specificity was set to 
trypsin with an allowance of up to 1 missed cleavage. Using Mascot internal export 
scripts, we transformed Mascot DAT files into XML files and parsed them with in-house 
scripts so that peptide sequences, scores, and intensities of the individual reporter ion 
channels were reported. Confidently identified and quantified peptides were selected 
with the following filters: rank 1 (best spectra assignment); ion score: > 15; and 
presence of iTRAQ intensity values for reporter channels 113 and 114. 
5.1.2.7 Quantification*of*relative*protein*abundance**
(these steps are described in the boxes of the lower half of Figure 1) 
Peptide reporter channel intensities were summed for each protein individually 
using R-scripts. Ratios were built from summed channels (113/114 to 121/114) for all 
proteins identified in each iTRAQ experiment. False discovery rates (FDRs) (24) were 
determined at the spectrum, peptide, and protein levels. The results of individual 
experiments were then merged into one matrix, which was used for statistical analysis 
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in R and Perseus (Version 1.2.7.4). All proteins identified with the same peptide(s) 
were grouped into families, each of which was identified by a unique protein family 
number. Ratios of the intensity of each ion channel to that of 114 were converted to 
base 2 logarithmic values and normalized respectively on the median (which was set at 
0), resulting in ratios that followed a Gaussian distribution. Proteins identified on the 
basis of the same peptide(s) shared the same family number and were represented 
once in our statistical analysis. The paired t-test was used to compare the expression 
of a given protein in each adenoma and that found in the corresponding sample of 
normal mucosa. To correct for multiple comparisons, the FDR was controlled with the 
Benjamini-Hochberg procedure. The average protein-expression fold change in 
adenomas, compared with the normal mucosa, was then calculated. For this, median 
normalized ratios for all proteins in each paired adenoma-normal mucosa sample were 
deconvoluted of the reference standard effects (114) to compute the adenoma vs. 
normal mucosa ratio per protein (deconvoluted fold change, i.e.[116/114] / [115/114] = 
[116/115]) and the mean fold change per protein in all tissue pairs. The Mascot emPAI 
value for all proteins were included in XML exports for each experiment. Thereafter, the 
mean Mascot emPAI value was calculated for all proteins. 
5.1.2.8 Functional*annotation*of*proteins*
Gene ontology (GO) annotations and GO terms for proteins in the 
UniProt/SwissProt database were sourced from http://www.ebi.ac.uk/. The Scaffold 
program (Version 3) was used to identify the cellular localizations and biological 
processes most represented in lists of proteins quantified in tissues and cell lines. The 
topGO Bioconductor software package in R was used to identify and screen for GO 
biological process categories displaying enrichment for proteins that were differentially 
regulated in adenomas (vs. normal mucosa) (25). First, we prepared a "Universe" 
comprising all the proteins quantified in our study, each matched to GO terms and 
annotations. This served as the "Background." The "Foreground" consisted of the list of 
significantly dysregulated proteins. The most significant GO terms were scored with the 
Eliminating Genes (elim) method (25).  
5.1.2.9 Western*Blotting*
Proteins were separated on a 10% SDS-polyacrylamide gel and transferred to a 
hydrophobic polyvinylidene difluoride membrane (GE Healthcare, Amersham Hybond-
P PVDF membrane, Pittsburgh, PA, USA) according to standard protocols (26). After 1 
h of blocking with 5% non-fat dry milk in TBS with 1% Tween 20 (milk-TBST), 
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membranes were incubated overnight with the primary antibody (anti-SORD 
[HPA040260 Sigma]; anti-aldose reductase, AKR1B1 [GTX113381 GeneTex]; anti-
ketohexokinase, KHK [GTX109591 GeneTex]) diluted 1:1000 in milk-TBST, washed 
once with milk-TBST (20 min) and twice with TBST (20 min). After 1 h of incubation in 
horseradish peroxidase-conjugated secondary antibody (anti-rabbit IgG, GE 
Healthcare) diluted 1:5000 in milk-TBST, membranes were washed once with milk (20 
min) and twice with TBST (20 min). Enhanced chemiluminescence (ECL, Amersham 
Pharmacia Biotech, Cat. No. RPN2106) was used to detect immunoreactive proteins. 
5.1.2.10 Immunostaining*of*cells*and*tissues*
HT29 and HCEC cells were seeded (3 x 105 per well) on 22 x 22 mm cover slips 
in 6-well plates and grown under standard conditions until cells reached 70-80% 
confluence. Cells were then washed twice with PBS and fixed in ethanol:methanol 
solution (50:50) for 10 min at room temperature. Fixed cells were permeabilized (10 
min with 0.25% Triton X-100), blocked (30 min in 10% goat serum [X0907, Dako, 
Glostrup, Denmark]), and incubated with primary antibody (rabbit polyclonal anti-SORD, 
HPA040260, Sigma, 1:100) for 18 h at 4 oC. After three washes with PBS, the cells 
were incubated for 1 h with secondary antibody conjugated to polymer-HRP anti-rabbit 
(Dako, EnVision+ System- HRP; Cat. No. K4010). They were then washed three times 
in PBS and incubated for 15 min in the substrate-chromogen, 3,3-diaminobenzidine 
tetrahydrochloride (DAB, Dako, EnVision+ System- HRP; Cat. No. K4010). Cells were 
washed quickly with PBS and mounted on slides (EUKITT, O. Kindler, GmbH, Freiburg, 
Germany) for light microscopy (Leica Microsystems GmbH, Wetzlar, Germany). 
Images were examined and recorded with Leica Application Suite (V3.3.0) software. 
Sorbitol dehydrogenase immunohistochemistry was performed as previously 
described (27). Tissue sections (normal colon and ileum, colorectal adenomas and 
adenocarcinomas) were incubated for 24 h at 4 oC with primary antibody (rabbit 
polyclonal anti-SORD, HPA040261, Sigma) at a 1:100 dilution.  
5.1.2.11 Measurement*of*SORD*activity*
Total protein was extracted from cell lines and tissues as described above. SORD 
catalyzes the reversible conversion of D-sorbitol to D-fructose, with β-NADH as a 
cofactor: 
D-fructose + β-NADH <--------------> D-sorbitol + β-NAD 
            SORD 
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SORD activity was quantified via continuous spectrophotometric rate 
measurement of the β-NAD formation rate (temperature 25 oC, pH 7.6, A340nm, light 
path of 1 cm) in a Cary 50 Scan UV-visible spectrophotometer using the Cary Kinetics 
Application (both from Varian Inc., Palo Alto, CA, USA) (28). The final reagent 
concentrations in a 1-mL cuvette were as follows: 78.33 mM triethonolamine, 183 mM 
D-fructose, 0.21 mM β-NADH, 0.033% (w/v) BSA. The absorbance reading was 
recorded when the enzyme was added. One unit of enzyme activity was defined as the 
amount of enzyme required per minute to convert 1.0 µmole of D-fructose to D-sorbitol 
at pH 7.6 at 25 oC. A mixture of reagents plus recombinant SORD was used as the 
positive control; negative controls consisted of the same reagent mixture with no 
recombinant SORD, with recombinant SORD but no D-fructose, or with recombinant 
SORD but no β-NADH.  
5.1.2.12 Extraction* and* quantification* of* intracellular* metabolites* by* targeted* gas*
chromatographyDcoupled*MS**
Frozen tissue (50 to 100 mg) was homogenized in 250 µl ice-cold 80% methanol 
using a glass borosilicate grinder from Wheaton. The homogenate was microscopically 
examined to ensure that it was cell-free and then transferred to Eppendorf vials and left 
on ice for 15 min to ensure efficient protein precipitation. After centrifugation (15,000g 
for 3 min at 0 oC), the supernatant was snap-frozen and stored at -80 oC, while the 
protein content of the pellet was determined by the Bradford method. 
For gas chromatography-coupled MS (GC-TOF-MS) analyses, 10 µL of 
supernatant was transferred to a 1.5-mL Eppendorf tube, and internal standards (13C1-
sorbitol, 13C1-fructose, and 13C1-glucose—1.2 pmoles of each) were added. The 
samples were then dried overnight in a vacuum centrifuge (Concentrator 5301, 
Eppendorf AG, Germany). Methoxyamine hydrochloride and N-methyl-N-(trimethylsilyl) 
trifluoroecetamide were used as derivatization reagents (29).  
The derivatized metabolites and internal standards were subjected to GC-TOF-
MS (GC 7890A, Agilent Technologies, Santa Clara, CA, USA; GCT Premier Micromass, 
Waters, Manchester, UK) with a Rxi-5Sil MS Integra-Guard column (length: 30 meters, 
internal diameter: 0.25 mm) and a film thickness of 0.25 µm (Restek, USA). One 
microliter of each derivatized sample was injected in splitless mode on a baffled glass 
liner and transferred to the capillary column by rapid heating of the liner from 50 oC to 
250 oC at a rate of 12 oC/sec. For the separation of the metabolites, helium was used 
at a flow rate of 1 ml/min and, after an initial hold time of 2 min, a temperature gradient 
from 80 oC to 320 oC (rate 8 oC/min) was applied. The TOF-MS was set to acquire 
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centroided standard electron ionization mass spectra over a range of 50 to 600 m/z at 
a rate of 3 spectra/sec. The GC-MS transfer line was heated to 280 oC. Dynamic range 
enhancement was activated. C6ClF5 was used as lock mass compound. 
The MassLynx and QuanLynx programs (Waters, UK) were used to review and 
analyze the acquired data. The absolute concentrations of D-sorbitol, α and β D-
fructose, and α and β D-glucose were calculated on the basis of the ratio of the 
intensity of specific fragments originating from the unlabeled compound to that of the 
added labeled analogue (internal standard). These concentrations were used to 
estimate intracellular levels per milligram of tissue (adenoma vs. normal mucosa). The 
relative concentration of lactate was estimated from the ratio of the intensity of specific 
fragments originating from the unlabelled compound and that of the added 13C1-sorbitol 
(internal standard). !
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5.1.3 RESULTS 
5.1.3.1 Proteomic*analysis*of*human*colorectal*tissues*and*colon*cell*lines.*
We used a quantitative-MS-based discovery strategy to explore the proteome of 
human colorectal tissues and colon cell lines (normal and neoplastic). The 
characteristics of the precancerous colorectal lesions are listed in Table 1. Protein 
extracts from these tumors and their paired samples of normal mucosa (total, 60 
samples) were analyzed using iTRAQ LC-MS/MS and the workflow described in Figure 
1.  
Table 1. Characteristics of the precancerous lesions included in the 
study 
Patient 
number Age Sex
Colon 
segment  
involved
Maximum 
lesion 
diameter 
(mm)
Paris 
classification 
# 
Pit pattern 
classification 
º
Microscopic 
appearance
Highest 
degree of 
dysplasia in 
the lesion ▪ 
No. of  
lesions at 
study 
colonoscopy 
∞
No. of 
previously  
excised 
lesions ‡
1 77 M S 25 IIa+IIc IIIs - IIIL TA LGD 1 0
2 73 F A 25 IIa+IIc IIIs-IIIL TA LGD 1 2
3 59 M T 30 IIa+IIc IIIs + IIIL TA LGD 1 0
4 73 F R 50 Is IV VA LGD 1 0
5 74 M R 40 Is IV VA HGD 2 1
6 77 M C 25 IIa IIIL VA LGD 1 0
7 80 M A 40 IIa IIIL TVA LGD 1 1
8 82 M A 15 IIa IIIL VA LGD 2 0
9 73 F S 20 Ip IV TVA LGD 1 0
10 70 F C 25 IIa IIIL TVA LGD 2 0
11 63 M A 45 Is IIIL-IV TVA LGD 0 0
12 68 M A 30 IIa+Is IIIL - IV TVA  HGD 0 0
13 60 M D 30 Is IV - Vi TVA  HGD 0 0
14 55 M C 25 IIa+Is IIIL-IV SSA LGD 0 0
15 70 M A 15 Is IV TVA LGD 7 0
16 85 F S 25 Is+IIa IV TA LGD 1 1
17 66 M A 30 IIa IIIL TA HGD 2 0
18 72 M A 30 Is IV TVA HGD 2 0
19 71 M S 30 IIa IIIL TVA LGD 2 0
20 59 M R 60 Is IV-Vi TVA HGD 1 0
21 78 M A 50 Is IV - Vi TA LGD 1 0
22 75 M R 25 Is IV - Vn TVA HGD 6 0
23 73 F D 25 Is IV TA LGD 1 0
24 69 F R 90 Is+IIa IV TVA LGD 1 0
25 75 M T 18 IIa IIIL TA LGD 1 0
26 61 M A 40 Is+IIa IV TVA LGD 20 0
27 76 M S 30 Is IV - Vi TA HGD 1 0
28 78 F R 60 IIa+Is IV TVA LGD 1 1
29 89 M R 30 Is IV TA LGD 3 0
30 75 M A 50 Is IV-Vn TVA HGD/cancer 7 0
∞ This number includes the lesion included in our proteomic study
Table 1.  Characteristics of the precancerous colorectal lesions included in the study.
Abbreviations: M, male; F, female; C, cecum; A, ascending colon; T, transverse colon;  D, descending colon; S, sigmoid colon; R, rectum; 
TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma;  SSA, sessile serrated adenoma; LGD, low-grade dysplasia; HGD, 
high-grade dysplasia.
# Macroscopic appearance of neoplastic lesions was classified according to Paris Endoscopic Classification.  The Paris Endoscopic 
Classification of Superficial Neoplastic Lesions. Gastrointest Endosc 2003;58(suppl.):S3-S27
º Morphological analysis of colon crypt patterns according to the Kudo classification. Kudo S, Rubio CA, Teixeira CR, et al. Pit pattern in 
colorectal neoplasia:endoscopic magnifying view. Endoscopy 2001;33;367-7
▪ Low-grade versus high-grade dysplasia as defined by the WHO classification of tumors of the digestive system, editorial and consensus 
conference in Lyon, France, November 6-9, 1999.IARC !
 
The inclusion of two reference sample mixes allowed us to control for technical 
variability across the ten experiments on tissue samples since the reference sample 
was analyzed twice in each experiment. OFFGEL electrophoresis was used to obtain 
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highly reproducible, pI-based, in-solution separation of pooled iTRAQ-labeled peptides. 
Furthermore, for relative quantification of proteins using iTRAQ reporter ions, we 
adopted a stringent FDR for protein spectra matches (PSMs), and high-confidence 
peptides for protein quantification were selected only if the reporter ions (113 and 114) 
were quantified in the reference sample mix (iTRAQ reporter channels 113 and 114).  
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Figure   1. Project design and iTRAQ 8plex-labeling scheme 
Project design and iTRAQ 8plex-labeling scheme. Sample preparation for shotgun MS/MS and important 
steps in the analysis of proteomic data for the detection of dysregulated proteins in adenomas and colon 
cancer cell lines. For each experiment on tissue samples, iTRAQ tags were assigned to a duplicate 
reference (two identical pools of normal and adenoma samples: 113 and 114, respectively), normal 
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tissues (115, 117, 119) and corresponding adenomas (116, 118, 121). The same pattern was repeated 
in all 10 experiments. In cell line experiments, two identical pools, each comprising all six cell lines, were 
used as reference (113 and 114), and each of the remaining six tags was used to label a single cell line. 
The data analysis flow chart depicted in this figure is described in Experimental procedures 
The data set generated with this approach was large and complex, but we 
developed a simplified analytical method that allowed us to work with and merge the 
large data files generated after MS/MS (Figure 1). High-resolution MS/MS spectra 
acquired on the LTQ-Orbitrap Velos spectrometer after duplicate analysis of OFFGEL 
tissue sample fractions produced a total of 240 raw files (10 experiments, 120 fractions, 
2 replicates).  
Table 2. Summary of proteomics data 
Total FDR (%) Total FDR (%)
Peptide spectra matches 285,929 0.2 27,922 0.4
Peptides 37,184 0.9 11,266 0.5
Proteins * 10,452 1.5 5,056 1.1
Proteins # 4,325 - 2,017 -
Proteins ^ 1,072 - 1,957 -
^ Non-redundant protein families quantified in all 60 tissues or in all 6 cell lines.
Tissues (n = 60) Cell lines (n = 6)
Table 2.  Summary of proteomics data
* Total number of proteins quantified in the 10 tissue experiments and the single 
experiment with cell lines.
# Non-redundant protein families quantified in our dataset. !!
A total of 37,184 (FDR = 0.9%) unique tryptic peptides were confidently identified 
and quantified from 285,929 unique PSMs (FDR = 0.2%) (Table 2, Supplementary 
Table 1). Ten thousand four hundred fifty-two proteins (FDR = 1.5%) were assembled 
from the quantified peptides. Proteins that were indistinguishable by MS/MS (i.e., two 
or more proteins identified on the basis of the same peptide sequence; see 
Experimental procedures for details) were represented as a single family. The result 
was a total of 4325 non-redundant protein families, two-thirds (2865, 66%) of which 
were relatively quantified in at least 9 normal mucosa/adenoma pairs and 1072 (25%) 
in all 30 pairs (Table 2, Supplementary Table 1).  
To verify the efficiency of iTRAQ protein labeling, we repeated the database 
search with Methylthio (C) set as a fixed modification and iTRAQ8plex (N-term), 
iTRAQ8plex (K), iTRAQ8plex (Y), and Oxidation (M) set as variable modifications. (All 
other search parameters were unchanged.) The assigned PSMs were filtered, as 
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described in Experimental procedures, and the average iTRAQ labeling efficiency 
achieved in each of the 10 tissue experiments was 96% (Supplementary Table 2).  
To ascertain the efficacy of including a standard sample mix as a reference for 
normalization, we compared combined Gaussian plots of log2-protein ratios of normal 
mucosa or adenoma samples with the respective reference channel per experiment 
(e.g., 115/114 vs. 113/114 for normal tissues, 116/114 vs. 113/114 for adenomas, see 
Figure 1). The ratios displayed normal distributions in all channels. For the reference 
channel (113/114), log2-ratios were largely centered around 0, whereas the distribution 
of adenoma and normal channel log2-ratios was broader and not always centered at 0 
(data not shown).  
Sample complexity is a common problem in the analysis of proteomic data from 
human colorectal tissues. It stems in part from contamination of the epithelial cell 
proteome by proteins from stromal cells (which were inevitably present in our 
specimens even though the endoscopic tissue sampling procedure we used yielded 
superficial specimens with consistently high epithelial contents). Microdissection can 
be utilized to isolate subpopulations of cells, but it can diminish the quantity and quality 
of the proteins, rendering them suboptimal for some types of proteomic analysis. To 
avoid this problem, we adopted a novel strategy for preliminary identification of the 
proteomic alterations that were most likely to involve the epithelial-cell component of 
the adenomas. The proteomic profiles of the colon tissues were compared with those 
of six colon epithelial cell lines (five colon cancer cell lines plus HCEC cells, to our 
knowledge, the only well-characterized line established from normal colorectal 
epithelium (23)). Changes in expression levels observed in adenomas (i.e., 
upregulation or downregulation with respect to normal mucosal levels) were presumed 
to be epithelial-cell-specific if similar changes were found in the colon cancer cell lines 
(relative to HCEC cells). After OFFGEL fractionation, duplicate MS analysis of iTRAQ-
labeled peptides (24 fractions) from the six cell lines was performed in an LTQ-Orbitrap 
Velos mass spectrometer, and 11,266 peptides (FDR = 0.5%) were confidently 
identified and quantified from 27,922 unique PSMs (FDR = 0.4%) (Table 2, 
Supplementary Table 3). A total of 2017 non-redundant protein families (FDR = 1.1%) 
were identified and relatively quantified in cell lines; 1957 (97%) were present in all six 
cell lines (Table 2). In the iTRAQ experiment with cell lines, peptide labeling efficiency 
was 95% (Supplementary Table 2).  
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5.1.3.2 Relative*quantification*of*the*proteomes*of*colorectal*tissues*and*cell*lines.*
The concentration range for proteins expressed in human tissues spans ten 
orders of magnitude. We chose not to deplete our protein samples of high-abundance 
proteins (e.g., albumin, IgG), because with the number of tissue samples being 
analyzed, additional sample preparation steps were considered potential sources of 
confounding variability (30). As an alternative, each of the ten pooled iTRAQ-labeled 
samples (ten experiments) were separated into 12 fractions based on the isoelectric 
point of peptides, reducing the complexity of our protein matrix and limiting the risk of a 
bias toward the more abundant proteins.  
The expression levels of the 4325 non-redundant protein families we were able to 
relatively quantify in colorectal tissues spanned four orders of magnitude, as deduced 
from the protein Mascot emPAI value (used as a proxy for the emPAI value (31) to 
estimate protein concentrations) (Figure 2A).  Uzozie A. et al. Figure 2
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Figure   2. Protein coverage with iTRAQ shotgun analysis in colorectal 
tissues 
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(A) Analysis of Mascot emPAI values (used as a proxy for emPAI values) revealed a dynamic range of 
protein abundance in tissues that spanned four orders of magnitude (y-axis) and corresponded with 
known abundance estimates for various proteins in these tissues. The high/moderate-abundance 
proteins (e.g., ACTB, FABP5, CHGA) and low-abundance protein (e.g., POLR3A) relatively quantified in 
our samples are highlighted relative to their mean Mascot emPAI value. (B) Distribution of reported 
abundance ranges for the proteins with ≥1 unique peptides identified in tissues, and the high-MW 
proteins with the highest number of unique peptides identified. (C) Subcellular localizations of the 
proteins identified in colorectal tissues and cell lines and (D) biological processes in which these proteins 
are involved. This analysis was performed using Scaffold and Gene Ontology annotations (see 
Experimental procedures). 
Thirty percent (1304/4325) of these families were relatively quantified on the basis 
of more than one unique peptide. At the top of this list were the large proteins AHNAK, 
DYNC1H1, DSP, and FCGBP (Figure 2B). In colon epithelial cell lines, 1174 of the 
2017 protein families were relatively quantified with more than one unique peptide. 
Gene Ontology Annotation in Scaffold was used to identify the subcellular 
localizations of these protein families and the biological processes they were involved 
in. The GO categories represented in the tissue and cell line proteomes were fairly 
similar. In the cell-line proteome, however, the categories generally contained fewer 
proteins since the total number of proteins detected in these cells was lower than that 
of the tissues (Figure 2C). Cytoplasmic and organelle- or membrane-associated 
proteins were the most highly represented categories in our extracts, but nuclear 
proteins were also readily identified, which indicates that our protein extraction 
procedure was not strongly biased toward a few cell compartments. The most highly 
represented biological processes in the tissue proteome were metabolic or biosynthetic 
processes, whereas cell component organization and developmental processes 
predominated in the cell line proteome (Figure 2D). Stromal contamination is probably 
responsible for the increased representation of immune system processes in the tissue 
proteome (compared with that of the cell lines).  
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Uzozie A. et al. Figure 3
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Figure   3. Principal component analysis of protein expression 
Three-dimensional principal component analysis (PCA) score plot of log2 protein expression intensity 
values for (A) tissues (normal mucosa, black; adenomas, red); (B) cell lines (HCEC, cyan; colon cancer 
cell lines, green); and (C) both. The first three principal components (PCs) account for 40%, 82%, and 
36% of the total variance in the tissue, cell line, and tissue+cell line sets, respectively. PC1, the main 
direction of spread in the three groupings, reflects intergroup variance based on tissue or cell-line type 
(i.e., normal/immortalized versus tumorous). Cell lines derived from the same patient: * SW480 and 
SW620 cells; ^ HT29 and CX1 cells.  
Log2-expression levels of the protein families identified in all tissues (n=1072) and 
cell lines (n=1957) (Table 2) were subjected to principal component analysis (PCA), 
which easily distinguished the adenomas from the normal mucosa samples (Figure 3A) 
and the five colon cancer cell lines from the immortalized normal colon epithelial cell 
line HCEC (Figure 3B). The cancer cell lines were also segregated into three distinct 
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groups reflecting their patient origins (Figure 3B). When PCA was performed on the 
expression intensity values of the 1496 non-redundant proteins expressed and 
quantified in all tissues and cell lines (i.e., those representing the intersection of the 
tissue [n=10,452] and cell-line [n=5056] protein sets reported in Table 2), colon cancer 
cell lines clustered with adenomas, while HCEC cells were closer to the normal 
mucosa samples (Figure 3C). 
 As a quality control measure, data for the 60 tissue samples (1072 protein 
families) were subjected to hierarchical clustering analysis. As shown in 
Supplementary Figure 1, three main clusters emerged: one consisting almost 
exclusively of normal mucosa samples, a second containing mainly adenomas, and a 
third that included both tissue types. The 18 samples in the third cluster (nine 
adenoma/normal mucosa pairs) formed three sub-clusters, which corresponded to 
three of the 10 experiments for which trypsin digestion, iTRAQ labeling, and LC-
MS/MS were performed on the same day. These findings were suggestive of an 
experimental bias. Indeed, when these 18 potentially sub-standard samples were 
included in subsequent statistical analyses, they diminished the stringency of our 
threshold and increased the error margin for false identification. We therefore excluded 
these samples from the analyses described in the following section.  
Proteins displaying dysregulated expression in colorectal adenomas and colon 
cell lines 
To identify proteins whose expression was significantly altered in adenomas 
(relative to normal mucosa), we analyzed data on the proteins quantified in the 
remaining 21 tissue pairs. The experimentally derived protein fold-change threshold 
defining differential expression was based on comparison of the distributions of 
average intensity log2 ratios in the reference standard (113 vs. 114, seven 
experiments) and in patient samples (adenoma vs. normal, seven experiments). The 
average ratios in the reference sample were centered around 1 (i.e., log2 0). Average 
fold-change ratios for the tissue samples displayed wider variance (Supplementary 
Figure 2). Seventeen percent of the log2 ratios for the tissue samples exceeded ± 0.5 
log2 scale (indicating a linear fold change of ≥ ± 1.4) as opposed to only 5% of those for 
the reference samples.  For each protein, a paired t-test was used to compare the 
intensity ratios in normal and adenomatous samples (i.e., normal/114; adenoma/114). 
After adjustment for multiple comparison (Benjamini-Hochberg method), we selected a 
stringent q value cutoff of ≤ 0.02.  
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The 212 proteins that satisfied this criterion and presented a mean expression 
fold change of ± 1.4 (log2 0.5) or more were classified as significantly dysregulated in 
adenomas. They included 76 with upregulated expression and 136 with downregulated 
expression in the tumor samples (Table 3).  
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Table 3. Proteins displaying differential expression in adenomas vs. 
normal mucosa 
UniProt accession no.* Gene name q value Average fold change (log2)
P12429 ANXA3 0.00000001 1.44
Q9UN36 NDRG2 0.00000001 -0.79
P00918 CA2 0.00000003 -2.26
P23946 CMA1 0.00000005 -1.38
P00488 F13A1 0.00000005 -1.30
Q9UBR2 CTSZ 0.00000016 -1.23
P10645 CHGA 0.00000016 -1.82
O60844 ZG16 0.00000024 -2.02
P17174 GOT1 0.00000045 -0.61
P31949 S100A11 0.00000062 1.49
P00338 ^; P07195 LDHA; LDHB 0.00000068 0.62
O60701 UGDH 0.00000104 -0.70
P55011 SLC12A2 0.00000115 0.85
O95571 ETHE1 0.00000120 -0.74
Q01105 SET 0.00000230 0.72
Q16851 UGP2 0.00000275 -0.53
Q00796 SORD 0.00000275 0.62
P20231; Q15661 TPSB2; TPSAB1 0.00000275 -1.51
Q15181; Q9H2U2 ^ PPA1; PPA2 0.00000421 0.64
Q9H3G5 CPVL 0.00000467 -0.69
P01282 VIP 0.00000722 -1.10
P07339 CTSD 0.00000856 -0.71
P19338 NCL 0.00000934 0.50
Q6UWP2 DHRS11 0.00001070 -1.20
P04066 FUCA1 0.00001240 -1.32
Q53EL6 PDCD4 0.00001270 -0.51
P07585 DCN 0.00001580 -1.36
P02511 CRYAB 0.00002720 -1.19
Q96CX2 KCTD12 0.00003590 -0.70
Q05707; P08123 COL14A1 0.00004020 -1.21
P51884 LUM 0.00004160 -0.96
Q15063 POSTN 0.00004240 -2.10
P21397 MAOA 0.00004240 -0.63
O00748 CES2 0.00004610 -0.88
Q56VL3 OCIAD2 0.00004960 0.95
Q9BYZ8 REG4 0.00004960 0.98
P55008 AIF1 0.00005650 -0.75
P50224; P50225 SULT1A3; SULT1A1 0.00005760 -0.63
O14773 TPP1 0.00006430 -0.52
Q16853 AOC3 0.00006650 -1.16
P53634 CTSC 0.00006940 -0.58
O95881 TXNDC12 0.00006940 0.55
O75795 UGT2B17 0.00006940 -1.57
O00391 QSOX1 0.00006940 -0.70
Q99538 LGMN 0.00006940 -0.63
P12111 COL6A3 0.00006990 -0.74
P80188 LCN2 0.00006990 1.32
P12956 ^ XRCC6 0.00007190 0.53
Q6NZI2 PTRF 0.00007860 -0.76
P09382 LGALS1 0.00007880 -0.84
P25815 S100P 0.00008020 3.38
Q15118 PDK1 0.00008120 -0.90
O75380 NDUFS6 0.00008650 -0.63
Q9HAW8 UGT1A10 0.00009090 -0.95
P01042 KNG1 0.00009660 -0.74
O75356 ENTPD5 0.00012385 -0.54
Table 3. Proteins displaying differential expression in adenomas vs. normal mucosa
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Table 3. (continued).
Q15293 RCN1 0.00012867 0.61
P17931 LGALS3 0.00013151 -0.62
P36952 SERPINB5 0.00013151 1.31
P09211 ^ GSTP1 0.00014809 0.55
P20774 OGN 0.00015467 -1.52
Q8NBJ4 GOLM1 0.00015467 -0.51
Q16563 SYPL1 0.00015568 1.16
P04229; P13761; Q30134; 
Q9TQE0; Q9GIY3; Q29974; 
P04440; P79483
HLA-DRB1; HLA-DRB1; HLA-
DRB1; HLA-DRB1; HLA-DRB1; 
HLA-DRB1; HLA-DPB1; HLA-
DRB3  
0.00015568 -0.81
P35555 FBN1 0.00017230 -0.74
Q9H4M9; Q9NZN4; Q9H223;  EHD1; EHD2; EHD4  0.00017230 -0.56
O00754 MAN2B1 0.00017278 -0.65
B4DR31 DPYSL2 0.00018023 -0.55
P06703 ^ S100A6 0.00018025 1.18
P19801 ABP1 0.00022289 -0.50
P20042 EIF2S2 0.00022417 0.68
P51858 HDGF 0.00024151 0.56
P49959 ^ MRE11A 0.00024174 0.64
O00299 ^; Q9Y696 CLIC1; CLIC4 0.00024726 0.67
P61604 ^ HSPE1 0.00024977 0.52
O43252; O95340 PAPSS1; PAPSS2 0.00027464 -0.57
Q12765 SCRN1 0.00029349 -0.64
Q9HB40 SCPEP1 0.00030328 -0.87
P48556 PSMD8 0.00032019 0.56
O60547 GMDS 0.00034711 0.58
Q9Y6R7 FCGBP 0.00035167 -0.73
P61626 LYZ 0.00036558 0.74
Q9Y224 C14orf166 0.00038868 0.52
P01765; P01764 (Ig heavy chain V-III region TIL; Ig heavy chain V-III region VH26) 0.00038868 -0.69
Q9NVP1 DDX18 0.00038996 0.67
P80365 HSD11B2 0.00039413 -0.68
P39687; Q92688 ANP32A; ANP32B 0.00039654 0.56
Q86WA6 BPHL 0.00046215 0.52
P24298 GPT 0.00047338 -0.56
Q12874 SF3A3 0.00052166 0.50
P04899; Q14344; P63092 GNAI2; GNA13; GNAS 0.00062192 -0.51
Q15124 PGM5 0.00068593 -0.68
Q9HAW7; Q9HAW9; O60656 UGT1A7; UGT1A8; UGT1A9 0.00071202 -0.87
P19224 UGT1A6 0.00071202 -0.87
P06748 NPM1 0.00071508 0.81
Q9NUV9 GIMAP4 0.00071508 -0.89
P18283 ^ GPX2 0.00071508 0.54
P13688 CEACAM1 0.00072482 -1.06
P01591 IGJ 0.00084082 -1.10
P19823 ITIH2 0.00085565 -0.71
P01774; P01776; P01779
(Ig heavy chain V-III region POM; 
Ig heavy chain V-III region WAS; Ig 
heavy chain V-III region TUR) 
0.00085565 -0.79
P27695 ^ APEX1 0.00086971 0.54
Q9C002 NMES1 0.00087016 -0.91
Q96F85 CNRIP1 0.00088956 -1.27
Q9BPX5 ARPC5L 0.00095098 0.67
P62263 RPS14 0.00095182 0.52
Q9BY32 ITPA 0.00095634 0.51
P01625 (Ig kappa chain V-IV region Len) 0.00097041 -0.61  
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Table 3. (continued).
Q15582 TGFBI 0.00097041 0.90
Q07021 ^ C1QBP 0.00101874 0.76
P00738 HP 0.00102030 -0.61
O15143 ARPC1B 0.00103757 -0.50
Q03154 ACY1 0.00108571 0.60
Q9HCB6 SPON1 0.00115609 -0.89
Q96HE7 ERO1L 0.00119027 0.50
P08575 PTPRC 0.00119950 -0.52
Q9Y266 NUDC 0.00152358 0.56
P63313; P62328 TMSB10; TMSB4X 0.00159602 0.98
Q96SQ9 CYP2S1 0.00162405 0.84
Q71U36 TUBA1A 0.00162405 0.54
P00915 CA1 0.00163258 -1.18
P04844 RPN2 0.00165748 0.55
P09669 COX6C 0.00171230 -0.61
P21980 TGM2 0.00174251 -0.55
P00325 ADH1B 0.00175658 -1.18
O14745 SLC9A3R1 0.00175658 -0.51
Q9H8H3 METTL7A 0.00179938 -0.50
P61009 SPCS3 0.00186488 -0.69
Q15746; O15264; Q16539 MYLK; MAPK13; MAPK14 0.00186488 -0.53
P01876; P01877; Q92973 IGHA1; IGHA2; TNPO1 0.00191760 -1.01
P12109 COL6A1 0.00194792 -0.67
Q9BX66 SORBS1 0.00205902 -0.64
E9PGJ9 CC2D1A 0.00213982 -0.53
P49006 MARCKSL1 0.00233532 0.51
Q01524 DEFA6 0.00233532 1.60
P01620 (Ig kappa chain V-III region SIE) 0.00238585 -0.56
P36873 PPP1CC 0.00240171 0.58
Q07507 DPT 0.00240576 -1.28
P37840 SNCA 0.00261720 -0.57
P00326; P07327 ADH1C; ADH1A 0.00271753 -1.17
P22105 TNXB 0.00271753 -0.51
O95299 NDUFA10 0.00272901 -0.84
Q9NRP0 OSTC 0.00275806 0.76
P10082 PYY 0.00282902 -1.59
P21810 BGN 0.00283401 -0.66
Q8IV08 PLD3 0.00295758 -0.74
P01857; P01859; P01860; P01861 IGHG1; IGHG2; IGHG3; IGHG4 0.00343621 -0.57
P62330 ARF6 0.00343645 0.84
Q03135 CAV1 0.00346186 -0.71
P22309; P35503; P22310; P35504 UGT1A1; UGT1A3; UGT1A4; UGT1A5 0.00349148 -0.87
Q9NSU2 TREX1 0.00349148 -0.76
Q9UKY7 CDV3 0.00355684 0.79
Q7Z4V5 HDGFRP2 0.00360855 0.65
P07357 C8A 0.00372327 -0.62
Q99757 TXN2 0.00377179 -0.73
P13686 ACP5 0.00385765 -0.80
Q8WWA0 ITLN1 0.00392858 -1.30
P62861 FAU 0.00395014 0.51
P57737 CORO7 0.00401004 -0.83
P10606 COX5B 0.00412793 -0.71
Q9Y259 CHKB 0.00420774 -0.59
Q9Y2J8 PADI2 0.00435864 -0.50
O94919 ENDOD1 0.00451988 -0.80
B9A064; P0CG05; A0M8Q6 IGLL5; IGLC2; IGLC7 0.00451988 -0.56
P20039 HLA-DRB1 0.00459324 -0.82  
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Table 3. (continued).
P63167 ^; Q96FJ2 DYNLL1; DYNLL2 0.00468484 0.63
Q9UNN8 PROCR 0.00480932 -0.78
P07099 EPHX1 0.00486543 -0.54
P32322 PYCR1 0.00495977 0.55
Q9P0J0 NDUFA13 0.00534323 -0.60
E7EUF8; E9PFN5 EPB41L3; GSTK1 0.00539222 -0.95
O75531 BANF1 0.00560405 0.73
P26447 S100A4 0.00562754 -0.53
Q9NVJ2 ARL8B 0.00562754 0.50
Q8N752 CSNK1A1 0.00562754 0.52
P40616 ARL1 0.00583778 0.60
Q96GA7 SDSL 0.00583778 -0.82
P01275 GCG 0.00607808 -1.33
P15289 ARSA 0.00633336 -0.57
O75521 ECI2 0.00635218 -0.60
P62158 ^ CALM1; CALM2; CALM3 0.00657472 0.67
P49821 NDUFV1 0.00669319 -0.66
Q15746-5 MYLK 0.00678109 -0.51
Q96BM9 ARL8A 0.00686655 0.54
Q6UX06 OLFM4 0.00696505 1.14
P10153 RNASE2 0.00724902 -0.50
P19075 ^ TSPAN8 0.00837908 0.59
Q8WU39 PACAP 0.00837978 -0.56
P21953 BCKDHB 0.00837978 0.54
O76041 NEBL 0.00837978 0.71
Q9H4G4 GLIPR2 0.00849532 -1.10
P01766; P01767; P01768
(Ig heavy chain V-III region BRO;Ig 
heavy chain V-III region BUT; Ig 
heavy chain V-III region CAM) 
0.00895132 -0.61
Q9NR56 ; Q5VZF2 MBNL1; MBNL2 0.00996176 0.55
P27105 STOM 0.01083127 -0.51
P05387 RPLP2 0.01100903 0.62
Q96AB3 ISOC2 0.01164408 -0.51
O43294 TGFB1I1 0.01198321 -0.57
Q08752 PPID 0.01211602 0.55
Q96DG6 CMBL 0.01289211 -0.51
P61619 SEC61A1 0.01375705 0.59
P56381; Q5VTU8 ATP5E; ATP5EP2 0.01440856 -0.52
P14174 ^ MIF 0.01488262 0.51
P12110 COL6A2 0.01526347 -0.53
Q14956 GPNMB 0.01546825 -0.63
P46952 HAAO 0.01570996 -0.53
Q86VN1 VPS36 0.01610077 0.67
Q96S52 PIGS 0.01626862 -0.61
P15559 ^ NQO1 0.01626862 0.56
O60575 SPINK4 0.01810104 0.77
P55735 SEC13 0.01827155 0.59
P02452 COL1A1 0.01933726 -1.32
P00403 MT-CO2 0.02012815 -0.62
^ Designated candidate cancer biomarkers in the Human Protein Atlas database
* Two or more accession numbers: proteins from the same family or isoforms from the same gene. 
Boldface numbers indicate "epithelial cell signature" proteins. (See text.) 
 
 
When protein abundance iTRAQ ratios for these 212 proteins were plotted on a 
heat map, adenomas and normal mucosa samples formed two distinct clusters (Figure 
4A).  
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Figure   4. Analysis of the 212 proteins displaying significant tumor-
related dysregulation. 
(A) Hierarchical clustering of iTRAQ abundance ratios (normal vs. 114, adenoma vs. 114) for the 212 
proteins displaying significant adenoma-related dysregulation grouped tissue samples into two discrete 
clusters: adenoma (A) and normal (N). (B) Pearson’s correlation test comparing average fold changes (≥ 
±0.5 log2) for the 212 proteins (red, upregulated; blue, downregulated) in the tissue series with average 
log2 fold changes for the corresponding mRNAs measured in another set of adenoma/normal mucosal 
samples. 
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As shown in Figure 4B, tissue expression levels for the 212 dysregulated proteins 
showed good correlation (r = 0.74, P < 0.001, 95% CI: 0.67 - 0.79) with those of 
mRNAs for the same genes (measured by our group in another set of colorectal 
adenomas) (26). 
Table 4 lists the biological processes that were over-represented in this set of 
proteins. At the top of this list was xenobiotic metabolism, a process already linked with 
adenoma formation on the basis of enrichment studies of transcriptomic datasets 
conducted by our group (32). Three of the dysregulated proteins involved in this 
process (CYP2S1, NQO1, and GSTP1) displayed upregulated expression in 
adenomas, but most were characterized by tumor-related downregulation (ADH1B, 
ADH1C/ADH1A, UGT1A9/UGT1A6, UGT1A1/UGT1A4/UGT1A3/UGT1A5, 
UGT1A7/UGT1A8, UGDH, MAOA, SULT1A3/SULT1A1, PAPSS1/PAPSS2, UGP2). 
Network-building analysis revealed that all these proteins were linked by sub-networks 
controlled by cancer-associated transcription factors, such as SP1 or, less frequently, 
MYC, HIF1A, or TP53 (Supplementary Figure 3). As noted in Table 4, a very similar 
picture emerged when gene ontology enrichment was also analyzed in a larger set of 
621 dysregulated proteins selected with less stringent criteria (q value cut-off ≤ 0.2; 
average log2 fold change ≥ ± 0.5). 
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Table 4. Gene ontology (GO) biological processes enriched in the set of 
212 proteins whose expression displayed adenoma-related 
dysregulation (see Table 3). 
GO ID GO Term Annotated * Significant * Up in adenomas
Down in 
adenomas Expected * elim P value *
GO:0006805 xenobiotic metabolic process † 64 21 3 18 2.8 1.70E-09
GO:0006958 complement activation, classical pathway † 74 17 0 17 3.24 1.10E-08
GO:0051552 flavone metabolic process † 5 5 0 5 0.22 1.50E-07
GO:0052696 flavonoid glucuronidation † 5 5 0 5 0.22 1.50E-07
GO:0052697 xenobiotic glucuronidation † 5 5 0 5 0.22 1.50E-07
GO:0042573 retinoic acid metabolic process † 9 6 0 6 0.39 5.00E-07
GO:0045087 innate immune response § 249 33 4 29 10.91 7.80E-07
GO:0031295 T cell costimulation § 34 10 0 10 1.49 1.10E-06
GO:0030199 collagen fibril organization  † 8 5 0 5 0.35 7.80E-06
GO:0001501 skeletal system development 54 11 1 10 2.37 1.60E-05
GO:0070208 protein heterotrimerization † 5 4 0 4 0.22 1.70E-05
GO:0050852 T cell receptor signaling pathway § 48 10 0 10 2.1 3.20E-05
* Annotated: proteins in TopGO Background list; Significant: 212 dysregulated proteins of Table 3; Expected: Number of 
signifcant proteins expected to map to the GO term if the significant proteins were randomly distributed over all GO terms. elim P 
value: P value from the elim method (ref. no. 25). Only processes with an elim P value < 1.0E-04 are shown.
Table 4.  Gene Ontology (GO) biological processes enriched in the set of 212 proteins whose expression displayed 
adenoma-related dysregulation (see Table 3).
†"Processes that were also among the top 12 processes displaying enrichment in a larger set of 621 dysregulated proteins 
selected with less stringent criteria (q value ≤ 0.2; average log2 fold change ≥ ± 0.5; see Results section for details); § processes 
that shared a common GO ancestor (immune system process) with the process displaying most significant enrichment in the 
larger set. 
 
 
The expression levels of 111 (52%) of the 212 proteins that were differentially 
expressed in adenomas were also quantified in cell lines (those shown in boldface in 
Table 3 and referred to hereafter as the "epithelial cell signature" proteins). Almost half 
(n=51, 46%) showed directionally similar tumor-related dysregulation in both analyses. 
Since cell-line studies were conducted with only one non-cancerous line, these findings 
obviously require further validation. They suggest, however, that these 51 proteins are 
indeed expressed in the epithelial cells of normal colorectal tissues and that their 
expression is dysregulated in the epithelial cells of adenomas.  
5.1.3.3 Upregulation*of*SORD*expression*and*activity*in*colorectal*adenomas*and*cancer*cell*
lines*
Sorbitol dehydrogenase, a key enzyme in the polyol pathway, was one of the 
most significantly upregulated proteins in our colorectal adenomas (based on q values) 
(Table 3). Because its increased expression could have metabolic consequences with 
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potential impact on tumorigenesis, we performed Western blotting and immunostaining 
studies to validate this finding. The reliability of the anti-SORD antibody we had chosen 
was first tested on protein extracts from the six colorectal epithelial cell lines (Figure 
5A).  
The tumor-related log2 fold changes detected with Western blotting were 
substantially larger than those documented with iTRAQ (2 to 6 vs. 0.4 to 1, 
respectively) (Figure 5B), which was not surprising since iTRAQ has been reported to 
underestimate protein abundance (33). However, the relative quantities of SORD found 
with the two methods were fully consistent. As for the 21 adenomas, the elevated 
SORD expression documented in these tumors by iTRAQ (Figure 5C) showed good 
correlation with the increased SORD mRNA levels we had previously found in other 42 
lesions of this type (26) (Figure 5D). Western blot analysis of four randomly selected 
adenoma/normal mucosa pairs from the present series revealed obvious upregulation 
of SORD expression in all four tumors although the magnitude of the increase varied 
(Figure 5E).  
SORD activity was then assayed (see Experimental procedures) to see how it 
corresponded with the enzyme expression levels reported above. As shown in Figure 
5F, the results of cell line assays were fully consistent with the Western blotting data: 
SORD activity was 7 times higher in HT29 than in HCEC cells, and more limited 
upregulation was found in SW480. High correlation between enzyme activity and 
protein level was also documented for three randomly selected adenoma/normal 
mucosa pairs (Figure 5F). 
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Figure  5. Significantly upregulated SORD expression and activity in 
colorectal cell lines and adenomas. 
(A) Tumor-related upregulation of sorbitol dehydrogenase (SORD) in colon cancer cell lines was 
confirmed with Western blotting. The SORD dysregulation trend was identical to that observed with 
iTRAQ-based MS/MS, although when immunoblot results were quantified (B), the log2 fold changes were 
over five times greater than those documented in the iTRAQ study. (C) SORD protein expression 
(iTRAQ analysis) in 21 normal mucosa/adenoma tissue pairs. (D) SORD mRNA expression in 42 other 
normal mucosa/adenomas from a previous study by our group (26). Error bars indicate the means and 
95% confidence intervals. (E) Western blots showing tumor-related upregulation of SORD expression in 
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four randomly selected adenoma [A] /normal mucosa [N] tissue pairs of the 21 shown in panel C (see 
Table 1 for sample descriptions). (F) SORD activity also displayed tumor-related upregulation in cell 
lines (HT29 and SW480 versus HCEC cells) and tissues (adenomas versus normal mucosa). Columns 
show mean enzyme activity measured in at least two replicates; error bars indicate standard deviations 
from means. The Western blot beneath the graph shows SORD levels measured in the extracts used for 
the enzyme activity assays. 
MS and Western blotting findings were further validated with immunostaining 
studies, as shown in Figure 6. Cytoplasmic SORD staining was evident in the colon 
cancer cell line HT29 but weaker or even absent in normal epithelial HCEC cells 
(Figures 6A and 6B). As for colorectal tissues, SORD cytoplasmic expression was 
limited to the bottom of the normal epithelial crypts (Figures 6C, 6D, and 6E), but its 
expression was markedly increased in adenomatous and cancerous glands (Figures 
6F - 6I). These findings suggests that SORD is likely to be expressed in proliferating 
cells, although it was largely absent in HCECs, which undergo regular proliferation in 
vitro. Furthermore, nuclear localization of SORD was noted in some adenomatous 
crypts (Supplementary Figure 4A and C), and the cells in question were almost always 
negative for the well-known proliferation marker Ki-67 (Supplementary Figure 4B and 
D). This mutually-exclusive staining pattern was also observed in normal crypts of the 
ileum where SORD, interestingly, appeared to be expressed in the nuclei of putative 
stem cells (Supplementary Figure 4E and F). 
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Figure   6. Anti-SORD immunostaining of colorectal cell lines and tissues. 
Consistent with proteomic data, SORD expression was (A) negligible or absent in HCECs,  but (B) 
clearly expressed in the cytoplasm of HT29 cells. (C) In normal colorectal mucosa, SORD expression 
was limited to the lower portion of the epithelial crypts, where stem cells and highly-proliferating cells are 
located. Higher magnification views show staining at (D) the base vs. (E) mouth of colonic crypts. (F) 
and (G): Its expression was markedly increased in adenomatous glands (red arrowheads) compared 
with normal crypts (green arrowheads). Panels (H) and (I) show abundant expression of SORD in a 
large adenoma and in a cancer, respectively.  
5.1.3.4 Polyol*pathway*enzyme*expression*and*metabolite*levels*in*cell*lines*and*tissues.*
 We then examined the state of the polyol pathway (Supplementary Figure 5A) in 
colorectal cell lines and tissues. As shown in Supplementary Figure 5B, immunoblot 
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studies revealed decreased AKR1B1 expression in HT29 (vs. HCEC cells) and 
adenomas (vs. corresponding normal mucosal samples), while SORD expression and 
that of KHK were upregulated in tumor cells and tissues. As for the metabolites 
(Supplementary Figure 5C), D-glucose levels were significantly decreased in 
adenomas. Less dramatic changes were observed in the levels of D-sorbitol and D-
fructose, which both showed a tendency to decrease in tumor tissues.  !
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5.1.4 DISCUSSION  
  Although a number of proteomic studies have comparatively analyzed 
different types of colorectal tissues, precancerous lesions have been considered in 
only three (21, 34, 35), and in two of these (21, 34), the number of adenomas analyzed 
was very small (≤ 4). The study by Lam et al. (35) is the only one that compared 
protein expression in a relatively large number (n=20) of paired adenoma and normal 
mucosa samples. They used 2-DE to resolve over 1000 proteins in the two tissue 
groups, and those displaying differential expression were then analyzed with MALDI-
TOF/TOF MS. MS/MS validation pinpointed four proteins (ANXA3, S100A11, EIF-5A1, 
S100P) whose expression in adenomas was significantly increased. Using MS with 
iTRAQ 8-plex peptide labeling and OFFGEL fractionation allowed us to quantitatively 
compare protein expression in 30 colorectal adenomas and paired samples of normal 
mucosa, and to investigate low-abundance proteins that cannot be evaluated with 2-
DE-based proteomics. All in all, 4325 non-redundant protein families were quantified in 
our colorectal tissues (25% of which were identified in all 60 samples) (Table 2). And 
the 212 proteins we flagged as being significantly dysregulated in adenomas included 
three of the four proteins identified by Lam et al. (upregulation of the fourth, EIF-5A1, 
failed to meet our stringent criterion for significance) (Table 3).  
The cell types in which these proteomic changes occur is of obvious interest since 
colorectal cancer arises from the epithelial component of the colorectal mucosa. 
Although our findings are preliminary and will naturally require validation in future 
studies, 51 of the 212 proteins listed in Table 3 were "epithelial cell signature" proteins 
and showed directionally similar expression changes in colon cancer cell lines vs. 
HCEC. It therefore seems likely that their dysregulated expression in adenomas is a 
feature of neoplastic transformation of colorectal epithelial cells. However, epithelial-
stromal cell interactions can also play important roles in tumorigenesis (20). Our 
approach also allowed us to identify 101 proteins displaying adenoma-related 
dysregulation that were probably of stromal-cell origin since they were not expressed in 
any of the six epithelial cell lines we examined (Table 3). These proteins were mainly 
involved in immune-related processes (immune response, complement activation, T 
cell co-stimulation), which are usually not represented in colon epithelial cell lines. 
Their expression changes are likely to have important effects on the microenvironment 
of an epithelial-cell tumor.  
Our search for potential biomarkers of early-stage colorectal tumorigenesis 
focused exclusively on the 76 proteins whose expression was significantly upregulated 
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in adenomas. According to the Human Protein Atlas (HPA) database (36), 69 (91%) of 
these have cancer-related features, and 16 of the 69 are already classified as 
candidate cancer biomarkers (Table 3). The HPA database contains information on 
protein expression in normal and cancer tissues, but not in those regarded as 
precancerous. The overlap between our findings and those of the HPA suggest that 
most protein expression changes identified thus far in colorectal adenocarcinomas are 
probably already detectable in the benign precursors of these lesions.  
Supplementary Figure 6 shows the expression profiles of the 10 proteins that 
were most markedly upregulated in adenomas. This group comprised two of the four 
proteins identified by Lam et al. (35) as significantly overexpressed in adenomas. 
Annexin A3 (ANXA3), for example, is at the top of our list (based on q values) (Table 
3). An angiogenic factor that induces VEGF production via the HIF-1 pathway (37), 
ANXA3 belongs to a family of calcium-dependent, phospholipid-binding proteins 
involved in diverse biological processes, including signal transduction, inflammatory 
responses, membrane organization, and the regulation of cellular growth (38, 39). 
Dysregulated ANXA expression is also a common feature of colorectal cancer (39) and 
most other cancers as well (40). S100A11 expression was also increased in these 
tumors, which is consistent with earlier reports (41). The cytosolic S100 proteins 
interact directly with peptides on the N-terminal domain of annexins (38, 42), and like 
the annexins, they also have diverse intracellular and extracellular functional roles (43).  
Among the other top ten proteins displaying adenoma-related upregulation is 
LDHA / LDHB. Their expression levels were not measured separately, but LDHA is 
presumably responsible for the increased expression observed in our adenomas. 
LDHB expression is in most cases epigenetically silenced in colon cancer cells (44, 45), 
whereas LDHA is over-expressed, and its activity is maintained via the oncogenic 
tyrosine kinase FGFR1 (46). LDHA is a key player in the reversible conversion of 
pyruvate to lactate during aerobic glycolysis, a typical feature of cancer cell metabolism 
first described by Otto Warburg (47). The sodium- and potassium-coupled chloride 
cotransporter, SLC12A2, is expressed on the basolateral membrane of the normal 
colon epithelium, where its recruitment and activation are regulated by calcium and 
cAMP. Loss of SLC12A2 leads to impaired chloride secretion in the intestine (48, 49), 
but to our knowledge, there are no published data linking this protein to colon cancer. 
The fifth markedly over-expressed protein is SET, one of the five proteins that make up 
the inhibitor of acetyltranferases (INHAT) complex. Two other INHAT components, 
APEX1 and ANP32A/ANP32B, were also upregulated in adenomas (albeit to a lesser 
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extent than SET) (Table 3). These changes are noteworthy because INHAT binds 
directly to histones, preventing their acetylation by histone acetyl transferases (50-52), 
and loss of histone acetylation is a crucial step in gene silencing (53, 54). Thus far, 
INHAT’s role in cancer has not been widely investigated, but overexpression of the 
complex components has been observed in serous epithelial ovarian cancer (55). The 
upregulated expression of PPA1/PPA2 in our adenomas might play various roles in 
colorectal tumorigenesis since these proteins are key players in the synthesis of fatty 
acids, nucleotides, amino acids, and other essential molecules (56). The 
phosphoprotein nucleolin (NCL), an essential protein for proliferating cells (57), 
appears to regulate several steps in the biogenesis of ribosomes, including 
transcription, ribosome assembly, and the processing of precursor ribosomal RNA (58-
60), all of which might be instrumental to adenoma growth. As for OCIAD2, strong 
immunoreactivity for this protein has been reported in early-stage adenocarcinomas of 
the lung and in ovarian cancers (61-63), but there are no published data linking it to 
colorectal tumorigenesis. In contrast, the secreted protein REG4, which promotes 
mitosis and enhances the motility and invasiveness of colon cancer cells, is strongly 
expressed in these cells and in the serum of patients with colorectal cancer (64-66).   
The final protein characterized by marked adenoma-related upregulation was 
SORD, a key enzyme in the polyol metabolic pathway. It was selected for validation 
studies, because although aberrant polyol pathway activity has been implicated in 
diabetic complications (67-70) and myocardial ischemia (71), the role of SORD in 
tumorigenesis was completely unknown. During the execution of this study, however, 
upregulated SORD expression was reported in prostate cancer (72) and in colorectal 
adenomas (21), and these findings strengthened our resolve to characterize this 
phenomenon in colorectal tumorigenesis.  
Upregulated SORD expression and activity in adenomas (Figure 5) would 
enhance the production of fructose (see schematic of Supplementary Figure 5A), 
thereby increasing the generation of triose sugars and diacylglycerol (intermediates in 
the glycolytic and lipid signaling pathways, respectively). Fructose is also several times 
more effective than glucose in promoting intracellular non-enzymatic glycation (73-75), 
and advanced glycation end products may contribute to the vascular complications of 
diabetes and other pathologic conditions (67, 76-78). Whether these fructose-driven 
metabolic events play a role in the development of adenomas is unclear, but the polyol 
pathway was very active in the adenomatous cells we examined. This activity was also 
reflected by the concomitant increase of the expression of KHK (Supplementary Figure 
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5B), the enzyme that catalyzes the transformation of fructose to fructose-1-P, 
downstream from the polyol pathway.  
The effects of these enzymatic changes on sorbitol and fructose concentrations in 
adenomas need to be investigated in larger tissue series, but our preliminary data 
suggest that the levels of both are slightly decreased in these lesions (Supplementary 
Figure 5C). In contrast, our adenomas exhibited dramatically reduced concentrations of 
glucose, the initial substrate in the polyol pathway (Supplementary Figure 5C). 
Adenoma-related dysregulation was also noted in the expression of AKR1B1, the 
enzyme that converts glucose to sorbitol (Supplementary Figure 5B). Exploitation of 
the polyol pathway to divert carbon from glucose to other energy intermediates might 
provide adenomatous cells with a selective advantage over normal cells. This pathway 
might prove to be another means of tumor-related glucose consumption in addition to 
the well-known glycolytic and pentose phosphate pathways (Supplementary Figure 5A). 
Advanced cancer cells consume glucose at a much higher rate than normal cells, and 
much of their energy is generated by aerobic glycolysis rather than by oxidative 
phosphorylation of glucose in the mitochondria (i.e., the Warburg effect) (79). The 
predominantly glycolytic phenotype of cancer cells results in low glucose levels and 
high concentrations of lactate (47, 80, 81). The relative concentrations of lactate in the 
three adenomas we tested were significantly higher than those found in matched 
samples of normal mucosa (Supplementary Figure 5C), indicating that the Warburg 
effect is already evident in precancerous colorectal lesions. Studies involving metabolic 
flux analysis to monitor the fate of isotopic tracers in in vitro and in vivo systems would 
provide further insight into the biological roles of the polyol pathway in tumorigenesis.  !!!!!
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5.1.6 SUPPLEMENTARY TABLES  
Supplementary table 1 and 3: Due to file size, the links to these tables are 
available in "Appendix" 
Total assigned
 With iTRAQ  
modification               
(N-term,Y, K)
 Without iTRAQ 
modification              
(N-term,Y,  K)
Tissue experiment 1 33935 32222 1713 95
Tissue experiment 2 33916 31737 2179 94
Tissue experiment 3 38708 38193 515 99
Tissue experiment 4 41273 40763 510 99
Tissue experiment 5 48340 47532 808 98
Tissue experiment 6 35650 33789 1861 95
Tissue experiment 7 29283 28558 725 98
Tissue experiment 8 28157 27133 1024 96
Tissue experiment 9 32311 30612 1699 95
Tissue experiment 10 33631 30018 3613 89
Cell line Experiment 34961 33361 1600 95
Supplementary table 2.  Mascot protein search summary for iTRAQ labeling efficiency
iTRAQ experiments on 
colorectal tissues and in 
cell lines
iTRAQ labeling 
efficiency        
(%)
PSMs*
* Assigned Peptide Spectra Matches (PSMs) after exclusion of decoy and contaminant hits.  
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5.1.7 SUPPLEMENTARY FIGURES 
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Supplementary figure 1. Hierarchical clustering analysis of colorectal 
tissue proteomics data (Ward method).  
Two distinct clusters emerged: one containing mainly adenomas (A, red bar), the other consisting mostly 
of normal mucosa samples (N, black bar). The 18 samples in the third cluster (orange bar) comprised 
nine normal/adenoma tissue pairs, which had been processed in the same labeling and shot-gun run 
batch. These samples were considered sub-standard since their clustering and sub-clustering appeared 
to be experiment specific. The samples analyzed in the same experiment (Exp) have the same color 
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Supplementary figure 2. Significance of protein expression changes.  
Histogram comparing average log2 fold changes (adenoma vs. normal, pink bars) for proteins identified 
in the 21 paired tissue samples (7 iTRAQ experiments) with average log2 ratios (reference 113:reference 
114) for the same proteins in the 7 reference standards.  Seventeen percent of the fold changes 
observed in the tissue samples (vs. only  5.3% of those in the reference standards) exceeded the 
experimentally defined threshold of ± 0.5 log2 (± 1.4 in linear scale) (sections indicated with horizontal 
black arrows). 
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Uzozie A. et al., Supplementary Figure 3
 
Supplementary figure 3. Network analysis of dysregulated proteins 
involved in xenobiotic metabolism.  
Transcription regulation pathways connecting the 21 proteins listed in the GO xenobiotic metabolism 
category were investigated using Metacore's Shortest Paths algorithm (GeneGo, Inc., St. Joseph, MI, 
USA). The transcription factors are represented by red symbols and localized in the nucleus. The 
functions of the 21 proteins are regulated by SP1 and other known cancer-related transcription factors, 
such as HIF1A, TP53, and MYC. Although HNF4 had a large number of connections, most of them were 
unspecified. Biological effects are indicated by green (activation), red (inhibition), and gray (unspecified) 
lines, with  arrows specifying the direction of the interaction. Red and blue circles represent proteins that 
displayed adenoma-related up- and downregulation, respectively, in our study. 
 
!! 97!
Uzozie A. et al. Supplementary Figure 4
SORD MKI67 (Ki-67)
A B
C D
E )
 
Supplementary figure 4. Nuclear SORD and Ki-67 immunostaining in 
colorectal adenomas and normal ileal mucosa.  
(A and C) Nuclear SORD staining was observed in certain crypts from two different colorectal adenomas, 
and (B and D) the stained cells were almost invariably negative for Ki-67 nuclear staining (arrowheads). 
(E) This pattern was also observed in sections of normal ileal crypts, where nuclear SORD staining was 
limited to the stem cell compartment at crypt bases (arrows; intermingled with Paneth cells), whereas (F) 
Ki-67 staining was restricted to rapidly proliferating cells in the next compartment, closer to the mouth of 
the crypt. 
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Supplementary figure 5. Enzyme expression and metabolite levels in the 
polyol and related pathways during colorectal tumorigenesis.   
(A) The polyol pathway for sorbitol metabolism (depicted in red) and related metabolic pathways (in 
black).  (B) Western blotting documented dysregulated expression of the polyol pathway enzymes, 
AKR1B1 and SORD, and of KHK in colorectal adenomas, and in HT29 and HCEC cell lines. Specific 
bands are indicated with arrowheads. The AKR1B1 antibodies (upper panel) detected a second, faster-
migrating protein (asterisk) whose levels were also altered in tumor cells but in the opposite direction 
relative to AKR1B1. The identity of this polypeptide is unknown. (C) Adenomas also presented 
decreased levels of D-glucose, D-fructose, and D-sorbitol and increased lactate concentrations (vs. 
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normal mucosa). P values were obtained using two-tailed, paired t-test for total D-glucose (α and β), total 
D-fructose (α and β), D-sorbitol, and lactate. Columns and error bars indicate means and SEMs for 
levels measured in three adenoma/normal mucosa pairs. 
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Supplementary figure 6. Proteins upregulated in adenomas.  
Log2 expression intensity for the 10 proteins displaying the most significant upregulation in adenomas 
(Table 3). iTRAQ measured protein abundance ratios in the normal mucosa (N) and corresponding 
adenomatous lesions (A) of patients is indicated with black dots and squares respectively. The error bars 
represent the mean protein abundance and 95% confidence intervals. 
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5.2 An optimized, large-scale SRM method for the detection and 
verification of early markers of colorectal tumorigenesis 
The second aim of my project was to develop and optimize a large-scale selected 
reaction monitoring (SRM) workflow to verify candidate colorectal tumor markers 
(identified from aim 1). 
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5.2.1 INTRODUCTION 
Non-hereditary colorectal cancer is ranked as one of the major causes of high 
cancer-related morbidity and mortality rates in adult individuals (Siegel et al., 2014; 
2013). Most of these sporadic forms of colorectal cancer occur along an adenoma-
adenocarcinoma-metastasis route (Fearon and Vogelstein, 1990). They begin with the 
formation of benign but precanceorus lesions of the colorectal mucosa (i.e. adenomas). 
With time, these neoplasms progresses from large adenomas, through malignant stage 
I-IV cancers to metastatic conditions (Anon, 2003; Cattaneo et al., 2010; Fearon and 
Vogelstein, 1990). Adenomatuous lesions carry genetic and epigenetic alterations, 
especially in the Wnt-APC-βcatenin pathway, which dysregulate normal cell 
proliferation-differentiation-apoptosis homeostasis, yet do not invade the underlying 
submucosa. They could however acquire further mutations with time, and advance to 
the cancerous state. Disease prognosis and treatment are highly positive when tumors 
are detected at the adenoma or early adenocarcinoma stage (Cunningham et al., 2010; 
de Wit et al., 2012; Siegel et al., 2014), facilitating their complete removal. Therefore, 
the early detection of neoplasms remains the best way to curb the incidence of 
colorectal cancer. Limitations in available screening techniques have hampered major 
progress in curbing this incidence (Ang et al., 2011; Jimenez et al., 2010; Luo et al., 
2013). Endoscopic techniques are invasive, costly and time-consuming, although they 
are highly precise diagnostically and allow prompt removal of early lesions. On the 
other hand, faecal-based tests have low specificity and have been reported to be more 
effective in detecting advanced tumors (Ang et al., 2011; Davies et al., 2005; Song et 
al., 2004). 
Targeted proteomic methods have improved in leaps and bounds over the last 
years (Liu et al., 2013a; 2013b). Some of the reasons for this include improved 
sensitivity, accuracy and reproducibility of these methods over data dependent 
techniques. Selected reaction monitoring (SRM), also known as multiple reaction 
monitoring (MRM), is a highly reproducible and sensitive targeted proteomic technique 
for the quantification of specific proteins in a complex sample background (Lange et al., 
2008; Picotti et al., 2009). An SRM workflow involves the monitoring of predetermined 
peptide coordinates over time to detect and precisely quantify protein abundance. 
These peptide coordinates include selected precursor ions and their corresponding 
fragment ions- collectively called transitions, as well as the elution time (retention time) 
of each transition. SRM experiments are performed in triple quadrupole instruments. 
While the first and third quadrupoles are set as filters to precisely choose pre-
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determined m/z values for the peptide precursor and corresponding fragment ions 
respectively, the second quadrupole acts as a collision cell where precursor ions are 
fragmented at an optimal collision energy. In a single SRM experiment, numerous 
precursor/fragment ion pairs (i.e., transitions) can be monitored across a relatively 
large number of samples. The resulting chromatographic trace comprises information 
on the retention time and signal intensity per transition, and is used to determine target 
peptide abundance. With the addition of known concentrations of high-purity heavy 
isotope-labelled reference peptides to the test sample, absolute peptide abundance 
can be measured. More so, protein abundance can be compared in various samples 
and test conditions since peptide abundance is measured relative to a defined 
concentration of the reference standard (Lange et al., 2008; Parker and Borchers, 
2014; Picotti and Aebersold, 2012). Advances in SRM technology have recently 
incorporated new statistical tools to support the design of SRM experiments and the 
analysis of large quantitative data sets generated from these experiments (Chang et 
al., 2012; Choi et al., 2014; Hüttenhain et al., 2009; 2012; MacLean et al., 2010; Reiter 
et al., 2011; Selevsek et al., 2011; Surinova et al., 2013). For example, open-source 
softwares such as Skyline and MSstats are of benefit in both upstream SRM assay 
development and refinement, and downstream analysis to determine significant protein 
changes across multiple conditions (Chang et al., 2012; Choi et al., 2014; MacLean et 
al., 2010). Also, the implementation of automated, high-confident peptide-scoring 
algorithms such as mProphet has greatly improved the accuracy of protein abundance 
measurements by SRM (Reiter et al., 2011). 
Although numerous candidate cancer biomarkers have been proposed based on 
proteomic studies on colorectal cancer, the on-going search for diagnostic clinical 
biomarkers for this disease is yet to yield promising results (de Wit et al., 2012; Füzéry 
et al., 2013; Jimenez et al., 2010; Luo et al., 2013). This is mainly due to the arduous 
path governing the translation of biomarker discovery to clinical application and the 
lack of appropriate tools to identify and reproducibly quantify biomarker candidates 
over multiple samples.  
The pipeline from biomarker discovery to clinical use involves clearly defined 
phases, discussed extensively in (Rifai et al., 2006), (Kulasingam et al., 2010), and 
(Surinova et al., 2011). In a discovery-based study, researchers comprehensively study 
the entire proteome, genome or metabolome and aim to discover interesting alterations 
characteristic to the diseased state (Domon and Aebersold, 2006; 2010).  Tissue 
samples are usually employed in most discovery phase studies because the 
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concentration of candidate biomarkers is usually highest at the disease site. More over, 
tumor-associated proteins in tissues could subsequently be shed or secreted into the 
blood stream. The preclinical verification phase serves as a bridge between biomarker 
discovery and clinical validation. Biomarker verification entails the development of 
sensitive, reproducible assays to precisely measure protein abundance changes in a 
large number of well-defined sample sets that are representative of the target 
population. The rationale here is to specifically target the tissue-derived proteins of 
interest in large cohorts of plasma samples to determine its clinical and analytical 
performance (Meng and Veenstra, 2011; Surinova et al., 2011). In the validation phase, 
standardized assays are used to determine the performance of the biomarker panel 
and to define the criteria for its application in the clinical evaluation of the disease 
(Surinova et al., 2011). Patient groups are designed retrospectively and the sample 
cohorts are much larger than in the verification phase. The next phase, clinical 
evaluation aims to employ approved state of the art technology to translate the 
outcome of the preclinical investigations to the clinics. And finally in the disease control 
phase, the impact of the biomarker test on the disease burden in the target population 
is assessed.    
Immuno-based tests such as enzyme-linked immunosorbent assays (ELISA) 
remain the preferred preclinical verification technique. In comparison to SRM, ELISA is 
an antibody-dependent technique, which is not ideal when a large number of tumor 
biomarkers are to be tested (Issaq and Veenstra, 2008; Parker and Borchers, 2014). 
Although recent reports show positive correlations between SRM and ELISA protein 
concentration levels, SRM technique was more effective in detecting protein variants 
and isoforms (Parker and Borchers, 2014; Shi et al., 2014). There are huge 
expectations in the proteomics community that targeted proteomic techniques would be 
adopted as standard complementary methods for the clinical verification and validation 
of candidate disease biomarkers. Besides, an increasing number of proteomic-based 
cancer studies have incorporated SRM for the verification of candidate biomarkers 
(Hüttenhain et al., 2009; Lopez et al., 2011; Muraoka et al., 2012; Parker and Borchers, 
2014; Selevsek et al., 2011). These biomarkers are most commonly identified from a 
preliminary discovery phase study.  
Candidate protein markers for colorectal cancer have been sourced largely from 
shotgun data (discovery phase), or predicted based on information from other -omic 
studies (genetic, epigenetic and transcriptomic studies). However, most proteomic data 
sourced this way have been largely from the cancerous lesions. We have earlier 
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reported a comprehensive quantitative shotgun proteomic study on a relatively large 
number of human colorectal precancerous lesions and their matching normal mucosa 
samples (Uzozie et al., 2014). In addition to the novel protein alterations detected in 
these tissues, we observed that over 90% of proteins with adenoma-related 
upregulation have been reported in literature to be associated with tumorigenesis. In 
continuation of our aim to verify putative diagnostic markers representing tumor stages 
along the adenoma-adenocarcinoma route, we proceeded to establish a reproducible, 
targeted assay to profile candidate protein markers from this study in an independent 
large group of colorectal neoplasms, comparative to the normal mucosa. We generated 
reliable SRM assays to uniquely and confidently quantify target proteins differentially 
expressed in early (adenomas) and advanced (adenocarcinomas) colorectal 
neoplasms. In addition to verifying putative tumor biomarkers for colorectal tumors, we 
describe a comprehensive and reproducible SRM workflow that would systematically 
aid the quantitative analysis of potential tumor markers across large cohorts of patient 
plasma samples. 
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5.2.2 EXPERIMENTAL PROCEDURES 
5.2.2.1 Human*tissue*samples*and*cell*lines*
The local ethics committee approved the use of tissue samples, and all samples 
were used in agreement with the Declaration of Helsinki. Human colorectal tissues 
were prospectively collected from patients during colonoscopy, at the Instituti 
Ospitalieri of Cremona, Italy. A coding system was applied to each donor to protect 
human confidentiality. All donors provided written consent to sample collection, testing, 
and data publication. The sample series comprised 19 adenomas and 17 
adenocarcinomas along with their corresponding normal mucosa (total, 72 tissue 
samples (Table 5). Each paired normal sample was collected from the same colon 
segment where the tumor was located, at >2 cm from the lesion. Samples were 
immediately frozen in liquid nitrogen and stored at -80 oC. 
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Table 5. Characteristics of the patients with neoplastic lesions included 
in the study. 
Patient 
number Age Sex
Colon 
segmen
t  
involved
Maximum 
lesion 
diameter 
(mm)
Paris 
classificatio
n # 
Pit pattern 
classification 
º
Microscopic 
appearance
Highest 
degree of 
dysplasia in 
the lesion ▪ 
No. of  
lesions at 
study 
colonoscopy 
∞
No. of 
previously  
excised 
lesions ‡
1 50 F C 30 0 - IIa IIIL TA LGD 1 1
2 72 F A 20 Is IV TVA LGD 1 0
3 66 F S 35 Ip IV TA LGD 1 0
4 78 M R 50 IIa + IIs IV + Vi TVA LGD 1 0
5 58 F R 20 IIa+IIc IIIL -Vi TA LGD 2 0
6 60 M C 30 Is IV TVA LGD 2 2
7 65 M A 40 IIa + Is IV TA LGD 1 0
8 70 F R 20 Is + IIa IV TVA LGD 1 0
9 70 M A 40 Is + IIa IV TA LGD 1 0
10 77 F R 80 IIa+Is IV VA LGD 1 0
11 83 M S 20 IIa+Is IIIL TVA LGD 3 0
12 75 F S 30 IIa+Is IIIL -IV TA LGD 1 3
13 63 M T 30 0 - Is IV TVA LGD 1 0
14 74 F A 80 Is + IIa IV TVA LGD 1 0
15 82 M D 50 Is + IIa IV AV LGD 1 0
16 61 F R 40 Is +IIa II SSA LGD 1 0
17 78 M R 60 IIa + Is Vi - IV TA HGD-ADK 1 1
18 72 F C 45 0 - Is IV TA HGD 1 0
19 58 M D 20 0 - Ip IV TA HGD 2 0
20 83 F C 35 Is IV TVA HGD 1 0
21 58 M S 40 Is IV + Vi TVA ADK 2 1
22 67 F R 40 0 - Is Vn (ADK) ADK 1 0
23 37 M R 60 0 - Is Vn (ADK) ADK 1 0
24 63 M S 80 0 - Is Vn (ADK) ADK 1 0
25 82 M S 65 0 - Is Vn (ADK) ADK 1 0
26 52 M S 60 0 - Is Vn (ADK) ADK 1 0
27 56 F A 65 0 - Is Vn (ADK) ADK 1 0
28 55 M R 70 0 - Is Vn (ADK) ADK 3 0
29 87 F T 70 0 - Is Vn (ADK) ADK 1 0
30 64 F A 60 0 - Is Vn (ADK) ADK 1 0
31 64 M C 70 Is NA (ADK) ADK 1 0
32 88 F A 55 0 - Is Vi (ADK) ADK 1 0
33 67 M T 80 0 - Is Vn (ADK) ADK 1 0
34 64 M R-S 100 0 - Is Vn (ADK) ADK 2 1
35 61 F T 60 0-Is Vn (ADK) ADK 1 0
36 53 F A 50 0-Is Vn (ADK) ADK 1 0
Abbreviations: M, male; F, female; C, caecum; A, ascending colon; T, transversum;  D, descending colon; S, sigma; R, rectum; TA, tubular 
adenoma; TVA, tubulovillous adenoma; VA, villous adenoma;  SSA, sessile serrated adenoma; LGD, low-grade dysplasia; HGD, high-grade 
dysplasia; ADK, Adenocarcinoma; NA, data not available
‡ Total no. adenomas detected and excised during previous colonoscopies. 
# Macroscopic appearance of neoplastic lesions was classified according to Paris Endoscopic Classification.  The Paris Endoscopic 
Classification of Superficial Neoplastic Lesions. Gastrointest Endosc 2003;58(suppl.):S3-S27
º Morphological analysis of colonic crypt patterns according to Kudo's classification. Kudo S, Rubio CA, Teixeira CR, et al. Pit pattern in 
colorectal neoplasia:endoscopic magnifying view. Endoscopy 2001;33;367-7
▪ Low-grade versus high-grade dysplasia as defined by the WHO classification of tumors of the digestive system, editorial and consensus 
conference in Lyon, France, November 6-9, 1999.IARC
∞ This number includes the lesion subjected to the proteomic study
 
 
5.2.2.2 Protein*extraction*from*tissues**
Frozen tissue samples were quickly weighed and homogenized on ice in a 
Wheaton glass borosilicate grinder containing a solution of 100 mM triethylammonium 
bicarbonate (Sigma, St Louis, MO, USA), 1X Complete EDTA-free Protease Inhibitor 
Cocktail (Roche, Mannheim, Germany), 1 M Urea, 5 mM β-glycerophosphate disodium 
salt hydrate, 1 mM sodium orthovanadate, and 5 mM sodium fluoride (Sigma, St Louis, 
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MO, USA). Homogenates were then sonicated with a Bioruptor (Diagenode, Denville, 
NJ, USA) (high power, five 10''/10'' ON/OFF cycles) and centrifuged (16,000 g for 5 
mins at 4 oC). The resulting supernatant containing proteins was collected and stored 
at -80 oC. 
5.2.2.3 Protein*digestion**
For each sample, 50 micrograms of protein was used. Proteins were reduced in 
denaturing buffer with 10 mM DTT at 35oC for 45 min, and alkylated with 50 mM 
iodoacetamide for 1 h at room temperature and in the dark. To terminate the alkylation 
reaction, 50 mM DTT was added, and samples were incubated for 10 min at room 
temperature. Samples were further incubated in sequencing grade endoproteinase 
Lys-C (Roche, Mannheim, Germany) at a final enzyme to substrate ratio of 1:100 for 3 
hrs at 23oC, with constant shaking, and then diluted with 50 mM ammonium 
bicarbonate to a final concentration of 1.4 M urea. Trypsin (sequencing-grade modified 
trypsin; Promega, Madison, WI, USA) digestion was performed at a final enzyme to 
substrate ratio of 1:50, for 15 hrs. Digestion was stopped by adding a solution of 30% 
acetonitrile, 1% trifluoroacetic acetic to a final concentration of 3% acetonitrile, and 1% 
trifluoroacetic acid. Peptide solutions were desalted on 100 mg SepPak C18 column 
(Finisterre, Teknokroma, Barcelona, Spain). Briefly, each column was wet once with 
1000 µL of 100% methanol, washed once with 1000 µL of 80% acetonitrile, and 
equilibrated twice with a solution of 3% acetonitrile and 0.1% trifluoroacetic acid. 
Acidified digests were then loaded and the column was washed twice with 1000 µL of a 
solution of 3% acetonitrile and 1% trifluoroacetic acid. Elution was done once with 500 
µl of 60% acetonitrile and 0.1% trifluoroacetic acid. Peptides were lyophilized in a 
vacuum centrifuge and resolubilized in 50 µl (1:1 v/w) of a solution of 3% acetonitrile, 
0.1% formic acid, and iRT 10x mix (iRT mix was prepared according to the 
manufacturer's protocol; Biognosys AG, Zurich, Switzerland) 
5.2.2.4 Selection*of*target*proteins*and*endogenous*(light)*proteotypic*peptides*
A schematic of the SRM workflow is detailed in Figure 14. The proteins of interest 
were selected based on the results of a quantitative (iTRAQ 8plex) shotgun study on 
human colorectal adenomatous lesions, reported in (Uzozie et al., 2014). The selection 
comprised proteins of the following categories: [1] those with adenoma-related 
dysregulation reported in (Uzozie et al., 2014), [2] those with adenoma-related 
dysregulation reported in (Cattaneo et al., 2011), [3] global standard control proteins 
(also known as housekeeping proteins), [4] proteins predicted to be involved in 
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pathways that [1] are involved in. A total of forty candidates, listed in Table 6, were 
chosen for verification by SRM.   
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Figure 14. Selected reaction monitoring (SRM) workflow employed in this study. 
The different steps from candidate protein selection through SRM assay development and refinement, 
and analysis of scheduled SRM data to identify proteins with significant protein changes in the tissue 
samples studied (see Experimental Procedures for details). 
For each target protein, the corresponding proteotypic light peptides for SRM 
were sourced in three ways (detailed in Figure 14) - [1] iTRAQ 8plex-based quantitative 
shotgun data from our previously reported study (Uzozie et al., 2014), [2] label-free 
shotgun data on a subset of paired tissue samples, and [3] data in Peptide Atlas. Each 
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proteotypic peptide selected was unique for the specified target protein. One hundred 
forty peptides were selected for the 40 protein targets (Table 6). The label free shotgun 
study was necessary to confirm peptide detection in tissue samples because no 
fractionation technique was included for the SRM study in comparison to our previous 
iTRAQ study (Uzozie et al., 2014). Briefly, label-free shotgun analysis was performed 
in an LTQ Orbitrap Velos, (Thermo Fisher Scientific, Bremen, Germany) on 1 
microgram of peptide sample. The acquired spectra were searched against a human 
protein database. Peptides with a protein FDR of <1% were selected for further use. 
Table 6. List of 40 proteins and corresponding 140 proteotypic peptides 
for SRM assay development. 
Uniprot Accession No. Protein Name Peptide Sequence 
O60218  [4] AK1BA HIDCAYVYQNEHEVGEAIQEK 
  
LSDEEMATILSFNR 
    ALGVSNFSHFQIEK 
O60575  [1] ISK4 QWVIALALAALLVVDR 
  
EVPVAAGK 
    QDIQIMK 
O75531  [1] BAF DFVAEPMGEKPVGSLAGIGEVLGK 
  
AYVVLGQFLVLK 
    DTCGANAK 
O76041  [1] NEBL TDPGSIFDLDPLEDNIQSR 
  
TTQQNISAVFYK 
  
GVHPHIVEMDR 
    NIGAFISEAK 
P00338  [1] LDHA DQLIYNLLK 
  
DLADELALVDVIEDK 
    QVVESAYEVIK 
P04406  [3] G3P GALQNIIPASTGAAK 
  
VPTANVSVVDLTCR 
  
LVINGNPITIFQER 
    LISWYDNEFGYSNR 
P07195  [1] LDHB LIAPVAEEEATVPNNK 
  
SLADELALVDVLEDK 
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    IVVVTAGVR 
P07900  [3] HS90A NPDDITNEEYGEFYK 
  
HLEINPDHSIIETLR 
  
DQVANSAFVER 
    APFDLFENR 
P11413  [4] G6PD NSYVAGQYDDAASYQR 
  
LQFHDVAGDIFHQQCK 
  
GGYFDEFGIIR 
    VGFQYEGTYK 
P12429  [1] ANXA3 DYPDFSPSVDAEAIQK 
  
SDTSGDYEITLLK 
  
HYGYSLYSAIK 
    LTFDEYR 
P15121  [4] ALDR SPPGQVTEAVK 
  
MPILGLGTWK 
  
VAIDVGYR 
    TTAQVLIR 
P19338  [1] NUCL FGYVDFESAEDLEK 
  
EVFEDAAEIR 
    GFGFVDFNSEEDAK 
P21695  [4] GPDA IVGGNAAQLAQFDPR 
  
LISEVIGER 
    ELYSILQHK 
P22223  [2] CADH3 EAEVTLEAGGAEQEPGQALGK 
  
DWVVAPISVPENGK 
  
STGTISVISSGLDR 
  
YEAHVPENAVGHEVQR 
  
LTVTDLDAPNSPAWR 
    GLEARPEVVLR 
P25815  [1] S100P YSGSEGSTQTLTK 
    ELPGFLQSGK 
P27695  [1] APEX1 EAAGEGPALYEDPPDQK 
  
QGFGELLQAVPLADSFR 
    LDYFLLSHSLLPALCDSK 
!! 112!
P31949  [1] S10AB ISSPTETER 
  
DGYNYTLSK 
    DPGVLDR 
P35557  [4] HXK4 LVDESSANPGQQLYEK 
  
ASGAEGNNVVGLLR 
    LPLGFTFSFPVR 
P36952  [1] SPB5 DLTDGHFENILADNSVNDQTK 
  
GDTANEIGQVLHFENVK 
  
ILVVNAAYFVGK 
    IIELPFQNK 
P39687  [1] AN32A ELVLDNSR 
    CPNLTHLNLSGNK 
P50053  [4] KHK EELFQLFGYGDVVFVSK 
  
HLGFQSAEEALR 
    LLHSDAFPPPR 
P55011  [1] S12A2 VELPGTAVPSVPEDAAPASR 
  
AFYAPVHADDLR 
  
EGLDISHLQGQEELLSSQEK 
    ITDNELELYK 
P62330  [1] ARF6 QDLPDAMKPHEIQEK 
  
ILMLGLDAAGK 
    FNVWDVGGQDK 
P80188  [1] NGAL TFVPGCQPGEFTLGNIK 
  
VPLQQNFQDNQFQGK 
  
WYVVGLAGNAILR 
    SYPGLTSYLVR 
Q00796  [1] DHSO (SORD) LENYPIPEPGPNEVLLR 
  
KPMVLGHEASGTVEK 
  
VAIEPGAPR 
  
YNLSPSIFFCATPPDDGNLCR 
  
LPDNVTFEEGALIEPLSVGIHACR 
  
AMGAAQVVVTDLSATR 
    EIGADLVLQISK 
Q01105  [1] SET VEVTEFEDIK 
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IDFYFDENPYFENK 
    EFHLNESGDPSSK 
Q15124  [1] PGM5 NYLPNFIQSVLSSIDLR 
  
DGLWAVLVWLSIIAAR 
    VPVYETPAGWR 
Q15181  [1] IPYR AAPFSLEYR 
  
GQYISPFHDIPIYADK 
  
DVFHMVVEVPR 
    DPLNPIK 
Q15293  [1] RCN1 HWILPQDYDHAQAEAR 
  
TFDQLTPDESK 
    YIFDNVAK 
Q15582  [1] BGH3 EGVYTVFAPTNEAFR 
  
GDELADSALEIFK 
    LTLLAPLNSVFK 
Q56VL3  [1] OCAD2 VALAGLLGFGLGK 
  
GAGFGPQHNR 
  
FHFFEDQLR 
    DAHFPPPSK 
Q6UX06  [1] OLFM4 VNLTTNTIAVTQTLPNAAYNNR 
  
GLYWVAPLNTDGR 
    GFSYLYGAWGR 
Q8WUJ3  [2] K1199 TLHPGGMAEGGYFFER 
  
HPWSFLTVK 
  
IWGPGGLDHSGR 
  
TLPIGQNFPIR 
  
STHYQQYQPVVTLQK 
    IFQVVPIPVVK 
Q92688  [1] AN32B ELVLDNCK 
    LPNLTHLNLSGNK 
Q96CX2  [1] KCD12 LGAPQQPGPGPPPSR 
  
DLQLVLPDYFPER 
  
EAEYFELPELVR 
    FNFLEQAFDK 
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Q96IF1  [2] AJUBA GATGGPGDEPLEPAR 
  
DYHFECYHCEDCR 
  
YQDELTALLR 
    SYHPGCFR 
Q9BYZ8  [1] REG4 SNCYGYFR 
    EASTIAEYISGYQR 
Q9C002  [1] NMES1 LITINQQWKPIEELQNVQR 
  
NPEPWETVDPTVPQK 
    TDVILDR 
Q9H2U2  [1] IPYR2 NVTGHYISPFHDIPLK 
  
ILGILALIDEGETDWK 
  
LIAINANDPEASK 
    AFALEVIK 
Q9UKY7  [1] CDV3 LQLDNQYAVLENQK 
  
VQAMQISSEK 
    SLDNFFAK 
   [1] Proteins with adenoma-related dysregulation reported in (Uzozie et al., 2014). 
[2] Proteins with adenoma-related dysregulation reported in (Cattaneo et al., 2011). 
[3] Global standard control proteins (also known as housekeeping proteins). 
[4] Proteins predicted to be involved in pathways that [1] are involved in. 
 
 
5.2.2.5 Synthetic*isotopeDlabelled*(heavy)*reference*peptides*for*SRM*assay*library*
Heavy isotope-labelled reference peptides were purchased from JPT Peptide 
Technologies GmbH (Berlin, Germany). Each heavy peptide had an identical sequence 
to the corresponding light peptide, but its C-terminal lysine or arginine was fully labelled 
with 15N,13C respectively. A pool of all heavy peptides (with known concentration of 
each peptide) in the sample matrix solution was prepared and analyzed on an LTQ 
Orbitrap Velos (Thermo Fischer Scientific, Bremen, Germany) by nanoLC-MS/MS. 
Mascot output .dat files were imported into Skyline and used to generate the spectral 
library for creation of SRM transitions. These high purity peptides were also used to 
optimize our SRM assay.  
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5.2.2.6 SRM*assay*development*and*scheduled*SRM*analysis*
SRM assay development was performed on a TSQ Vantage Triple Quadrupole 
Mass Spectrometer (Thermo Fischer Scientific, Bremen, Germany), using a sample 
mixture containing known amounts of each heavy isotope-labelled peptide and 
unscheduled SRM methods generated from the spectral library. A preliminary SRM-
transition list was created from the spectral library in Skyline and up to six fragment 
ions were selected for each precursor ion.  
Chromatograms from unscheduled SRM runs were imported into Skyline, and a 
maximum of four best performing transitions was selected for each peptide. Retention 
times from unscheduled runs were extracted and used to calculate iRT values (Escher 
et al., 2012) for each peptide in Skyline.  
For scheduled SRM runs, iRT peptides were used to calibrate the retention time 
of each target peptide (Escher et al., 2012). An initial scheduled SRM method was then 
exported for parameter optimization. Individual parameters such as light peptide 
contamination of reference mixture, collision energy, dwell time, and predicted 
retention time were optimized for each transition. Retention time scheduling for all 
transitions was done according to Skyline scheduling predictions. A window of ± 2.5 
min was used to schedule all transitions. The finalized transition list consisted of 600 
transitions. Each protein had at least one proteotypic peptide and two to four transitions. 
To aid the detection of low abundant peptides, without comprising the dwell time of 
0.020 s per transition, the 600 transitions were split in two scheduled methods based 
on proteins. The two complete transition lists, including information on peptide 
sequence Q1, Q3, CE and RT window are available in Supplementary table 1 (Method 
1 transitions) and Supplementary table 2 (Method 2 transitions) respectively. SRM 
transitions for the two global standard peptides and iRT peptides were monitored in 
each method, while target proteins were monitored in either the first or the second 
method. 
5.2.2.7 HighDresolution*liquid*chromatographyDtandem*mass*spectrometry*(LCDMSMS)**
Scheduled SRM measurements were performed on a TSQ Vantage triple 
quadrupole mass spectrometer (Thermo Fischer Scientific, Bremen, Germany), 
equipped with nanoelectrospray iononization source, and coupled to a NanoLC Ultra 
2D HPLC system (Eksigent Technologies, Dublin, CA, USA). The instrument method 
was set to SRM acquisition mode, and with the following parameters: a Q1 resolution 
of 0.7 fwhm, a Q3 resolution of 0.7 fwhm, cycle time of 2 s, and dwell time of 0.020 s. A 
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spray voltage of 1.3 keV was used with a heated ion transfer tube set at a temperature 
of 270 oC. Argon was used as the collision gas at a nominal pressure of 1.5 mTorr. 
Chromatographic separation of peptides was performed on an in-house-made frit 
column (150 mm x 75 µm) coupled to a fused silica emitter (100 mm x 75 µm) (New 
Objective Inc., Woburn, MA, USA). Frit columns were packed with reverse-phase C18 
material (AQ, 3 µm 200 Å, Bischoff, GmbH, Leonberg, Germany) and maintained at 
50oC with an automatic heater during all SRM experiments. Peptides were loaded on 
the column from a cooled (4oC) Eksigent autosampler and separated with a linear 
gradient of acetonitrile/water, containing 0.1% formic acid, at a flow rate of 300 nL/min. 
An elution gradient from 5% to 35% acetonitrile in 60 min was used. Four µL of sample, 
corresponding to 1.25 µg peptide mass was injected. To avoid sample carryover, blank 
samples were measured between SRM measurements of paired biological samples.   
5.2.2.8 Sample*randomization*and*blocking*
A block-randomized strategy (Oberg and Vitek, 2009) was employed in our 
experimental design. Based on the experiment phases illustrated in Figure 15, 
adenoma and adenocarcinoma pairs were randomly assigned and a balanced 
allocation of each group was maintained both at the sample preparation and SRM 
analysis phases.  
Protein extraction from samples was randomized based on the tumor type. For 
the 72 samples investigated, total protein from the same number of normal/adenoma 
pair and normal/adenocarcinoma pair were prepared per extraction experiment. The 
digestion of protein extracts from the 72 samples was performed in three groups. One 
random sample pair from each group was digested twice. This resulted in an additional 
6 samples, and a total of 78 samples for scheduled SRM analysis. The order of 
spectral acquisition on the TSQ Vantage was also randomized for each SRM method 
(Figure 15). Sample queue for each method was created using the random function in 
excel and randomization was done based on protein digestion group, protein extraction 
pairs, day of sample processing and SRM data acquisition. Each patient sample was 
analyzed twice for transitions in method 1 and 2, and both SRM methods were 
performed separately. Statistical analysis of SRM data targeted the differences in 
adenoma vs. normal mucosa group and adenocarcinoma vs. normal mucosa group.  
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Figure 15. Description of sample preparation and scheduled SRM 
analysis 
One random sample was digested twice in each group (72 to 78 samples total). SRM transitions in 
Method 1 and Method 2 were monitored in each of the 78 samples spiked with iRT and heavy isotope-
labelled peptides according to a randomized SRM sequence. Evaluation and analysis of the SRM 
spectra was sequencially achieved with mProphet, Skyline and MSstats. (see Experimental procedures 
for details). 
5.2.2.9 Data*analysis*
SRM data analysis was performed according to the scheme shown in Figure 15. 
Peak group identification and peptide scoring were actualized using SpectroDive 
software (Version 5.5.5478.20997, Biognosys AG, Zurich, Switzerland). The data files 
containing SRM spectra acquired for each sample during the scheduled runs, and the 
transition assay list containing specified parameters (see Supplementary table 3) 
served as input files for this analysis. SpectroDive processes the SRM data using the 
assay list of target and reference peptides, and applies extraction and scoring strategy 
incorporated in mProphet (Reiter et al., 2011). mProphet is a fully automated system 
that computes accurate error rates for the identification of target peptides in SRM data 
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sets and maximises specificity and sensitivity by combining relevant features such as 
coelution of endogeneous and reference transitions, peak shape and peak intensities, 
in a probabilistic statistical model. The top-ranked peak groups for each target and 
decoy transition group are then used to estimate the false discovery rate (FDR) as 
described by Reiter et al., (Reiter et al., 2011) and Cscore, as implemented in 
SpectroDive. Only peptides identified with a false discovery rate below 1% and a 
Cscore above 10 in the resulting file from SpectroDive were further processed for 
quantification (Supplementary table 4).  
The output file from SpectroDive (Supplementary table 4), with identified peak 
groups was reviewed in Skyline to confirm transitions, integrate peak groups and 
perform protein quantification. Peptides identified in less than 6 samples based on 
mProphet and Skyline visual analysis were excluded from further processing. Heavy 
and light peak area intensity for all transitions were exported from Skyline and used to 
determine proteins with significant abundance differences in adenomas vs. normal 
mucosa and adenocarcinoma vs. normal mucosa.  
Protein significance analysis was performed with MSstats (MSstats.daily 2.1.6) in 
R statistical package (Chang et al., 2012; Choi et al., 2014). The input file for MSstats 
analysis contained values for Conditon, Bioreplicate, and Run, pre-assigned in Skyline 
according to our experimental design (See Supplementary table 5 and Supplementary 
table 6). Data processing was first performed, transforming all transition intensities into 
log2 values. Next, normalization using global standard proteins was done on the basis 
of the transitions for the two housekeeping proteins (G3P and HS90A). This equalized 
the endogeneous intensities of global standard proteins (i.e. house keeping proteins) 
across all MS runs and applied similar between-run shifts to the remaining 
endogeneous proteins in the experiment. Quantification of protein abundance level and 
testing for differential abundance in the patient groups were performed with the linear 
mixed effect model for SRM workflows utilising heavy isotope-labelled reference 
peptides (Chang et al., 2012; Choi et al., 2014). Calculated P values were adjusted to 
control the FDR at a cut-off of 0.02. Proteins with a P value below 0.02 and a fold 
change larger than 1.2 were considered to be significantly dysregulated in adenoma 
and/or adenocarcinoma in comparison to the normal mucosa. 
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5.2.3 RESULTS 
5.2.3.1 Development*of*SRM*assays*for*candidate*colorectal*tumor*markers*
Our objective was to create a quantitative workflow to detect and measure the 
abundance of tumor biomarkers in colorectal adenomas and carcinomas in order to 1) 
verify tumor markers from our previous shotgun proteomics analysis (Uzozie et al., 
2014), and 2) to establish SRM assays that would be applied on blood samples for the 
diagnosis of these localized colorectal neoplasms. The features of the neoplastic 
lesions are listed in Table 5. Forty target proteins were selected (Table 6). This 
comprised [1] twenty-nine candidates reported in our previous discovery phase study 
to be differentially expressed in colorectal precancerous lesions (Uzozie et al., 2014); 
[2] three candidates with increased gene expression in adenomas (Cattaneo et al., 
2011), [3] two global standard control proteins, and [4] six proteins proposed to be 
involved in the same or related pathways as [1] (Table 6). We included adenomas as 
well as carcinomas since most of the candidate markers we identified in the former 
(Uzozie et al., 2014) have been found dysregulated also in colorectal cancers by others 
(Besson et al., 2011; de Wit et al., 2012; F Lam et al., 2010; Uzozie et al., 2014). 
Furthermore, since the chance of finding blood biomarkers of preinvasive adenomas 
might be lower than that for carcinomas, we intended to test our targets in both types of 
tissue.  
Targeted SRM assays for the 40 selected proteins were developed and optimized 
as illustrated in Figure 14. Most proteotypic peptides for our target proteins were 
identified from an initial study where sample fractionation was performed prior to 
shotgun analysis (Uzozie et al., 2014), and from accessible data in Peptide Atlas. We 
also performed label-free shotgun analysis on unfractionated samples from 5 randomly 
selected colorectal tissues pairs. This was essential to determine the detectability of 
these endogenous peptides in the complex matrix of our unfractionated samples. 
Although sample fractionation facilitates improved sensitivity when combined with 
discovery proteomic workflows, it is not fully compatible with SRM workflows 
(Hüttenhain et al., 2009). This is because additional sample preparation steps can 
introduce variation in abundance measurement. Moreover, the level of sample 
throughput is reduced since the different fractions from each sample have to be 
measured individually. The 140 peptides chosen for our target 40 proteins had the best 
mass spectrometry performance and are listed in Table 6.  
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With the aid of heavy isotope-labelled reference peptides, we created SRM 
assays for 140 proteotypic peptides. Reference peptides with corresponding amino 
acid sequence were synthesized for each endogenous peptide. We generated a 
spectral library with data acquired after shotgun analysis on a mixture comprising all 
heavy reference peptides. At least 4 to 8 transitions per peptide were initially tested in 
an unscheduled analysis on the reference peptide pool. This resulted in peptide 
transitions with optimum mass spectrometry performance and iRT values (Escher et 
al., 2012) for defining scheduled methods to monitor our target proteins. The use of 
heavy isotope-labelled peptides also facilitated the elimination of interfering transitions 
from the endogeneous peptides. We further optimized relevant SRM parameters 
including collision energy, reference peptide spike-in concentration, and dwell time for 
each transition. We successfully created SRM assays for 74 peptides, corresponding 
to 33 proteins and applied these assays to detect and quantify protein abundance in 
tissue samples.  
5.2.3.2 Targeted*SRM*measurement*on*colorectal*tissues*
 An obvious benefit of SRM technique is the ability to perform sensitive and 
reproducible quantitative measurement on several target analytes in multiple samples. 
We utilized our SRM assays to monitor 33 target proteins in 72 colorectal tissues 
samples (Figure 15). The same amount of each heavy peptide was introduced into 
each sample from a pooled reference peptide mixture. In addition to this, iRT peptides 
(Escher et al., 2012) were also added to each tissue peptide sample. Heavy reference 
peptides were used as internal controls during statistical analysis of our SRM data, 
while iRT reference peptides served as internal controls to monitor instrument and 
technical variations during scheduled SRM measurements. Based on precursor and 
fragment ion intensities, at least two to four transitions were selected for each peptide. 
To maintain a minimum dwell time of 0.020 s per transition along the elution gradient, 
we split the 600 transitions in two scheduled methods based on protein number (Figure 
15). Only transitions for iRT peptides and global standard proteins were analyzed in 
both methods. The total number of transitions and all SRM parameters for each 
scheduled method is listed in Supplementary tables 1 and 2 respectively.  
5.2.3.3 Reproducibility*of*SRM*measurement*
Two main categories of variability can affect the sensitivity and validity of SRM 
measurements (Parker and Borchers, 2014). Firstly, pre-analytical variability can occur 
from sources such as sample preparation. And analytical variability could result from 
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undesirable variation in instrument parameters during SRM data acquisition. Our block-
randomized study design (Oberg and Vitek, 2009) ensured complete randomization 
and balance in sample allocation at the sample processing and SRM spectral 
acquisition phases respectively (Figure 15). Protein extracts from a total of 72 tissue 
samples were obtained in a manner that involved the random processing of the same 
number of adenoma and adenocarcinoma pairs per experiment. Spectral acquisition 
for samples pairs was also randomized as described in Experimental Procedure. The 
paired feature for each patient was maintained in our randomized design. In addition to 
controlling for bias due to potentially unknown experimental artifacts during sample 
processing, we minimized confounding effects from instrument variance on our 
measured data and also on the inferred results. We examined our SRM data for 
unwanted bias due to variation in instrument performance.  
First, the measured retention time for each of the 11 iRT peptides monitored in 
the sample background was compared across all the SRM runs. As shown in 
Supplementary figure 7, a retention time shift of less than 1 min was maintained for 
each iRT peptide in all samples analyzed with scheduled SRM. Even though each 
sample was analyzed twice with the two scheduled methods, instrument parameters 
were stable throughout the SRM measurements. 
Next, we investigated the reproducibility of our SRM spectral peak measurements 
for each peptide by comparing the endogenous light to heavy peptide (L/H) peak ratios 
for each peptide monitored in the duplicate digest samples (Supplementary figure 8). 
Three pairs of tumor/normal samples (6 samples) were digested twice (Figure 15) and 
each of the 12 digest samples were analysed separately, according to a randomized 
SRM sequence. For each duplicate digest pair we compared, an R2 value greater than 
0.9 and intercept of approximately 1 was observed, indicating that a highly reproducible 
peak area was achieved for all peptides monitored in each duplicate pair. 
5.2.3.4 Identification*of*peptide*peak*groups*and*corresponding*proteins*
SRM data acquisition on the triple quadrupole instrument was constantly 
monitored in SpectroDive and Skyline. We achieved automated, high-confidence 
identification of peptides using the mProphet statistical tool, implemented in 
SpectroDive. mProphet employs a 'decoy-transition' approach to probabilistically score 
individual features in the SRM peaks and integrates them into a combined discriminant 
score (Cscore) while controlling for the false discovery rate (FDR) (Reiter et al., 2011). 
Decoy transitions are transitions for peptide species that do no exist in the biological 
sample and they function as negative controls. We opted for the synthetic decoy 
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approach because our workflow included heavy isotope-labelled internal standards. 
SRM spectral data files for each sample, and a list of defined parameters for the 74 
endogenous and reference peptides were imported into the SpectroDive user 
workspace.  A comprehensive list of the peptide parameters is detailed in 
Supplementary table 3. For further processing, we selected peak groups with a Cscore 
threshold greater than 10 at a controlled FDR (Qvalue) cutoff of less than 1%. At this 
stringent cutoff, we achieved a sensitivity of 71.48% in confident peak group selection. 
Additionally, 28 target proteins were confidently identified with the 53 peptides that 
satisfied these criteria.  
5.2.3.5 Quantification*of*protein*abundance*in*tissue*samples*
The 53 high-confidence peptide peak groups were initially visualized in Skyline 
using the acquired SRM spectra file. This was necessary to confirm the absence of 
incorrect transitions. More so, a peptide peak group was chosen for protein 
quantification only if the reference groups were observed in each of the 72 samples 
analyzed, and the endogenous groups were detected in at least 6 samples. In addition 
to this, peak groups for the global standard proteins were selected only if both 
reference and endogenous peptides were seen in all samples. The 39 peptides that 
fulfilled these conditions were used to quantify a total of 25 of our protein targets. 
Therefore, we achieved a success rate of 62.5% (that is 25 out of 40) in the 
development of SRM assays to reproducibly and consistently quantify selected 
proteins in colorectal tissues (Figure 16).  
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Figure 16. Target proteins and peptides selected, identified, and 
quantified in colorectal tissues 
Each shaded circle represents the number of candidate tumor peptides and corresponding proteins 
selected for targeted proteomics, the total number identified with our SRM workflow, and the number of 
proteins quantified in normal and neoplastic lesions. Protein number is indicated with *. 
Each protein was quantified with one to three proteotypic peptides 
(Supplementary figure 9). We proceeded with statistical analysis on proteins quantified 
with just one peptide because the proteotypic peptide verified protein identity. Also, the 
corresponding heavy reference peptide was included in all samples to serve as internal 
controls and as a standard reference for the normalization of the endogenous peptide 
intensity. 
5.2.3.6 Verification*of*putative*biomarkers*for*colorectal*neoplasms*by*SRM*
We determined the capacity of the SRM assays developed in this study to monitor 
candidate biomarkers for colorectal cancer in a relatively large group of patient tumors. 
Tumors were stratified into two categories: the early-stage precancerous adenomas, 
and the invasive cancerous adenocarcinomas. With our tests, we demonstrate that 25 
of our candidates are detectable by SRM in unfractionated digests of the tissue 
proteome. We proceeded to confirm that the SRM assays we developed could 
reproducibly quantify the proteins across patient tumor samples and detect protein 
expression changes in tumor and normal mucosa samples.  In total, we monitored 25 
proteins across 72 tissues samples - 19 adenomatous and matching normal mucosa 
samples; 17 adencarcinomas and paired samples of the normal mucosa. We 
confidently identified peptides and proteins detected in the sample groups with 
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mProphet (Reiter et al., 2011) (implemented in SpectroDive) and performed protein 
significance analysis with MSstats (Chang et al., 2012; Choi et al., 2014). 
Proteins with an adjusted P value below 0.02 and a fold change greater then 1.2 
were considered significant. Eighteen proteins showed significant abundance 
differences comparing colorectal adenomas and normal mucosa samples (Figure 17, 
and Table 7). The expression levels of ALDR, APEX1, ARF6, KCD12 and PGM5 were 
significantly lower, while proteins AN32A, ANXA3, DHSO, G6PD, LDHA, NGAL, NUCL, 
S10AB, SPB5, CDV3, IPYR, OLFM4, REG4 were significantly over expressed. A total 
of 17 proteins displayed adenocarcinoma-related protein expression changes. The 
expression of proteins ALDR ARF6, KCD12 and PGM5 were significantly 
downregulated, while that of AN32A, ANXA3, DHSO, G6PD, LDHA, NGAL, NUCL, 
S10AB, SPB5, REG4, AN32B, RCN1 and SET were significantly upregulated (Figure 
17, and Table 7). 
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Figure 17. Quantification of target proteins in colorectal neoplasms 
Protein abundance differences in adenomas (A) and adenocarcinomas (B). Proteins with an adjusted P 
value below 0.02, and a fold change above 1.2 were considered significant. Significantly 
dysregulatedproteins in tumor tissues compared to the matching sample of the normal mucosa are 
highlighted in red (upregulated) and blue (downregulated) dots respectively. 
Table 7. SRM-based quantification of target proteins in colorectal adenomas and adenocarcinomas. 
Protein name Gene name Fold change Adjusted P value Significant Trend reported in Uzozie et al. Fold change Adjusted P value Significant
ALDR AKR1B1 1.24 0.01422872 Yes      Down 1.36 0.00100745 Yes     
AN32A ANP32A 1.25 0.00213412 Yes      Up 1.30 0.00064141 Yes     
ANXA3 ANXA3 1.93 0.00421451 Yes      Up 2.62 0.00016874 Yes     
APEX1 APEX1 1.27 0.00225812 Yes      Up 1.16 0.08251550           No
ARF6 ARF6 1.73 0.00000000 Yes      Up 1.65 0.00000000 Yes     
DHSO SORD 1.91 0.00000000 Yes      Up 1.56 0.00000000 Yes     
G3P_mtd1 GAPDH 1.16 0.00020606       No NA 1.05 0.27636653           No
G6PD G6PD 1.34 0.01887495 Yes      NA 1.65 0.00028178 Yes     
HS90A_mtd1 HS90AA1 1.01 0.87666686       No NA 1.06 0.45145255           No
LDHA LDHA 1.90 0.00000000 Yes      Up 1.78 0.00000000 Yes     
LDHB LDHB 1.06 0.52593138      No Up * 1.10 0.31248696           No
NGAL LCN2 1.81 0.00362583 Yes      Up 2.50 0.00005031 Yes     
NUCL NCL 1.64 0.00000000 Yes      Up 1.75 0.00000000 Yes     
S10AB S100A11 2.71 0.00000000 Yes      Up 2.42 0.00000000 Yes     
SPB5 SERPINB5 7.86 0.00000000 Yes      Up 4.40 0.00000000 Yes     
AN32B ANP32B 1.18 0.03715907      No Up * 1.24 0.01267792 Yes     
CDV3 CDV3 1.55 0.00485012 Yes      Up 1.46 0.02455417           No
G3P_mtd2 GAPDH 1.13 0.00177703      No NA 1.06 0.19298791           No
HS90A_mtd2 HS90AA1 1.02 0.85064932      No NA 1.06 0.45145255           No
IPYR PPA1 1.28 0.00495606 Yes      Up * 1.17 0.10750496           No
IPYR2 PPA2 1.08 0.54662624      No Up * 1.09 0.45145255           No
KCD12 KCTD12 1.39 0.00065986 Yes      Down 1.42 0.00055367 Yes     
OLFM4 OLFM4 1.45 0.01231441 Yes      Up 1.21 0.23544211           No
PGM5 PGM5 2.60 0.00000000 Yes      Down 1.83 0.00027326 Yes     
RCN1 RCN1 1.01 0.94704940      No Up 1.44 0.00050460 Yes     
REG4 REG4 1.96 0.00000001 Yes      Up 1.87 0.00000077 Yes     
SET SET 1.08 0.38705860      No Up 1.37 0.00018142 Yes     
Adenoma vs. Normal mucosa Adenocarcinoma vs. Normal mucosa
Proteins upregulated () or downregulated ( ) in colorectal adenomas and/or adenocarcinomas compared to the normal mucosa. Significantly dysregulated proteins met the cutoff criteria: fold 
change >1.2, adjusted P value <0.02. The global standard proteins were monitored in the two scheduled SRM runs (denoted as _mtd1 and _mtd2) and they consistently show no significant 
changes in expression level. NA indicates proteins that were not selected from Uzozie et al., while indistinguishable isoforms reported in Uzozie et al., are denoted with *.  
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Fourteen (14) proteins displaying significant tumor-related dysregulation had very 
similar fold change pattern in both adenomas and adenocarcinomas (Table 7 and 
Figure 18). Ten of these proteins (AN32A, ANXA3, SORD, G6PD, LDHA, NGAL, 
NUCL, S10AB, SPB5, and REG4) were significantly upregulated in both neoplastic 
lesions compared to the normal mucosa.  
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Figure 18. Fold changes for candidate proteins in adenomas and 
adenocarcinomas 
Fourteen proteins displayed similar direction of fold change in adenomas and adenocarcinomas. Fold 
change cutoff is > +/-1.2 at an adjusted P value < 0.02. Downregulated proteins are denoted with #. 
Excluding G6PD, all quantified proteins were targets from our previous shotgun 
study. Our inability to detect the three proteins (AJUBA, K1199, CADH3) selected 
based on data from a previous gene expression study (Cattaneo et al., 2011) and 
some of the other protein targets could be due to a number of factors. With SRM, the 
limit of detection for low abundance proteins in an unfractionated, complex sample 
background is most often not attained (Kulasingam et al., 2010; Surinova et al., 2011). 
Tissue protein concentration covers a dynamic range over 5 orders of magnitude and 
we did not include additional enrichment or sample fractionation steps to improve the 
detection of low abundance proteins. Furthermore, the endogenous proteotypic 
peptides targeted may be absent in our sample digests. Our protein extraction process 
may have eluded proteins enriched in a specific cellular compartment. 
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5.2.4 DISCUSSION 
This study demonstrates the applicability of SRM technique to quantify putative 
biomarkers for colorectal tumors across multiple patient samples. Over the last decade, 
there have been several proteomic studies on the verification of multiple putative 
biomarkers in colorectal cancer (Fijneman et al., 2012; Hamelin et al., 2011; Han et al., 
2011; Kume et al., 2014; Murakoshi et al., 2011; Xie et al., 2010; Xue et al., 2010) but 
none primarily focused on early stage tumors (de Wit et al., 2012; Jimenez et al., 2010). 
Our approach to investigate both colorectal adenomas and adenocarcinomas provided 
a consistent means to detect protein changes that occur early in colorectal 
tumorigenesis and that are likely to persist during the transformation of adenomas to 
cancerous lesions. 
Literature is vast with numerous candidate biomarkers for colorectal cancer but till 
date, very few of these proteins have been further verified for clinical application (Luo 
et al., 2013; Shi et al., 2011). This is largely due to a lack of robust methods for the 
reproducible verification of candidate tumor markers in multiple samples. Recent 
developments in SRM-based targeted proteomics strongly affirm its capacity to 
complement conventional immunoassay-based techniques and accelerate the 
verification of putative biomarkers in a large number of patient samples (Maiolica et al., 
2012; Picotti and Aebersold, 2012; Surinova et al., 2013). In addition to SRM (Lange et 
al., 2008; Picotti et al., 2009; Picotti and Aebersold, 2012), Sequential Window 
Acquisition of All Theoretical fragment ion spectra (SWATH) mass spectrometry (Gillet 
et al., 2012; Liu et al., 2013a; 2013b) and Parallel Reaction Monitoring (PRM) 
(Peterson et al., 2012) are two recently reported methods with worthy future prospects 
for their application in clinical biomarker discovery and targeted therapeutics.  
The application of proteomics in biomarker research generally involves two main 
phases: a discovery phase to identify promising target analytes and a 
verification/validation phase to determine the suitability of these analytes as markers 
for the tumor(s) of interest in large scale studies. Indeed studies on colorectal cancer 
have yielded potential biomarker candidates (de Wit et al., 2012; Shi et al., 2011) from 
discovery stage studies employing gel electrophoresis and more recently, shotgun 
proteomics (Albrethsen et al., 2010; Besson et al., 2011; F Lam et al., 2010). But most 
studies fall short of verifying identified putative markers to advance their clinical 
application. It has been shown that most research has focused on only a few 
extensively studied proteins solely because the analytical tools for their study are 
available (Edwards et al., 2011).  
!! 129!
We developed SRM assays for 40 proteins (Table 6), most of which have been 
previously reported in a discovery phase study (Uzozie et al., 2014). Without sample 
fractionation and depletion of high abundance proteins we verified promising tumor 
markers for colorectal tumorigenesis by SRM-based quantification of proteins in 
precancerous and cancerous lesions. Protein abundance measurements were 
achieved with the use of heavy isotope-labelled reference standards, and recently 
updated tools (mProphet, Skyline and MSstats) for sensitive and reproducible SRM 
analysis. SRM assays were created in a multistep approach (Figure 14 and Figure 15), 
in which SRM coordinates were first obtained from fragment spectra with heavy 
reference peptides, refined by measuring these peptides in scheduled SRM mode, and 
built into definitive assays for peptide and protein quantification. The positive evaluation 
of the sample preparation protocol and SRM measurements in terms of sensitivity and 
reproducibility (Supplementary figure 7 and Supplementary figure 8) demonstrate that 
optimized SRM assays can be accurately replicated and hence adapted for use in 
various laboratories.  
Among the 40 proteins we developed SRM assays for, 28 were confidently 
detected in colorectal adenomas with stringent peptide scoring thresholds (Cscore 
greater than 10, FDR less than 1%). Most of these proteins had been observed in 
extensively fractionated colorectal tissue samples by mass spectrometry (Uzozie et al., 
2014). It was therefore anticipated that some proteins would not be detected in the 
unfractionated, complex samples for SRM analysis. As shown in Figure 16, 62.5% of 
the selected proteins (25 of 40) were consistently quantified across tissue samples. 
The direction of abundance changes for most proteins with tumor-related dysregulation 
(Figure 17 and Table 7) was consistent with the discovery phase results that were 
based on iTRAQ 8plex shotgun proteomics (Uzozie et al., 2014). Literature review 
suggests that none of the proteins we detected with significant abundance changes in 
colorectal neoplasms (Figure 17 and Figure 18) have been validated in clinical 
biomarker studies (de Wit et al., 2012; Jimenez et al., 2010; Kim, 2009; Luo et al., 
2013). Based on discovery proteomic studies performed on clinical material (human 
tissue, plasma, serum, and faeces) from colorectal cancer patients, a number of these 
proteins have been reported to show differential expression levels in carcinomas when 
compared to the normal mucosa (Besson et al., 2011; Conrotto et al., 2008; de Wit et 
al., 2012; F Lam et al., 2010; Friedman et al., 2004; Jimenez et al., 2010; Kim et al., 
2006; Luo et al., 2013; Shi et al., 2011; Uzozie et al., 2014; Watanabe et al., 2008).  
Our SRM analysis identified 10 proteins, consisting of AN32A, ANXA3, SORD, 
G6PD, LDHA, NGAL, NUCL, S10AB, SPB5, and REG4, which were significantly 
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upregulated in colorectal adenomas and adenocarcinomas compared to the normal 
mucosa (Figure 17 and Figure 18). Even though proteins SET and RCN1 were not 
significantly overexpressed in adenomas, adenocarcinomas displayed significant 
elevated levels for both proteins in comparison to normal mucosa samples.  
Examination of documented reports indicates that the 10 proteins with significant 
abundance changes in early and late neoplastic lesions of the large bowel are involved 
in processes that could contribute to tumorigenesis and progression of cancer. And 
three of them (LDHA, SORD, G6PD) are indicative of metabolic reprogramming to 
enable robust biosynthesis and antioxidant defence. SET and AN32A are often co-
isolated and are reported to be parts of a protein complex involved in chromatin 
remodelling through the inhibition of histone acetylation (Seo et al., 2001; Shi et al., 
2014). Depending on the nature of intracellular signals, SET and AN32A containing 
complex may either stimulate or silence gene transcriptions (Cervoni, 2002; Seo et al., 
2002; Shi et al., 2014). Regarding cell proliferation, SET could either positively regulate 
cell cycle by activating cyclin E/cdk2 or suppress cell proliferation by inhibiting the ERK 
pathway (Estanyol et al.; Fukukawa et al., 2005; Shi et al., 2014). The overexpression 
of LDHA in adenomas and adenocarcinomas is representative of increased pyruvate 
metabolism, which is further associated with increased glucose metabolism via aerobic 
glycolysis. This established alteration in metabolism is further supported by discoveries 
that cancer-associated genes regulate various enzymes involved in glucose 
breakdown (Hsu and Sabatini, 2008; Koppenol et al., 2011; Sillars-Hardebol et al., 
2012; WARBURG, 1956; Ward, 2012). For example LDHA is activated by HIF1 
(Koppenol et al., 2011). SORD is a metabolic enzyme involved in the polyol pathway. 
We recently reported evidence of a dysregulated polyol pathway during colorectal 
cancer carcinogenesis in a discovery phase study on colorectal adenomas (Uzozie et 
al., 2014). This SRM data also concurs with our previous report on the other enzyme of 
the polyol pathway, ALDR (Table 7), which we found to be downregulated in 
adenomatuous lesions (Uzozie et al., 2014). G6PD is the rate-limiting enzyme of the 
pentose phosphate pathway (PPP). While G6PD may be dispensable for pentose 
synthesis, it is crucial for cellular defence against redox-stress-induced apoptosis (Fico 
et al., 2004; P P Pandolfi, 1995). NUCL is a highly phosphorylated multi-functional 
protein located in the nucleolus. It's expression is linked to the growth rate of the cell, 
and a loss of NUCL expression has been shown to occur in differentiating cells 
(Bicknell et al., 2005). The potential functions of the secreted protein, REG4, include 
cell proliferation, migration, invasion, and resistance to apoptosis (Rafa et al., 2010; 
Violette et al., 2003). Its expression is also regulated by signalling events linked to 
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known tumorigenic pathways (Beelen Granlund et al., 2013; Rafa et al., 2010; Violette 
et al., 2003). ANXA3 is considered to be a novel angiogenic factor that induces 
vascular endothelial growth factor production through the HIF-1 pathway (Mussunoor 
and Murray, 2008; Park et al., 2005). Furthermore, NGAL overexpression in neoplastic 
cells promotes tumor invasion while decreasing E-cadherin-mediated cell-cell adhesion 
(Conrotto et al., 2008; Sun et al., 2011). The function of S10AB (also known as 
S100A11) in carcinogenesis is still unclear. It is best described as a dual mediator that 
acts as a tumor suppressor gene in some cancers (such as breast cancer) and as an 
oncogenic promoter in other cancers (such as colorectal cancer), depending on its 
localization and interacting partners (Emberley et al., 2004; He et al., 2009). Similar to 
S10AB, oncogenic and tumor suppressor activities are reported for SPB5 (Snoeren et 
al., 2013). Recent biomarker studies on colorectal cancer correlate elevated SPB5 
expression to CEA levels and poor patient prognosis (Baek et al., 2013; Snoeren et al., 
2013). 
The targeted SRM workflow described here provides sensitive SRM assays to 
enable the direct detection and consistent quantification of putative biomarkers. Using 
the outlined workflow, together with the software tools mProphet, Skyline and MSstats 
accelerates assay development and improves the high-confidence analysis of large-
scale SRM data sets. This approach is suitable for the verification of several putative 
biomarkers in a large group of patient tissue samples and provides a basis for further 
clinical verification studies on the selected biomarkers.  
In line with the goals of a biomarker verification study, a worthwhile future step 
would be to apply the established SRM assays to profile the identified candidate 
biomarkers in plasma samples from patients with colorectal cancers and individuals 
without the disease (controls). Ideally, this should be a large cohort study, 
representative of the target population. We have commenced verification studies to 
evaluate the performance of our SRM workflow in plasma samples. It is known that 
plasma proteins range in concentration over 12 orders of magnitude and over 95% of 
the protein mass is comprised of a few high abundance proteins (Anderson, 2002; 
Kulasingam et al., 2010). Regardless of this issue of sample complexity, current 
improvements in mass spectrometry have facilitated the quantitation of low and high 
abundance plasma proteins (Addona et al., 2009; Anderson and Hunter, 2006; 
Anderson et al., 2009; 2004; Hüttenhain et al., 2009; Kuzyk et al., 2009; Surinova et 
al., 2011). As tissue-derived proteins are often diluted in the systematic blood stream, 
our SRM workflow could be refined to include affinity enrichment techniques, depletion 
of high abundance plasma proteins or fractionation steps to improve detection 
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sensitivity for low abundance proteins(Meng and Veenstra, 2011). Using plasma 
samples, SRM assays for each candidate biomarker would be examined in terms of 
dynamic range, reproducibility, limit of detection, specificity and sensitivity for the 
diseased state. 
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Supplementary figure 7. Distribution of retention time (RT) for iRT 
peptides in samples. 
A retention time shift of <1min was observed for each of the 11 iRT peptides, measured in the sample 
matrix, during the scheduled SRM runs with method 1 and method 2 transitions respectively. The y-axis 
represents the segment of the elution gradient (20 - 35 min) within which the iRT peptides eluted. Error 
bars indicate the average RT of the peptide in all samples and the1st and 3rd quartiles. 
!! 141!
10 5 0 5
Reproducibility of SRM measurement
Lo
g 2
 L
/H
 (D
ig
es
t d
up
lic
at
e 
1)
Log2 L/H (Digest duplicate 2)
10
5
0
5 Adjusted R2
0.9238 (Sample A)
0.9577 (Sample B)
0.9664 (Sample C)
0.9604 (Sample D)
0.9458 (Sample E)
0.9391 (Sample F)
 
Intercept Slope Adjusted R-squared p-value
Sample A  (Digest duplicate 1 vs. Digest Duplicate 2) -0.46661 0.941 0.9238 < 2.2e-16
Sample B (Digest duplicate 1 vs. Digest Duplicate 2) -0.85477 0.96551 0.9577 < 2.2e-16
Sample C  (Digest duplicate 1 vs. Digest Duplicate 2) 0.14011 0.99369 0.9664 < 2.2e-16
Sample D (Digest duplicate 1 vs. Digest Duplicate 2) 0.39564 0.96607 0.9604 < 2.2e-16
Sample E (Digest duplicate 1 vs. Digest Duplicate 2) 0.27327 0.9626 0.9458 < 2.2e-16
Sample F (Digest duplicate 1 vs. Digest Duplicate 2) -0.58602 1.01149 0.9391 < 2.2e-16  
Supplementary figure 8. Reproducibility of SRM measurements in 
duplicate sample digests 
Six samples (3 normal and disease pairs) were digested in duplicate and analyzed during scheduled 
SRM experiments. Peptides monitored in method 1 and method 2 were combined for this plot. For each 
duplicate digest compared, the correlation of log2 light/heavy ratio for the 39 peptides used for protein 
quantification is shown. The intercept, slope and adjusted R2 values for each regression are listed. 
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Supplementary figure 9. Quantified peptides for each protein 
The abundance of twenty five proteins was quantified in colorectal tissues with a minimum of one to 
three high-confidence proteotypic peptide per protein (see Results). 
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5.2.7 SUPPLEMENTARY TABLES 
Supplementary table 1. List of transitions selected for scheduled SRM on 
the TSQ Vantage (Method 1). 
Q1 Q3 CE RT-2.5 RT+2.5 Polarity Trigger Reference Peptide Sequence
560.32 763.47 19.7 31.25 36.25 1 5000 0 DQLIYNLLK
560.32 650.39 19.7 31.25 36.25 1 5000 0 DQLIYNLLK
560.32 487.32 19.7 31.25 36.25 1 5000 0 DQLIYNLLK
564.33 771.49 19.7 31.25 36.25 1 5000 0 DQLIYNLLK
564.33 658.40 19.7 31.25 36.25 1 5000 0 DQLIYNLLK
564.33 495.34 19.7 31.25 36.25 1 5000 0 DQLIYNLLK
829.43 1001.55 27.8 35.33 40.33 1 5000 0 DLADELALVDVIEDK
829.43 930.51 27.8 35.33 40.33 1 5000 0 DLADELALVDVIEDK
829.43 718.36 27.8 35.33 40.33 1 5000 0 DLADELALVDVIEDK
833.44 1009.57 27.8 35.33 40.33 1 5000 0 DLADELALVDVIEDK
833.44 938.53 27.8 35.33 40.33 1 5000 0 DLADELALVDVIEDK
833.44 726.38 27.8 35.33 40.33 1 5000 0 DLADELALVDVIEDK
632.84 1037.55 21.9 25.6 30.6 1 5000 0 QVVESAYEVIK
632.84 938.48 21.9 25.6 30.6 1 5000 0 QVVESAYEVIK
632.84 809.44 21.9 25.6 30.6 1 5000 0 QVVESAYEVIK
636.85 1045.57 21.9 25.6 30.6 1 5000 0 QVVESAYEVIK
636.85 946.50 21.9 25.6 30.6 1 5000 0 QVVESAYEVIK
636.85 817.45 21.9 25.6 30.6 1 5000 0 QVVESAYEVIK
706.40 1042.59 24.1 26.81 31.81 1 5000 0 GALQNIIPASTGAAK
706.40 928.55 24.1 26.81 31.81 1 5000 0 GALQNIIPASTGAAK
706.40 815.46 24.1 26.81 31.81 1 5000 0 GALQNIIPASTGAAK
710.41 1050.60 24.1 26.81 31.81 1 5000 0 GALQNIIPASTGAAK
710.41 936.56 24.1 26.81 31.81 1 5000 0 GALQNIIPASTGAAK
710.41 823.48 24.1 26.81 31.81 1 5000 0 GALQNIIPASTGAAK
882.40 1101.46 29.4 29.99 34.99 1 5000 0 LISWYDNEFGYSNR
882.40 986.43 29.4 29.99 34.99 1 5000 0 LISWYDNEFGYSNR
882.40 743.35 29.4 29.99 34.99 1 5000 0 LISWYDNEFGYSNR
887.41 1111.47 29.4 29.99 34.99 1 5000 0 LISWYDNEFGYSNR
887.41 996.44 29.4 29.99 34.99 1 5000 0 LISWYDNEFGYSNR
887.41 753.36 29.4 29.99 34.99 1 5000 0 LISWYDNEFGYSNR
847.95 1201.57 28.3 25.51 30.51 1 5000 0 LIAPVAEEEATVPNNK
847.95 571.32 28.3 25.51 30.51 1 5000 0 LIAPVAEEEATVPNNK
847.95 472.25 28.3 25.51 30.51 1 5000 0 LIAPVAEEEATVPNNK
851.96 1209.58 28.3 25.51 30.51 1 5000 0 LIAPVAEEEATVPNNK
851.96 579.33 28.3 25.51 30.51 1 5000 0 LIAPVAEEEATVPNNK
851.96 480.27 28.3 25.51 30.51 1 5000 0 LIAPVAEEEATVPNNK
815.43 1001.55 27.4 35.22 40.22 1 5000 0 SLADELALVDVLEDK
815.43 930.51 27.4 35.22 40.22 1 5000 0 SLADELALVDVLEDK
815.43 817.43 27.4 35.22 40.22 1 5000 0 SLADELALVDVLEDK
819.44 1009.57 27.4 35.22 40.22 1 5000 0 SLADELALVDVLEDK
819.44 938.53 27.4 35.22 40.22 1 5000 0 SLADELALVDVLEDK
819.44 825.44 27.4 35.22 40.22 1 5000 0 SLADELALVDVLEDK
457.30 701.43 16.6 23.78 28.78 1 5000 0 IVVVTAGVR
457.30 602.36 16.6 23.78 28.78 1 5000 0 IVVVTAGVR
457.30 503.29 16.6 23.78 28.78 1 5000 0 IVVVTAGVR
462.30 711.44 16.6 23.78 28.78 1 5000 0 IVVVTAGVR
462.30 612.37 16.6 23.78 28.78 1 5000 0 IVVVTAGVR
462.30 513.30 16.6 23.78 28.78 1 5000 0 IVVVTAGVR
596.32 831.49 24.9 27.5 32.5 1 5000 0 HLEINPDHSIIETLR
596.32 744.46 24.9 27.5 32.5 1 5000 0 HLEINPDHSIIETLR
596.32 631.38 24.9 27.5 32.5 1 5000 0 HLEINPDHSIIETLR
599.66 841.50 24.9 27.5 32.5 1 5000 0 HLEINPDHSIIETLR
599.66 754.47 24.9 27.5 32.5 1 5000 0 HLEINPDHSIIETLR
599.66 641.39 24.9 27.5 32.5 1 5000 0 HLEINPDHSIIETLR
618.30 992.52 21.5 22.73 27.73 1 5000 0 DQVANSAFVER
618.30 893.45 21.5 22.73 27.73 1 5000 0 DQVANSAFVER
623.31 1002.52 21.5 22.73 27.73 1 5000 0 DQVANSAFVER
623.31 903.46 21.5 22.73 27.73 1 5000 0 DQVANSAFVER
904.40 1344.58 30 23.92 28.92 1 5000 0 NSYVAGQYDDAASYQR
904.40 1088.46 30 23.92 28.92 1 5000 0 NSYVAGQYDDAASYQR
904.40 925.40 30 23.92 28.92 1 5000 0 NSYVAGQYDDAASYQR
909.40 1354.59 30 23.92 28.92 1 5000 0 NSYVAGQYDDAASYQR
909.40 1098.47 30 23.92 28.92 1 5000 0 NSYVAGQYDDAASYQR
909.40 935.41 30 23.92 28.92 1 5000 0 NSYVAGQYDDAASYQR
637.31 996.51 22 31.07 36.07 1 5000 0 GGYFDEFGIIR
637.31 849.45 22 31.07 36.07 1 5000 0 GGYFDEFGIIR
637.31 605.38 22 31.07 36.07 1 5000 0 GGYFDEFGIIR  
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642.32 1006.52 22 31.07 36.07 1 5000 0 GGYFDEFGIIR
642.32 859.45 22 31.07 36.07 1 5000 0 GGYFDEFGIIR
642.32 615.39 22 31.07 36.07 1 5000 0 GGYFDEFGIIR
891.42 1144.58 29.6 28.29 33.29 1 5000 0 DYPDFSPSVDAEAIQK
891.42 1057.55 29.6 28.29 33.29 1 5000 0 DYPDFSPSVDAEAIQK
895.42 1152.60 29.6 28.29 33.29 1 5000 0 DYPDFSPSVDAEAIQK
895.42 1065.57 29.6 28.29 33.29 1 5000 0 DYPDFSPSVDAEAIQK
721.36 1138.60 24.5 27.96 32.96 1 5000 0 SDTSGDYEITLLK
721.36 1051.57 24.5 27.96 32.96 1 5000 0 SDTSGDYEITLLK
725.36 1146.61 24.5 27.96 32.96 1 5000 0 SDTSGDYEITLLK
725.36 1059.58 24.5 27.96 32.96 1 5000 0 SDTSGDYEITLLK
472.23 729.32 17.1 24.29 29.29 1 5000 0 LTFDEYR
472.23 582.25 17.1 24.29 29.29 1 5000 0 LTFDEYR
477.23 739.33 17.1 24.29 29.29 1 5000 0 LTFDEYR
477.23 592.26 17.1 24.29 29.29 1 5000 0 LTFDEYR
556.80 928.51 19.6 20.5 25.5 1 5000 0 SPPGQVTEAVK
556.80 831.46 19.6 20.5 25.5 1 5000 0 SPPGQVTEAVK
556.80 646.38 19.6 20.5 25.5 1 5000 0 SPPGQVTEAVK
560.81 936.52 19.6 20.5 25.5 1 5000 0 SPPGQVTEAVK
560.81 839.47 19.6 20.5 25.5 1 5000 0 SPPGQVTEAVK
560.81 654.39 19.6 20.5 25.5 1 5000 0 SPPGQVTEAVK
558.32 887.53 19.7 31.13 36.13 1 5000 0 MPILGLGTWK
558.32 774.45 19.7 31.13 36.13 1 5000 0 MPILGLGTWK
558.32 661.37 19.7 31.13 36.13 1 5000 0 MPILGLGTWK
562.32 895.55 19.7 31.13 36.13 1 5000 0 MPILGLGTWK
562.32 782.47 19.7 31.13 36.13 1 5000 0 MPILGLGTWK
562.32 669.38 19.7 31.13 36.13 1 5000 0 MPILGLGTWK
446.75 722.38 16.3 23.89 28.89 1 5000 0 VAIDVGYR
446.75 609.30 16.3 23.89 28.89 1 5000 0 VAIDVGYR
446.75 494.27 16.3 23.89 28.89 1 5000 0 VAIDVGYR
451.75 732.39 16.3 23.89 28.89 1 5000 0 VAIDVGYR
451.75 619.31 16.3 23.89 28.89 1 5000 0 VAIDVGYR
451.75 504.28 16.3 23.89 28.89 1 5000 0 VAIDVGYR
824.87 1182.52 27.7 30.13 35.13 1 5000 0 FGYVDFESAEDLEK
824.87 1067.49 27.7 30.13 35.13 1 5000 0 FGYVDFESAEDLEK
824.87 791.38 27.7 30.13 35.13 1 5000 0 FGYVDFESAEDLEK
828.88 1190.53 27.7 30.13 35.13 1 5000 0 FGYVDFESAEDLEK
828.88 1075.50 27.7 30.13 35.13 1 5000 0 FGYVDFESAEDLEK
828.88 799.39 27.7 30.13 35.13 1 5000 0 FGYVDFESAEDLEK
589.79 950.46 20.6 25.28 30.28 1 5000 0 EVFEDAAEIR
589.79 803.39 20.6 25.28 30.28 1 5000 0 EVFEDAAEIR
589.79 674.35 20.6 25.28 30.28 1 5000 0 EVFEDAAEIR
594.79 960.47 20.6 25.28 30.28 1 5000 0 EVFEDAAEIR
594.79 813.40 20.6 25.28 30.28 1 5000 0 EVFEDAAEIR
594.79 684.36 20.6 25.28 30.28 1 5000 0 EVFEDAAEIR
781.34 1153.50 26.3 29.72 34.72 1 5000 0 GFGFVDFNSEEDAK
781.34 1054.43 26.3 29.72 34.72 1 5000 0 GFGFVDFNSEEDAK
781.34 939.41 26.3 29.72 34.72 1 5000 0 GFGFVDFNSEEDAK
785.35 1161.51 26.3 29.72 34.72 1 5000 0 GFGFVDFNSEEDAK
785.35 1062.45 26.3 29.72 34.72 1 5000 0 GFGFVDFNSEEDAK
785.35 947.42 26.3 29.72 34.72 1 5000 0 GFGFVDFNSEEDAK
696.87 933.50 23.8 26.65 31.65 1 5000 0 STGTISVISSGLDR
696.87 747.40 23.8 26.65 31.65 1 5000 0 STGTISVISSGLDR
696.87 634.32 23.8 26.65 31.65 1 5000 0 STGTISVISSGLDR
701.87 943.51 23.8 26.65 31.65 1 5000 0 STGTISVISSGLDR
701.87 757.41 23.8 26.65 31.65 1 5000 0 STGTISVISSGLDR
701.87 644.32 23.8 26.65 31.65 1 5000 0 STGTISVISSGLDR
828.42 1013.48 27.8 28.53 33.53 1 5000 0 LTVTDLDAPNSPAWR
828.42 898.45 27.8 28.53 33.53 1 5000 0 LTVTDLDAPNSPAWR
828.42 827.42 27.8 28.53 33.53 1 5000 0 LTVTDLDAPNSPAWR
833.43 1023.49 27.8 28.53 33.53 1 5000 0 LTVTDLDAPNSPAWR
833.43 908.46 27.8 28.53 33.53 1 5000 0 LTVTDLDAPNSPAWR
833.43 837.42 27.8 28.53 33.53 1 5000 0 LTVTDLDAPNSPAWR
893.91 1329.63 29.7 23.57 28.57 1 5000 0 EAAGEGPALYEDPPDQK
893.91 991.44 29.7 23.57 28.57 1 5000 0 EAAGEGPALYEDPPDQK
893.91 584.30 29.7 23.57 28.57 1 5000 0 EAAGEGPALYEDPPDQK
897.92 1337.65 29.7 23.57 28.57 1 5000 0 EAAGEGPALYEDPPDQK
897.92 999.45 29.7 23.57 28.57 1 5000 0 EAAGEGPALYEDPPDQK
897.92 592.32 29.7 23.57 28.57 1 5000 0 EAAGEGPALYEDPPDQK
924.49 1103.58 30.6 35.51 40.51 1 5000 0 QGFGELLQAVPLADSFR
924.49 975.53 30.6 35.51 40.51 1 5000 0 QGFGELLQAVPLADSFR
924.49 805.42 30.6 35.51 40.51 1 5000 0 QGFGELLQAVPLADSFR
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929.49 1113.59 30.6 35.51 40.51 1 5000 0 QGFGELLQAVPLADSFR
929.49 985.53 30.6 35.51 40.51 1 5000 0 QGFGELLQAVPLADSFR
929.49 815.43 30.6 35.51 40.51 1 5000 0 QGFGELLQAVPLADSFR
1046.54 790.38 34.3 34.88 39.88 1 5000 0 LDYFLLSHSLLPALC[+57.0]DSK
1046.54 622.29 34.3 34.88 39.88 1 5000 0 LDYFLLSHSLLPALC[+57.0]DSK
1046.54 392.18 34.3 34.88 39.88 1 5000 0 LDYFLLSHSLLPALC[+57.0]DSK
1050.55 798.39 34.3 34.88 39.88 1 5000 0 LDYFLLSHSLLPALC[+57.0]DSK
1050.55 630.30 34.3 34.88 39.88 1 5000 0 LDYFLLSHSLLPALC[+57.0]DSK
1050.55 392.18 34.3 34.88 39.88 1 5000 0 LDYFLLSHSLLPALC[+57.0]DSK
510.25 906.42 18.2 23.11 28.11 1 5000 0 ISSPTETER
510.25 819.38 18.2 23.11 28.11 1 5000 0 ISSPTETER
510.25 732.35 18.2 23.11 28.11 1 5000 0 ISSPTETER
515.26 916.42 18.2 23.11 28.11 1 5000 0 ISSPTETER
515.26 829.39 18.2 23.11 28.11 1 5000 0 ISSPTETER
515.26 742.36 18.2 23.11 28.11 1 5000 0 ISSPTETER
530.75 725.38 18.8 22.9 27.9 1 5000 0 DGYNYTLSK
530.75 611.34 18.8 22.9 27.9 1 5000 0 DGYNYTLSK
530.75 448.28 18.8 22.9 27.9 1 5000 0 DGYNYTLSK
534.76 733.40 18.8 22.9 27.9 1 5000 0 DGYNYTLSK
534.76 619.35 18.8 22.9 27.9 1 5000 0 DGYNYTLSK
534.76 456.29 18.8 22.9 27.9 1 5000 0 DGYNYTLSK
386.20 559.32 14.5 21.14 26.14 1 5000 0 DPGVLDR
386.20 502.30 14.5 21.14 26.14 1 5000 0 DPGVLDR
386.20 403.23 14.5 21.14 26.14 1 5000 0 DPGVLDR
391.21 569.33 14.5 21.14 26.14 1 5000 0 DPGVLDR
391.21 512.31 14.5 21.14 26.14 1 5000 0 DPGVLDR
391.21 413.24 14.5 21.14 26.14 1 5000 0 DPGVLDR
551.32 746.42 19.4 28.44 33.44 1 5000 0 IIELPFQNK
551.32 633.34 19.4 28.44 33.44 1 5000 0 IIELPFQNK
555.33 754.43 19.4 28.44 33.44 1 5000 0 IIELPFQNK
555.33 641.35 19.4 28.44 33.44 1 5000 0 IIELPFQNK
473.25 703.37 17.1 22.02 27.02 1 5000 0 ELVLDNSR
473.25 604.30 17.1 22.02 27.02 1 5000 0 ELVLDNSR
473.25 491.22 17.1 22.02 27.02 1 5000 0 ELVLDNSR
478.26 713.38 17.1 22.02 27.02 1 5000 0 ELVLDNSR
478.26 614.31 17.1 22.02 27.02 1 5000 0 ELVLDNSR
478.26 501.23 17.1 22.02 27.02 1 5000 0 ELVLDNSR
489.92 745.42 20.9 24.6 29.6 1 5000 0 C[+57.0]PNLTHLNLSGNK
489.92 632.34 20.9 24.6 29.6 1 5000 0 C[+57.0]PNLTHLNLSGNK
489.92 405.21 20.9 24.6 29.6 1 5000 0 C[+57.0]PNLTHLNLSGNK
492.59 753.43 20.9 24.6 29.6 1 5000 0 C[+57.0]PNLTHLNLSGNK
492.59 640.35 20.9 24.6 29.6 1 5000 0 C[+57.0]PNLTHLNLSGNK
492.59 413.22 20.9 24.6 29.6 1 5000 0 C[+57.0]PNLTHLNLSGNK
982.01 1295.66 32.4 26.97 31.97 1 5000 0 VELPGTAVPSVPEDAAPASR
982.01 1196.59 32.4 26.97 31.97 1 5000 0 VELPGTAVPSVPEDAAPASR
982.01 913.44 32.4 26.97 31.97 1 5000 0 VELPGTAVPSVPEDAAPASR
987.01 1305.67 32.4 26.97 31.97 1 5000 0 VELPGTAVPSVPEDAAPASR
987.01 1206.60 32.4 26.97 31.97 1 5000 0 VELPGTAVPSVPEDAAPASR
987.01 923.45 32.4 26.97 31.97 1 5000 0 VELPGTAVPSVPEDAAPASR
687.84 993.51 23.5 25.18 30.18 1 5000 0 AFYAPVHADDLR
687.84 922.47 23.5 25.18 30.18 1 5000 0 AFYAPVHADDLR
687.84 726.35 23.5 25.18 30.18 1 5000 0 AFYAPVHADDLR
692.85 1003.52 23.5 25.18 30.18 1 5000 0 AFYAPVHADDLR
692.85 932.48 23.5 25.18 30.18 1 5000 0 AFYAPVHADDLR
692.85 736.36 23.5 25.18 30.18 1 5000 0 AFYAPVHADDLR
458.90 922.47 19.7 25.18 30.18 1 5000 0 AFYAPVHADDLR
458.90 726.35 19.7 25.18 30.18 1 5000 0 AFYAPVHADDLR
458.90 589.29 19.7 25.18 30.18 1 5000 0 AFYAPVHADDLR
462.23 932.48 19.7 25.18 30.18 1 5000 0 AFYAPVHADDLR
462.23 736.36 19.7 25.18 30.18 1 5000 0 AFYAPVHADDLR
462.23 599.30 19.7 25.18 30.18 1 5000 0 AFYAPVHADDLR
747.37 804.45 30.7 28.6 33.6 1 5000 0 EGLDISHLQGQEELLSSQEK
747.37 691.36 30.7 28.6 33.6 1 5000 0 EGLDISHLQGQEELLSSQEK
747.37 578.28 30.7 28.6 33.6 1 5000 0 EGLDISHLQGQEELLSSQEK
750.04 812.46 30.7 28.6 33.6 1 5000 0 EGLDISHLQGQEELLSSQEK
750.04 699.38 30.7 28.6 33.6 1 5000 0 EGLDISHLQGQEELLSSQEK
750.04 586.29 30.7 28.6 33.6 1 5000 0 EGLDISHLQGQEELLSSQEK
619.32 1124.55 21.5 26.04 31.04 1 5000 0 ITDNELELYK
619.32 1023.50 21.5 26.04 31.04 1 5000 0 ITDNELELYK
619.32 310.18 21.5 26.04 31.04 1 5000 0 ITDNELELYK
623.33 1132.56 21.5 26.04 31.04 1 5000 0 ITDNELELYK
623.33 1031.51 21.5 26.04 31.04 1 5000 0 ITDNELELYK
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623.33 318.19 21.5 26.04 31.04 1 5000 0 ITDNELELYK
632.80 1003.48 21.9 27.78 32.78 1 5000 0 FNVWDVGGQDK
632.80 904.42 21.9 27.78 32.78 1 5000 0 FNVWDVGGQDK
632.80 718.34 21.9 27.78 32.78 1 5000 0 FNVWDVGGQDK
636.81 1011.50 21.9 27.78 32.78 1 5000 0 FNVWDVGGQDK
636.81 912.43 21.9 27.78 32.78 1 5000 0 FNVWDVGGQDK
636.81 726.35 21.9 27.78 32.78 1 5000 0 FNVWDVGGQDK
628.34 1005.57 21.8 28.96 33.96 1 5000 0 SYPGLTSYLVR
628.34 908.52 21.8 28.96 33.96 1 5000 0 SYPGLTSYLVR
633.34 1015.58 21.8 28.96 33.96 1 5000 0 SYPGLTSYLVR
633.34 918.53 21.8 28.96 33.96 1 5000 0 SYPGLTSYLVR
975.52 1333.75 32.2 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
975.52 1220.66 32.2 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
975.52 994.57 32.2 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
980.52 1343.76 32.2 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
980.52 1230.67 32.2 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
980.52 1004.58 32.2 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
650.68 994.57 27 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
650.68 897.52 27 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
650.68 840.49 27 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
654.02 1004.58 27 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
654.02 907.52 27 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
654.02 850.50 27 30.44 35.44 1 5000 0 LENYPIPEPGPNEVLLR
791.92 1226.64 26.7 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
791.92 1127.57 26.7 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
791.92 1014.49 26.7 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
795.92 1234.65 26.7 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
795.92 1135.58 26.7 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
795.92 1022.50 26.7 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
528.28 820.40 22.4 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
528.28 691.36 22.4 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
528.28 620.32 22.4 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
530.95 828.42 22.4 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
530.95 699.38 22.4 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
530.95 628.34 22.4 20.5 25.5 1 5000 0 KPMVLGHEASGTVEK
879.78 1351.72 35.7 33.18 38.18 1 5000 0 LPDNVTFEEGALIEPLSVGIHAC[+57.0]R
879.78 1238.63 35.7 33.18 38.18 1 5000 0 LPDNVTFEEGALIEPLSVGIHAC[+57.0]R
879.78 1109.59 35.7 33.18 38.18 1 5000 0 LPDNVTFEEGALIEPLSVGIHAC[+57.0]R
883.12 1361.72 35.7 33.18 38.18 1 5000 0 LPDNVTFEEGALIEPLSVGIHAC[+57.0]R
883.12 1248.64 35.7 33.18 38.18 1 5000 0 LPDNVTFEEGALIEPLSVGIHAC[+57.0]R
883.12 1119.60 35.7 33.18 38.18 1 5000 0 LPDNVTFEEGALIEPLSVGIHAC[+57.0]R
795.42 961.53 26.8 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
795.42 862.46 26.8 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
795.42 763.39 26.8 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
800.42 971.54 26.8 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
800.42 872.47 26.8 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
800.42 773.40 26.8 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
530.62 434.24 22.4 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
530.62 728.38 22.4 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
530.62 1043.52 22.4 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
533.95 444.24 22.4 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
533.95 728.38 22.4 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
533.95 1043.52 22.4 29.11 34.11 1 5000 0 AMGAAQVVVTDLSATR
643.37 1043.61 22.2 30.34 35.34 1 5000 0 EIGADLVLQISK
643.37 687.44 22.2 30.34 35.34 1 5000 0 EIGADLVLQISK
643.37 588.37 22.2 30.34 35.34 1 5000 0 EIGADLVLQISK
647.38 1051.62 22.2 30.34 35.34 1 5000 0 EIGADLVLQISK
647.38 695.45 22.2 30.34 35.34 1 5000 0 EIGADLVLQISK
647.38 596.39 22.2 30.34 35.34 1 5000 0 EIGADLVLQISK
487.26 860.42 17.5 17.5 22.5 1 5000 0 LGGNEQVTR
487.26 803.40 17.5 17.5 22.5 1 5000 0 LGGNEQVTR
487.26 503.29 17.5 17.5 22.5 1 5000 0 LGGNEQVTR
644.82 1016.53 22.2 19.75 24.75 1 5000 0 AGGSSEPVTGLADK
644.82 800.45 22.2 19.75 24.75 1 5000 0 AGGSSEPVTGLADK
644.82 604.33 22.2 19.75 24.75 1 5000 0 AGGSSEPVTGLADK
683.83 819.39 23.4 22.24 27.24 1 5000 0 VEATFGVDESANK
683.83 966.45 23.4 22.24 27.24 1 5000 0 VEATFGVDESANK
683.83 663.29 23.4 22.24 27.24 1 5000 0 VEATFGVDESANK
547.30 817.44 19.3 23.89 28.89 1 5000 0 YILAGVENSK
547.30 704.36 19.3 23.89 28.89 1 5000 0 YILAGVENSK
547.30 633.32 19.3 23.89 28.89 1 5000 0 YILAGVENSK
669.84 1041.50 23 24.62 29.62 1 5000 0 TPVISGGPYYER
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669.84 928.42 23 24.62 29.62 1 5000 0 TPVISGGPYYER
669.84 841.38 23 24.62 29.62 1 5000 0 TPVISGGPYYER
683.85 1069.53 23.4 25.32 30.32 1 5000 0 TPVITGAPYYER
683.85 956.45 23.4 25.32 30.32 1 5000 0 TPVITGAPYYER
683.85 855.40 23.4 25.32 30.32 1 5000 0 TPVITGAPYYER
699.34 926.47 23.9 27.02 32.02 1 5000 0 GDLDAASYYAPVR
699.34 855.44 23.9 27.02 32.02 1 5000 0 GDLDAASYYAPVR
699.34 605.34 23.9 27.02 32.02 1 5000 0 GDLDAASYYAPVR
726.84 1066.48 24.7 27.94 32.94 1 5000 0 DAVTPADFSEWSK
726.84 584.27 24.7 27.94 32.94 1 5000 0 DAVTPADFSEWSK
726.84 533.75 24.7 27.94 32.94 1 5000 0 DAVTPADFSEWSK
622.85 826.48 21.6 30.57 35.57 1 5000 0 TGFIIDPGGVIR
622.85 713.39 21.6 30.57 35.57 1 5000 0 TGFIIDPGGVIR
622.85 598.37 21.6 30.57 35.57 1 5000 0 TGFIIDPGGVIR
636.87 854.51 22 32.8 37.8 1 5000 0 GTFIIDPAAIVR
636.87 741.43 22 32.8 37.8 1 5000 0 GTFIIDPAAIVR
636.87 626.40 22 32.8 37.8 1 5000 0 GTFIIDPAAIVR
776.93 1051.56 26.2 34.1 39.1 1 5000 0 FLLQFGAQGSPLFK
776.93 904.49 26.2 34.1 39.1 1 5000 0 FLLQFGAQGSPLFK
776.93 504.32 26.2 34.1 39.1 1 5000 0 FLLQFGAQGSPLFK
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Supplementary table 2. List of transitions selected for scheduled SRM on 
the TSQ Vantage (Method 2) 
Q1 Q3 CE RT-2.5 RT+2.5 Polarity Trigger Reference Peptide Sequence
487.26 860.42 17.5 17.22 22.22 1 5000 0 LGGNEQVTR
487.26 803.40 17.5 17.22 22.22 1 5000 0 LGGNEQVTR
487.26 503.29 17.5 17.22 22.22 1 5000 0 LGGNEQVTR
644.82 1016.53 22.2 19.69 24.69 1 5000 0 AGGSSEPVTGLADK
644.82 800.45 22.2 19.69 24.69 1 5000 0 AGGSSEPVTGLADK
644.82 604.33 22.2 19.69 24.69 1 5000 0 AGGSSEPVTGLADK
683.83 819.39 23.4 22.08 27.08 1 5000 0 VEATFGVDESANK
683.83 966.45 23.4 22.08 27.08 1 5000 0 VEATFGVDESANK
683.83 663.29 23.4 22.08 27.08 1 5000 0 VEATFGVDESANK
547.30 817.44 19.3 23.66 28.66 1 5000 0 YILAGVENSK
547.30 704.36 19.3 23.66 28.66 1 5000 0 YILAGVENSK
547.30 633.32 19.3 23.66 28.66 1 5000 0 YILAGVENSK
669.84 1041.50 23 24.3 29.3 1 5000 0 TPVISGGPYYER
669.84 928.42 23 24.3 29.3 1 5000 0 TPVISGGPYYER
669.84 841.38 23 24.3 29.3 1 5000 0 TPVISGGPYYER
683.85 1069.53 23.4 25.08 30.08 1 5000 0 TPVITGAPYYER
683.85 956.45 23.4 25.08 30.08 1 5000 0 TPVITGAPYYER
683.85 855.40 23.4 25.08 30.08 1 5000 0 TPVITGAPYYER
699.34 926.47 23.9 26.34 31.34 1 5000 0 GDLDAASYYAPVR
699.34 855.44 23.9 26.34 31.34 1 5000 0 GDLDAASYYAPVR
699.34 605.34 23.9 26.34 31.34 1 5000 0 GDLDAASYYAPVR
726.84 1066.48 24.7 27.73 32.73 1 5000 0 DAVTPADFSEWSK
726.84 584.27 24.7 27.73 32.73 1 5000 0 DAVTPADFSEWSK
726.84 533.75 24.7 27.73 32.73 1 5000 0 DAVTPADFSEWSK
622.85 826.48 21.6 30.59 35.59 1 5000 0 TGFIIDPGGVIR
622.85 713.39 21.6 30.59 35.59 1 5000 0 TGFIIDPGGVIR
622.85 598.37 21.6 30.59 35.59 1 5000 0 TGFIIDPGGVIR
636.87 854.51 22 32.9 37.9 1 5000 0 GTFIIDPAAIVR
636.87 741.43 22 32.9 37.9 1 5000 0 GTFIIDPAAIVR
636.87 626.40 22 32.9 37.9 1 5000 0 GTFIIDPAAIVR
776.93 1051.56 26.2 34 39 1 5000 0 FLLQFGAQGSPLFK
776.93 904.49 26.2 34 39 1 5000 0 FLLQFGAQGSPLFK
776.93 504.32 26.2 34 39 1 5000 0 FLLQFGAQGSPLFK
604.81 980.49 21 26.62 31.62 1 5000 0 VEVTEFEDIK
604.81 881.43 21 26.62 31.62 1 5000 0 VEVTEFEDIK
604.81 651.33 21 26.62 31.62 1 5000 0 VEVTEFEDIK
608.81 988.51 21 26.62 31.62 1 5000 0 VEVTEFEDIK
608.81 889.44 21 26.62 31.62 1 5000 0 VEVTEFEDIK
608.81 659.35 21 26.62 31.62 1 5000 0 VEVTEFEDIK
920.91 1302.56 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
920.91 1155.50 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
920.91 797.38 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
920.91 537.27 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
924.91 1310.58 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
924.91 1163.51 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
924.91 805.40 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
924.91 545.28 30.5 32.32 37.32 1 5000 0 IDFYFDENPYFENK
723.83 1033.48 24.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
723.83 920.40 24.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
723.83 418.23 24.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
727.84 1041.49 24.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
727.84 928.41 24.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
727.84 426.24 24.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
482.89 590.28 20.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
482.89 418.23 20.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
482.89 321.18 20.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
485.56 598.29 20.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
485.56 426.24 20.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
485.56 329.19 20.6 19.12 24.12 1 5000 0 EFHLNESGDPSSK
637.83 1078.53 22 26.11 31.11 1 5000 0 VPVYETPAGWR
637.83 979.46 22 26.11 31.11 1 5000 0 VPVYETPAGWR
637.83 816.40 22 26.11 31.11 1 5000 0 VPVYETPAGWR
642.83 1088.54 22 26.11 31.11 1 5000 0 VPVYETPAGWR
642.83 989.47 22 26.11 31.11 1 5000 0 VPVYETPAGWR  
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642.83 826.41 22 26.11 31.11 1 5000 0 VPVYETPAGWR
527.27 911.46 18.7 26.59 31.59 1 5000 0 AAPFSLEYR
527.27 814.41 18.7 26.59 31.59 1 5000 0 AAPFSLEYR
527.27 667.34 18.7 26.59 31.59 1 5000 0 AAPFSLEYR
532.28 921.47 18.7 26.59 31.59 1 5000 0 AAPFSLEYR
532.28 824.42 18.7 26.59 31.59 1 5000 0 AAPFSLEYR
532.28 677.35 18.7 26.59 31.59 1 5000 0 AAPFSLEYR
932.47 706.38 30.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
932.47 496.24 30.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
932.47 1158.56 30.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
936.47 714.39 30.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
936.47 504.25 30.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
936.47 1158.56 30.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
621.98 934.49 25.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
621.98 706.38 25.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
621.98 496.24 25.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
624.65 942.50 25.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
624.65 714.39 25.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
624.65 504.25 25.9 29.75 34.75 1 5000 0 GQYISPFHDIPIYADK
664.34 829.46 22.8 29.63 34.63 1 5000 0 DVFHMVVEVPR
664.34 698.42 22.8 29.63 34.63 1 5000 0 DVFHMVVEVPR
664.34 599.35 22.8 29.63 34.63 1 5000 0 DVFHMVVEVPR
669.35 839.47 22.8 29.63 34.63 1 5000 0 DVFHMVVEVPR
669.35 708.43 22.8 29.63 34.63 1 5000 0 DVFHMVVEVPR
669.35 609.36 22.8 29.63 34.63 1 5000 0 DVFHMVVEVPR
443.23 829.46 19.1 29.63 34.63 1 5000 0 DVFHMVVEVPR
443.23 599.35 19.1 29.63 34.63 1 5000 0 DVFHMVVEVPR
443.23 500.28 19.1 29.63 34.63 1 5000 0 DVFHMVVEVPR
446.57 839.47 19.1 29.63 34.63 1 5000 0 DVFHMVVEVPR
446.57 609.36 19.1 29.63 34.63 1 5000 0 DVFHMVVEVPR
446.57 510.29 19.1 29.63 34.63 1 5000 0 DVFHMVVEVPR
650.65 324.15 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
650.65 897.42 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
650.65 782.39 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
650.65 574.29 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
653.98 324.15 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
653.98 907.43 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
653.98 792.40 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
653.98 584.30 27 25.1 30.1 1 5000 0 HWILPQDYDHAQAEAR
485.26 806.44 17.5 24.74 29.74 1 5000 0 YIFDNVAK
485.26 693.36 17.5 24.74 29.74 1 5000 0 YIFDNVAK
485.26 546.29 17.5 24.74 29.74 1 5000 0 YIFDNVAK
485.26 431.26 17.5 24.74 29.74 1 5000 0 YIFDNVAK
489.26 814.45 17.5 24.74 29.74 1 5000 0 YIFDNVAK
489.26 701.37 17.5 24.74 29.74 1 5000 0 YIFDNVAK
489.26 554.30 17.5 24.74 29.74 1 5000 0 YIFDNVAK
489.26 439.28 17.5 24.74 29.74 1 5000 0 YIFDNVAK
850.92 1151.58 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
850.92 1052.52 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
850.92 905.45 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
850.92 834.41 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
855.92 1161.59 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
855.92 1062.52 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
855.92 915.46 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
855.92 844.42 28.4 29.83 34.83 1 5000 0 EGVYTVFAPTNEAFR
658.40 1101.67 22.7 34.29 39.29 1 5000 0 LTLLAPLNSVFK
658.40 988.58 22.7 34.29 39.29 1 5000 0 LTLLAPLNSVFK
658.40 875.50 22.7 34.29 39.29 1 5000 0 LTLLAPLNSVFK
662.41 1109.68 22.7 34.29 39.29 1 5000 0 LTLLAPLNSVFK
662.41 996.60 22.7 34.29 39.29 1 5000 0 LTLLAPLNSVFK
662.41 883.51 22.7 34.29 39.29 1 5000 0 LTLLAPLNSVFK
608.38 861.52 21.2 34.25 39.25 1 5000 0 VALAGLLGFGLGK
608.38 691.41 21.2 34.25 39.25 1 5000 0 VALAGLLGFGLGK
608.38 578.33 21.2 34.25 39.25 1 5000 0 VALAGLLGFGLGK
612.38 869.53 21.2 34.25 39.25 1 5000 0 VALAGLLGFGLGK
612.38 699.43 21.2 34.25 39.25 1 5000 0 VALAGLLGFGLGK
612.38 586.34 21.2 34.25 39.25 1 5000 0 VALAGLLGFGLGK
332.50 428.25 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
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332.50 331.20 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
332.50 471.20 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
332.50 568.25 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
335.17 436.26 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
335.17 339.21 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
335.17 471.20 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
335.17 568.25 14.9 19.45 24.45 1 5000 0 DAHFPPPSK
731.38 942.50 24.8 29.83 34.83 1 5000 0 GLYWVAPLNTDGR
731.38 843.43 24.8 29.83 34.83 1 5000 0 GLYWVAPLNTDGR
736.38 952.51 24.8 29.83 34.83 1 5000 0 GLYWVAPLNTDGR
736.38 853.44 24.8 29.83 34.83 1 5000 0 GLYWVAPLNTDGR
638.81 822.43 22.1 29.83 34.83 1 5000 0 GFSYLYGAWGR
638.81 709.34 22.1 29.83 34.83 1 5000 0 GFSYLYGAWGR
638.81 546.28 22.1 29.83 34.83 1 5000 0 GFSYLYGAWGR
643.81 832.43 22.1 29.83 34.83 1 5000 0 GFSYLYGAWGR
643.81 719.35 22.1 29.83 34.83 1 5000 0 GFSYLYGAWGR
643.81 556.29 22.1 29.83 34.83 1 5000 0 GFSYLYGAWGR
628.36 1041.58 21.8 28.48 33.48 1 5000 0 TLPIGQNFPIR
628.36 944.53 21.8 28.48 33.48 1 5000 0 TLPIGQNFPIR
628.36 831.45 21.8 28.48 33.48 1 5000 0 TLPIGQNFPIR
633.37 1051.59 21.8 28.48 33.48 1 5000 0 TLPIGQNFPIR
633.37 954.54 21.8 28.48 33.48 1 5000 0 TLPIGQNFPIR
633.37 841.46 21.8 28.48 33.48 1 5000 0 TLPIGQNFPIR
607.32 784.49 25.4 24.53 29.53 1 5000 0 STHYQQYQPVVTLQK
607.32 588.37 25.4 24.53 29.53 1 5000 0 STHYQQYQPVVTLQK
607.32 489.30 25.4 24.53 29.53 1 5000 0 STHYQQYQPVVTLQK
609.99 792.51 25.4 24.53 29.53 1 5000 0 STHYQQYQPVVTLQK
609.99 596.39 25.4 24.53 29.53 1 5000 0 STHYQQYQPVVTLQK
609.99 497.32 25.4 24.53 29.53 1 5000 0 STHYQQYQPVVTLQK
619.90 751.51 21.5 30.79 35.79 1 5000 0 IFQVVPIPVVK
619.90 652.44 21.5 30.79 35.79 1 5000 0 IFQVVPIPVVK
619.90 442.30 21.5 30.79 35.79 1 5000 0 IFQVVPIPVVK
623.90 759.52 21.5 30.79 35.79 1 5000 0 IFQVVPIPVVK
623.90 660.45 21.5 30.79 35.79 1 5000 0 IFQVVPIPVVK
623.90 450.32 21.5 30.79 35.79 1 5000 0 IFQVVPIPVVK
495.75 748.37 17.8 21.94 26.94 1 5000 0 ELVLDNC[+57.0]K
495.75 649.30 17.8 21.94 26.94 1 5000 0 ELVLDNC[+57.0]K
495.75 536.21 17.8 21.94 26.94 1 5000 0 ELVLDNC[+57.0]K
499.76 756.38 17.8 21.94 26.94 1 5000 0 ELVLDNC[+57.0]K
499.76 657.31 17.8 21.94 26.94 1 5000 0 ELVLDNC[+57.0]K
499.76 544.23 17.8 21.94 26.94 1 5000 0 ELVLDNC[+57.0]K
474.27 745.42 20.3 26.92 31.92 1 5000 0 LPNLTHLNLSGNK
474.27 632.34 20.3 26.92 31.92 1 5000 0 LPNLTHLNLSGNK
474.27 405.21 20.3 26.92 31.92 1 5000 0 LPNLTHLNLSGNK
476.94 753.43 20.3 26.92 31.92 1 5000 0 LPNLTHLNLSGNK
476.94 640.35 20.3 26.92 31.92 1 5000 0 LPNLTHLNLSGNK
476.94 413.22 20.3 26.92 31.92 1 5000 0 LPNLTHLNLSGNK
728.39 989.52 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
728.39 861.46 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
728.39 707.38 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
728.39 553.31 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
733.39 999.52 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
733.39 871.47 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
733.39 717.39 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
733.39 563.32 24.8 19.46 24.46 1 5000 0 LGAPQQPGPGPPPSR
747.88 1002.56 25.3 32.04 37.04 1 5000 0 EAEYFELPELVR
747.88 855.49 25.3 32.04 37.04 1 5000 0 EAEYFELPELVR
747.88 726.45 25.3 32.04 37.04 1 5000 0 EAEYFELPELVR
752.88 1012.57 25.3 32.04 37.04 1 5000 0 EAEYFELPELVR
752.88 865.50 25.3 32.04 37.04 1 5000 0 EAEYFELPELVR
752.88 736.46 25.3 32.04 37.04 1 5000 0 EAEYFELPELVR
629.81 997.50 21.8 31.03 36.03 1 5000 0 FNFLEQAFDK
629.81 850.43 21.8 31.03 36.03 1 5000 0 FNFLEQAFDK
629.81 737.35 21.8 31.03 36.03 1 5000 0 FNFLEQAFDK
633.82 1005.51 21.8 31.03 36.03 1 5000 0 FNFLEQAFDK
633.82 858.44 21.8 31.03 36.03 1 5000 0 FNFLEQAFDK
633.82 745.36 21.8 31.03 36.03 1 5000 0 FNFLEQAFDK
533.72 865.37 18.9 23.84 28.84 1 5000 0 SNC[+57.0]YGYFR
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533.72 705.34 18.9 23.84 28.84 1 5000 0 SNC[+57.0]YGYFR
533.72 542.27 18.9 23.84 28.84 1 5000 0 SNC[+57.0]YGYFR
538.73 875.37 18.9 23.84 28.84 1 5000 0 SNC[+57.0]YGYFR
538.73 715.34 18.9 23.84 28.84 1 5000 0 SNC[+57.0]YGYFR
538.73 552.28 18.9 23.84 28.84 1 5000 0 SNC[+57.0]YGYFR
794.39 1086.52 26.7 29.1 34.1 1 5000 0 EASTIAEYISGYQR
794.39 886.44 26.7 29.1 34.1 1 5000 0 EASTIAEYISGYQR
794.39 610.29 26.7 29.1 34.1 1 5000 0 EASTIAEYISGYQR
799.39 1096.53 26.7 29.1 34.1 1 5000 0 EASTIAEYISGYQR
799.39 896.45 26.7 29.1 34.1 1 5000 0 EASTIAEYISGYQR
799.39 620.30 26.7 29.1 34.1 1 5000 0 EASTIAEYISGYQR
784.10 1225.65 32.1 30.67 35.67 1 5000 0 LITINQQWKPIEELQNVQR
784.10 886.47 32.1 30.67 35.67 1 5000 0 LITINQQWKPIEELQNVQR
787.44 1235.66 32.1 30.67 35.67 1 5000 0 LITINQQWKPIEELQNVQR
787.44 896.48 32.1 30.67 35.67 1 5000 0 LITINQQWKPIEELQNVQR
416.23 730.41 15.4 21.82 26.82 1 5000 0 TDVILDR
416.23 615.38 15.4 21.82 26.82 1 5000 0 TDVILDR
421.24 740.42 15.4 21.82 26.82 1 5000 0 TDVILDR
421.24 625.39 15.4 21.82 26.82 1 5000 0 TDVILDR
613.32 1166.66 25.6 27.68 32.68 1 5000 0 NVTGHYISPFHDIPLK
613.32 1053.57 25.6 27.68 32.68 1 5000 0 NVTGHYISPFHDIPLK
613.32 966.54 25.6 27.68 32.68 1 5000 0 NVTGHYISPFHDIPLK
616.00 1174.67 25.6 27.68 32.68 1 5000 0 NVTGHYISPFHDIPLK
616.00 1061.59 25.6 27.68 32.68 1 5000 0 NVTGHYISPFHDIPLK
616.00 974.55 25.6 27.68 32.68 1 5000 0 NVTGHYISPFHDIPLK
678.36 1129.55 23.3 23.93 28.93 1 5000 0 LIAINANDPEASK
678.36 945.43 23.3 23.93 28.93 1 5000 0 LIAINANDPEASK
678.36 531.28 23.3 23.93 28.93 1 5000 0 LIAINANDPEASK
682.37 1137.56 23.3 23.93 28.93 1 5000 0 LIAINANDPEASK
682.37 953.44 23.3 23.93 28.93 1 5000 0 LIAINANDPEASK
682.37 539.29 23.3 23.93 28.93 1 5000 0 LIAINANDPEASK
445.77 819.50 16.3 27.77 32.77 1 5000 0 AFALEVIK
445.77 672.43 16.3 27.77 32.77 1 5000 0 AFALEVIK
445.77 601.39 16.3 27.77 32.77 1 5000 0 AFALEVIK
449.78 827.51 16.3 27.77 32.77 1 5000 0 AFALEVIK
449.78 680.44 16.3 27.77 32.77 1 5000 0 AFALEVIK
449.78 609.41 16.3 27.77 32.77 1 5000 0 AFALEVIK
471.24 741.36 17 26.68 31.68 1 5000 0 SLDNFFAK
471.24 626.33 17 26.68 31.68 1 5000 0 SLDNFFAK
471.24 512.29 17 26.68 31.68 1 5000 0 SLDNFFAK
475.25 749.37 17 26.68 31.68 1 5000 0 SLDNFFAK
475.25 634.34 17 26.68 31.68 1 5000 0 SLDNFFAK
475.25 520.30 17 26.68 31.68 1 5000 0 SLDNFFAK
706.40 1042.59 24.1 26.62 31.62 1 5000 0 GALQNIIPASTGAAK
706.40 928.55 24.1 26.62 31.62 1 5000 0 GALQNIIPASTGAAK
706.40 815.46 24.1 26.62 31.62 1 5000 0 GALQNIIPASTGAAK
710.41 1050.60 24.1 26.62 31.62 1 5000 0 GALQNIIPASTGAAK
710.41 936.56 24.1 26.62 31.62 1 5000 0 GALQNIIPASTGAAK
710.41 823.48 24.1 26.62 31.62 1 5000 0 GALQNIIPASTGAAK
882.40 1101.46 29.4 29.84 34.84 1 5000 0 LISWYDNEFGYSNR
882.40 986.43 29.4 29.84 34.84 1 5000 0 LISWYDNEFGYSNR
882.40 743.35 29.4 29.84 34.84 1 5000 0 LISWYDNEFGYSNR
887.41 1111.47 29.4 29.84 34.84 1 5000 0 LISWYDNEFGYSNR
887.41 996.44 29.4 29.84 34.84 1 5000 0 LISWYDNEFGYSNR
887.41 753.36 29.4 29.84 34.84 1 5000 0 LISWYDNEFGYSNR
596.32 831.49 24.9 27.32 32.32 1 5000 0 HLEINPDHSIIETLR
596.32 744.46 24.9 27.32 32.32 1 5000 0 HLEINPDHSIIETLR
596.32 631.38 24.9 27.32 32.32 1 5000 0 HLEINPDHSIIETLR
599.66 841.50 24.9 27.32 32.32 1 5000 0 HLEINPDHSIIETLR
599.66 754.47 24.9 27.32 32.32 1 5000 0 HLEINPDHSIIETLR
599.66 641.39 24.9 27.32 32.32 1 5000 0 HLEINPDHSIIETLR
618.30 992.52 21.5 22.5 27.5 1 5000 0 DQVANSAFVER
618.30 893.45 21.5 22.5 27.5 1 5000 0 DQVANSAFVER
623.31 1002.52 21.5 22.5 27.5 1 5000 0 DQVANSAFVER
623.31 903.46 21.5 22.5 27.5 1 5000 0 DQVANSAFVER
891.42 1144.58 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
891.42 1057.55 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
891.42 960.50 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
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891.42 774.40 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
891.42 659.37 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
895.42 1152.60 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
895.42 1065.57 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
895.42 968.51 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
895.42 782.41 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
895.42 667.39 29.6 28.12 33.12 1 5000 0 DYPDFSPSVDAEAIQK
721.36 1138.60 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
721.36 1051.57 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
721.36 994.55 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
721.36 879.52 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
721.36 587.41 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
721.36 474.33 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
725.36 1146.61 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
725.36 1059.58 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
725.36 1002.56 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
725.36 887.53 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
725.36 595.43 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
725.36 482.34 24.5 27.78 32.78 1 5000 0 SDTSGDYEITLLK
472.23 830.37 17.1 24.07 29.07 1 5000 0 LTFDEYR
472.23 729.32 17.1 24.07 29.07 1 5000 0 LTFDEYR
472.23 582.25 17.1 24.07 29.07 1 5000 0 LTFDEYR
472.23 467.22 17.1 24.07 29.07 1 5000 0 LTFDEYR
472.23 338.18 17.1 24.07 29.07 1 5000 0 LTFDEYR
477.23 840.38 17.1 24.07 29.07 1 5000 0 LTFDEYR
477.23 739.33 17.1 24.07 29.07 1 5000 0 LTFDEYR
477.23 592.26 17.1 24.07 29.07 1 5000 0 LTFDEYR
477.23 477.23 17.1 24.07 29.07 1 5000 0 LTFDEYR
477.23 348.19 17.1 24.07 29.07 1 5000 0 LTFDEYR
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Supplementary table 3. Input file for SpectroDrive analysis (complete transition list). 
ProteinId StrippedSequence iRT 
Precursor 
Charge 
Precursor 
Mz
Fragment 
Charge 
Fragment 
Type 
Fragment 
Number 
Fragment 
Mz 
Relative Fragment 
Intensity ModifiedSequence Workflow
sp|P00338|LDHA_HUMAN DQLIYNLLK 82.81 2 560.32 1 y 6 763.47 750100.00 DQLIYNLLK SPIKE_IN
sp|P00338|LDHA_HUMAN DQLIYNLLK 82.81 2 560.32 1 y 5 650.39 914700.00 DQLIYNLLK SPIKE_IN
sp|P00338|LDHA_HUMAN DQLIYNLLK 82.81 2 560.32 1 y 4 487.32 262800.00 DQLIYNLLK SPIKE_IN
sp|P00338|LDHA_HUMAN DQLIYNLLK 82.81 2 564.33 1 y 6 771.49 750100.00 DQLIYNLLK SPIKE_IN
sp|P00338|LDHA_HUMAN DQLIYNLLK 82.81 2 564.33 1 y 5 658.40 914700.00 DQLIYNLLK SPIKE_IN
sp|P00338|LDHA_HUMAN DQLIYNLLK 82.81 2 564.33 1 y 4 495.34 262800.00 DQLIYNLLK SPIKE_IN
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 117.88 2 829.43 1 y 9 1001.55 194700.00 DLADELALVDVIEDK SPIKE_IN
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 117.88 2 829.43 1 y 8 930.51 135400.00 DLADELALVDVIEDK SPIKE_IN
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 117.88 2 829.43 1 y 6 718.36 131900.00 DLADELALVDVIEDK SPIKE_IN
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 117.88 2 833.44 1 y 9 1009.57 194700.00 DLADELALVDVIEDK SPIKE_IN
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 117.88 2 833.44 1 y 8 938.53 135400.00 DLADELALVDVIEDK SPIKE_IN
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 117.88 2 833.44 1 y 6 726.38 131900.00 DLADELALVDVIEDK SPIKE_IN
sp|P00338|LDHA_HUMAN QVVESAYEVIK 34.32 2 632.84 1 y 9 1037.55 14350.00 QVVESAYEVIK SPIKE_IN
sp|P00338|LDHA_HUMAN QVVESAYEVIK 34.32 2 632.84 1 y 8 938.48 13220.00 QVVESAYEVIK SPIKE_IN
sp|P00338|LDHA_HUMAN QVVESAYEVIK 34.32 2 632.84 1 y 7 809.44 11420.00 QVVESAYEVIK SPIKE_IN
sp|P00338|LDHA_HUMAN QVVESAYEVIK 34.32 2 636.85 1 y 9 1045.57 14350.00 QVVESAYEVIK SPIKE_IN
sp|P00338|LDHA_HUMAN QVVESAYEVIK 34.32 2 636.85 1 y 8 946.50 13220.00 QVVESAYEVIK SPIKE_IN
sp|P00338|LDHA_HUMAN QVVESAYEVIK 34.32 2 636.85 1 y 7 817.45 11420.00 QVVESAYEVIK SPIKE_IN
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 44.65 2 706.40 1 y 11 1042.59 971600.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 44.65 2 706.40 1 y 10 928.55 750800.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 44.65 2 706.40 1 y 9 815.46 5160000.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 44.65 2 710.41 1 y 11 1050.60 971600.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 44.65 2 710.41 1 y 10 936.56 750800.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 44.65 2 710.41 1 y 9 823.48 5160000.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN LISWYDNEFGYSNR 72.02 2 882.40 1 y 9 1101.46 177100.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN LISWYDNEFGYSNR 72.02 2 882.40 1 y 8 986.43 79510.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN LISWYDNEFGYSNR 72.02 2 882.40 1 y 6 743.35 152300.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN LISWYDNEFGYSNR 72.02 2 887.41 1 y 9 1111.47 177100.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN LISWYDNEFGYSNR 72.02 2 887.41 1 y 8 996.44 79510.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN LISWYDNEFGYSNR 72.02 2 887.41 1 y 6 753.36 152300.00 LISWYDNEFGYSNR SPIKE_IN
sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 33.47 2 847.95 1 y 11 1201.57 467700.00 LIAPVAEEEATVPNNK SPIKE_IN
sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 33.47 2 847.95 1 y 5 571.32 179900.00 LIAPVAEEEATVPNNK SPIKE_IN
sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 33.47 2 847.95 1 y 4 472.25 1845000.00 LIAPVAEEEATVPNNK SPIKE_IN
sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 33.47 2 851.96 1 y 11 1209.58 467700.00 LIAPVAEEEATVPNNK SPIKE_IN  
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sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 33.47 2 851.96 1 y 5 579.33 179900.00 LIAPVAEEEATVPNNK SPIKE_IN
sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 33.47 2 851.96 1 y 4 480.27 1845000.00 LIAPVAEEEATVPNNK SPIKE_IN
sp|P07195|LDHB_HUMAN SLADELALVDVLEDK 116.93 2 815.43 1 y 9 1001.55 1069.00 SLADELALVDVLEDK SPIKE_IN
sp|P07195|LDHB_HUMAN SLADELALVDVLEDK 116.93 2 815.43 1 y 8 930.51 698.90 SLADELALVDVLEDK SPIKE_IN
sp|P07195|LDHB_HUMAN SLADELALVDVLEDK 116.93 2 815.43 1 y 7 817.43 673.20 SLADELALVDVLEDK SPIKE_IN
sp|P07195|LDHB_HUMAN SLADELALVDVLEDK 116.93 2 819.44 1 y 9 1009.57 1069.00 SLADELALVDVLEDK SPIKE_IN
sp|P07195|LDHB_HUMAN SLADELALVDVLEDK 116.93 2 819.44 1 y 8 938.53 698.90 SLADELALVDVLEDK SPIKE_IN
sp|P07195|LDHB_HUMAN SLADELALVDVLEDK 116.93 2 819.44 1 y 7 825.44 673.20 SLADELALVDVLEDK SPIKE_IN
sp|P07195|LDHB_HUMAN IVVVTAGVR 18.66 2 457.30 1 y 7 701.43 2742000.00 IVVVTAGVR SPIKE_IN
sp|P07195|LDHB_HUMAN IVVVTAGVR 18.66 2 457.30 1 y 6 602.36 1159000.00 IVVVTAGVR SPIKE_IN
sp|P07195|LDHB_HUMAN IVVVTAGVR 18.66 2 457.30 1 y 5 503.29 820000.00 IVVVTAGVR SPIKE_IN
sp|P07195|LDHB_HUMAN IVVVTAGVR 18.66 2 462.30 1 y 7 711.44 2742000.00 IVVVTAGVR SPIKE_IN
sp|P07195|LDHB_HUMAN IVVVTAGVR 18.66 2 462.30 1 y 6 612.37 1159000.00 IVVVTAGVR SPIKE_IN
sp|P07195|LDHB_HUMAN IVVVTAGVR 18.66 2 462.30 1 y 5 513.30 820000.00 IVVVTAGVR SPIKE_IN
sp|P07900|HS90A_HUMAN HLEINPDHSIIETLR 50.57 3 596.32 1 y 7 831.49 1195000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN HLEINPDHSIIETLR 50.57 3 596.32 1 y 6 744.46 531500.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN HLEINPDHSIIETLR 50.57 3 596.32 1 y 5 631.38 624000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN HLEINPDHSIIETLR 50.57 3 599.66 1 y 7 841.50 1195000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN HLEINPDHSIIETLR 50.57 3 599.66 1 y 6 754.47 531500.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN HLEINPDHSIIETLR 50.57 3 599.66 1 y 5 641.39 624000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN DQVANSAFVER 9.64 2 618.30 1 y 9 992.52 461800.00 DQVANSAFVER SPIKE_IN
sp|P07900|HS90A_HUMAN DQVANSAFVER 9.64 2 618.30 1 y 8 893.45 775100.00 DQVANSAFVER SPIKE_IN
sp|P07900|HS90A_HUMAN DQVANSAFVER 9.64 2 623.31 1 y 9 1002.52 461800.00 DQVANSAFVER SPIKE_IN
sp|P07900|HS90A_HUMAN DQVANSAFVER 9.64 2 623.31 1 y 8 903.46 775100.00 DQVANSAFVER SPIKE_IN
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 19.81 2 904.40 1 y 12 1344.58 8702.00 NSYVAGQYDDAASYQR SPIKE_IN
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 19.81 2 904.40 1 y 9 1088.46 8640.00 NSYVAGQYDDAASYQR SPIKE_IN
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 19.81 2 904.40 1 y 8 925.40 8096.00 NSYVAGQYDDAASYQR SPIKE_IN
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 19.81 2 909.40 1 y 12 1354.59 8702.00 NSYVAGQYDDAASYQR SPIKE_IN
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 19.81 2 909.40 1 y 9 1098.47 8640.00 NSYVAGQYDDAASYQR SPIKE_IN
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 19.81 2 909.40 1 y 8 935.41 8096.00 NSYVAGQYDDAASYQR SPIKE_IN
sp|P11413|G6PD_HUMAN GGYFDEFGIIR 81.28 2 637.31 1 y 8 996.51 265500.00 GGYFDEFGIIR SPIKE_IN
sp|P11413|G6PD_HUMAN GGYFDEFGIIR 81.28 2 637.31 1 y 7 849.45 389300.00 GGYFDEFGIIR SPIKE_IN
sp|P11413|G6PD_HUMAN GGYFDEFGIIR 81.28 2 637.31 1 y 5 605.38 271600.00 GGYFDEFGIIR SPIKE_IN
sp|P11413|G6PD_HUMAN GGYFDEFGIIR 81.28 2 642.32 1 y 8 1006.52 265500.00 GGYFDEFGIIR SPIKE_IN
sp|P11413|G6PD_HUMAN GGYFDEFGIIR 81.28 2 642.32 1 y 7 859.45 389300.00 GGYFDEFGIIR SPIKE_IN
sp|P11413|G6PD_HUMAN GGYFDEFGIIR 81.28 2 642.32 1 y 5 615.39 271600.00 GGYFDEFGIIR SPIKE_IN
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sp|P12429|ANXA3_HUMAN DYPDFSPSVDAEAIQK 57.41 2 891.42 1 y 11 1144.58 358100.00 DYPDFSPSVDAEAIQK SPIKE_IN
sp|P12429|ANXA3_HUMAN DYPDFSPSVDAEAIQK 57.41 2 891.42 1 y 10 1057.55 700900.00 DYPDFSPSVDAEAIQK SPIKE_IN
sp|P12429|ANXA3_HUMAN DYPDFSPSVDAEAIQK 57.41 2 895.42 1 y 11 1152.60 358100.00 DYPDFSPSVDAEAIQK SPIKE_IN
sp|P12429|ANXA3_HUMAN DYPDFSPSVDAEAIQK 57.41 2 895.42 1 y 10 1065.57 700900.00 DYPDFSPSVDAEAIQK SPIKE_IN
sp|P12429|ANXA3_HUMAN SDTSGDYEITLLK 54.51 2 721.36 1 y 10 1138.60 13560.00 SDTSGDYEITLLK SPIKE_IN
sp|P12429|ANXA3_HUMAN SDTSGDYEITLLK 54.51 2 721.36 1 y 9 1051.57 24290.00 SDTSGDYEITLLK SPIKE_IN
sp|P12429|ANXA3_HUMAN SDTSGDYEITLLK 54.51 2 725.36 1 y 10 1146.61 13560.00 SDTSGDYEITLLK SPIKE_IN
sp|P12429|ANXA3_HUMAN SDTSGDYEITLLK 54.51 2 725.36 1 y 9 1059.58 24290.00 SDTSGDYEITLLK SPIKE_IN
sp|P12429|ANXA3_HUMAN LTFDEYR 22.99 2 472.23 1 y 5 729.32 3802000.00 LTFDEYR SPIKE_IN
sp|P12429|ANXA3_HUMAN LTFDEYR 22.99 2 472.23 1 y 4 582.25 493000.00 LTFDEYR SPIKE_IN
sp|P12429|ANXA3_HUMAN LTFDEYR 22.99 2 477.23 1 y 5 739.33 3802000.00 LTFDEYR SPIKE_IN
sp|P12429|ANXA3_HUMAN LTFDEYR 22.99 2 477.23 1 y 4 592.26 493000.00 LTFDEYR SPIKE_IN
sp|P15121|ALDR_HUMAN SPPGQVTEAVK -9.56 2 556.80 1 y 9 928.51 442800.00 SPPGQVTEAVK SPIKE_IN
sp|P15121|ALDR_HUMAN SPPGQVTEAVK -9.56 2 556.80 1 y 8 831.46 53200.00 SPPGQVTEAVK SPIKE_IN
sp|P15121|ALDR_HUMAN SPPGQVTEAVK -9.56 2 556.80 1 y 6 646.38 34170.00 SPPGQVTEAVK SPIKE_IN
sp|P15121|ALDR_HUMAN SPPGQVTEAVK -9.56 2 560.81 1 y 9 936.52 442800.00 SPPGQVTEAVK SPIKE_IN
sp|P15121|ALDR_HUMAN SPPGQVTEAVK -9.56 2 560.81 1 y 8 839.47 53200.00 SPPGQVTEAVK SPIKE_IN
sp|P15121|ALDR_HUMAN SPPGQVTEAVK -9.56 2 560.81 1 y 6 654.39 34170.00 SPPGQVTEAVK SPIKE_IN
sp|P15121|ALDR_HUMAN MPILGLGTWK 81.78 2 558.32 1 y 8 887.53 13140.00 MPILGLGTWK SPIKE_IN
sp|P15121|ALDR_HUMAN MPILGLGTWK 81.78 2 558.32 1 y 7 774.45 21660.00 MPILGLGTWK SPIKE_IN
sp|P15121|ALDR_HUMAN MPILGLGTWK 81.78 2 558.32 1 y 6 661.37 29920.00 MPILGLGTWK SPIKE_IN
sp|P15121|ALDR_HUMAN MPILGLGTWK 81.78 2 562.32 1 y 8 895.55 13140.00 MPILGLGTWK SPIKE_IN
sp|P15121|ALDR_HUMAN MPILGLGTWK 81.78 2 562.32 1 y 7 782.47 21660.00 MPILGLGTWK SPIKE_IN
sp|P15121|ALDR_HUMAN MPILGLGTWK 81.78 2 562.32 1 y 6 669.38 29920.00 MPILGLGTWK SPIKE_IN
sp|P15121|ALDR_HUMAN VAIDVGYR 19.56 2 446.75 1 y 6 722.38 235200.00 VAIDVGYR SPIKE_IN
sp|P15121|ALDR_HUMAN VAIDVGYR 19.56 2 446.75 1 y 5 609.30 140900.00 VAIDVGYR SPIKE_IN
sp|P15121|ALDR_HUMAN VAIDVGYR 19.56 2 446.75 1 y 4 494.27 45000.00 VAIDVGYR SPIKE_IN
sp|P15121|ALDR_HUMAN VAIDVGYR 19.56 2 451.75 1 y 6 732.39 235200.00 VAIDVGYR SPIKE_IN
sp|P15121|ALDR_HUMAN VAIDVGYR 19.56 2 451.75 1 y 5 619.31 140900.00 VAIDVGYR SPIKE_IN
sp|P15121|ALDR_HUMAN VAIDVGYR 19.56 2 451.75 1 y 4 504.28 45000.00 VAIDVGYR SPIKE_IN
sp|P19338|NUCL_HUMAN FGYVDFESAEDLEK 73.18 2 824.87 1 y 10 1182.52 1537.00 FGYVDFESAEDLEK SPIKE_IN
sp|P19338|NUCL_HUMAN FGYVDFESAEDLEK 73.18 2 824.87 1 y 9 1067.49 843.20 FGYVDFESAEDLEK SPIKE_IN
sp|P19338|NUCL_HUMAN FGYVDFESAEDLEK 73.18 2 824.87 1 y 7 791.38 961.40 FGYVDFESAEDLEK SPIKE_IN
sp|P19338|NUCL_HUMAN FGYVDFESAEDLEK 73.18 2 828.88 1 y 10 1190.53 1537.00 FGYVDFESAEDLEK SPIKE_IN
sp|P19338|NUCL_HUMAN FGYVDFESAEDLEK 73.18 2 828.88 1 y 9 1075.50 843.20 FGYVDFESAEDLEK SPIKE_IN
sp|P19338|NUCL_HUMAN FGYVDFESAEDLEK 73.18 2 828.88 1 y 7 799.39 961.40 FGYVDFESAEDLEK SPIKE_IN
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sp|P19338|NUCL_HUMAN EVFEDAAEIR 31.54 2 589.79 1 y 8 950.46 51910.00 EVFEDAAEIR SPIKE_IN
sp|P19338|NUCL_HUMAN EVFEDAAEIR 31.54 2 589.79 1 y 7 803.39 32050.00 EVFEDAAEIR SPIKE_IN
sp|P19338|NUCL_HUMAN EVFEDAAEIR 31.54 2 589.79 1 y 6 674.35 31030.00 EVFEDAAEIR SPIKE_IN
sp|P19338|NUCL_HUMAN EVFEDAAEIR 31.54 2 594.79 1 y 8 960.47 51910.00 EVFEDAAEIR SPIKE_IN
sp|P19338|NUCL_HUMAN EVFEDAAEIR 31.54 2 594.79 1 y 7 813.40 32050.00 EVFEDAAEIR SPIKE_IN
sp|P19338|NUCL_HUMAN EVFEDAAEIR 31.54 2 594.79 1 y 6 684.36 31030.00 EVFEDAAEIR SPIKE_IN
sp|P19338|NUCL_HUMAN GFGFVDFNSEEDAK 69.63 2 781.34 1 y 10 1153.50 438000.00 GFGFVDFNSEEDAK SPIKE_IN
sp|P19338|NUCL_HUMAN GFGFVDFNSEEDAK 69.63 2 781.34 1 y 9 1054.43 738300.00 GFGFVDFNSEEDAK SPIKE_IN
sp|P19338|NUCL_HUMAN GFGFVDFNSEEDAK 69.63 2 781.34 1 y 8 939.41 332100.00 GFGFVDFNSEEDAK SPIKE_IN
sp|P19338|NUCL_HUMAN GFGFVDFNSEEDAK 69.63 2 785.35 1 y 10 1161.51 438000.00 GFGFVDFNSEEDAK SPIKE_IN
sp|P19338|NUCL_HUMAN GFGFVDFNSEEDAK 69.63 2 785.35 1 y 9 1062.45 738300.00 GFGFVDFNSEEDAK SPIKE_IN
sp|P19338|NUCL_HUMAN GFGFVDFNSEEDAK 69.63 2 785.35 1 y 8 947.42 332100.00 GFGFVDFNSEEDAK SPIKE_IN
sp|P22223|CADH3_HUMAN STGTISVISSGLDR 43.28 2 696.87 1 y 9 933.50 2257000.00 STGTISVISSGLDR SPIKE_IN
sp|P22223|CADH3_HUMAN STGTISVISSGLDR 43.28 2 696.87 1 y 7 747.40 834400.00 STGTISVISSGLDR SPIKE_IN
sp|P22223|CADH3_HUMAN STGTISVISSGLDR 43.28 2 696.87 1 y 6 634.32 480500.00 STGTISVISSGLDR SPIKE_IN
sp|P22223|CADH3_HUMAN STGTISVISSGLDR 43.28 2 701.87 1 y 9 943.51 2257000.00 STGTISVISSGLDR SPIKE_IN
sp|P22223|CADH3_HUMAN STGTISVISSGLDR 43.28 2 701.87 1 y 7 757.41 834400.00 STGTISVISSGLDR SPIKE_IN
sp|P22223|CADH3_HUMAN STGTISVISSGLDR 43.28 2 701.87 1 y 6 644.32 480500.00 STGTISVISSGLDR SPIKE_IN
sp|P22223|CADH3_HUMAN LTVTDLDAPNSPAWR 59.46 2 828.42 1 y 9 1013.48 1537000.00 LTVTDLDAPNSPAWR SPIKE_IN
sp|P22223|CADH3_HUMAN LTVTDLDAPNSPAWR 59.46 2 828.42 1 y 8 898.45 2471000.00 LTVTDLDAPNSPAWR SPIKE_IN
sp|P22223|CADH3_HUMAN LTVTDLDAPNSPAWR 59.46 2 828.42 1 y 7 827.42 2043000.00 LTVTDLDAPNSPAWR SPIKE_IN
sp|P22223|CADH3_HUMAN LTVTDLDAPNSPAWR 59.46 2 833.43 1 y 9 1023.49 1537000.00 LTVTDLDAPNSPAWR SPIKE_IN
sp|P22223|CADH3_HUMAN LTVTDLDAPNSPAWR 59.46 2 833.43 1 y 8 908.46 2471000.00 LTVTDLDAPNSPAWR SPIKE_IN
sp|P22223|CADH3_HUMAN LTVTDLDAPNSPAWR 59.46 2 833.43 1 y 7 837.42 2043000.00 LTVTDLDAPNSPAWR SPIKE_IN
sp|P27695|APEX1_HUMAN EAAGEGPALYEDPPDQK 16.82 2 893.91 1 y 12 1329.63 131400.00 EAAGEGPALYEDPPDQK SPIKE_IN
sp|P27695|APEX1_HUMAN EAAGEGPALYEDPPDQK 16.82 2 893.91 1 y 8 991.44 224000.00 EAAGEGPALYEDPPDQK SPIKE_IN
sp|P27695|APEX1_HUMAN EAAGEGPALYEDPPDQK 16.82 2 893.91 1 y 5 584.30 2859000.00 EAAGEGPALYEDPPDQK SPIKE_IN
sp|P27695|APEX1_HUMAN EAAGEGPALYEDPPDQK 16.82 2 897.92 1 y 12 1337.65 131400.00 EAAGEGPALYEDPPDQK SPIKE_IN
sp|P27695|APEX1_HUMAN EAAGEGPALYEDPPDQK 16.82 2 897.92 1 y 8 999.45 224000.00 EAAGEGPALYEDPPDQK SPIKE_IN
sp|P27695|APEX1_HUMAN EAAGEGPALYEDPPDQK 16.82 2 897.92 1 y 5 592.32 2859000.00 EAAGEGPALYEDPPDQK SPIKE_IN
sp|P27695|APEX1_HUMAN QGFGELLQAVPLADSFR 119.43 2 924.49 1 y 10 1103.58 1906.00 QGFGELLQAVPLADSFR SPIKE_IN
sp|P27695|APEX1_HUMAN QGFGELLQAVPLADSFR 119.43 2 924.49 1 y 9 975.53 1749.00 QGFGELLQAVPLADSFR SPIKE_IN
sp|P27695|APEX1_HUMAN QGFGELLQAVPLADSFR 119.43 2 924.49 1 y 7 805.42 3167.00 QGFGELLQAVPLADSFR SPIKE_IN
sp|P27695|APEX1_HUMAN QGFGELLQAVPLADSFR 119.43 2 929.49 1 y 10 1113.59 1906.00 QGFGELLQAVPLADSFR SPIKE_IN
sp|P27695|APEX1_HUMAN QGFGELLQAVPLADSFR 119.43 2 929.49 1 y 9 985.53 1749.00 QGFGELLQAVPLADSFR SPIKE_IN
sp|P27695|APEX1_HUMAN QGFGELLQAVPLADSFR 119.43 2 929.49 1 y 7 815.43 3167.00 QGFGELLQAVPLADSFR SPIKE_IN
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sp|P27695|APEX1_HUMAN LDYFLLSHSLLPALCDSK 113.98 2 1046.54 1 y 7 790.38 88430.00 LDYFLLSHSLLPALC[+57]DSK SPIKE_IN
sp|P27695|APEX1_HUMAN LDYFLLSHSLLPALCDSK 113.98 2 1046.54 1 y 5 622.29 22500.00 LDYFLLSHSLLPALC[+57]DSK SPIKE_IN
sp|P27695|APEX1_HUMAN LDYFLLSHSLLPALCDSK 113.98 2 1046.54 1 b 3 392.18 31790.00 LDYFLLSHSLLPALC[+57]DSK SPIKE_IN
sp|P27695|APEX1_HUMAN LDYFLLSHSLLPALCDSK 113.98 2 1050.55 1 y 7 798.39 88430.00 LDYFLLSHSLLPALC[+57]DSK SPIKE_IN
sp|P27695|APEX1_HUMAN LDYFLLSHSLLPALCDSK 113.98 2 1050.55 1 y 5 630.30 22500.00 LDYFLLSHSLLPALC[+57]DSK SPIKE_IN
sp|P27695|APEX1_HUMAN LDYFLLSHSLLPALCDSK 113.98 2 1050.55 1 b 3 392.18 31790.00 LDYFLLSHSLLPALC[+57]DSK SPIKE_IN
sp|P31949|S10AB_HUMAN ISSPTETER -8.63 2 510.25 1 y 8 906.42 6767000.00 ISSPTETER SPIKE_IN
sp|P31949|S10AB_HUMAN ISSPTETER -8.63 2 510.25 1 y 7 819.38 3382000.00 ISSPTETER SPIKE_IN
sp|P31949|S10AB_HUMAN ISSPTETER -8.63 2 510.25 1 y 6 732.35 3798000.00 ISSPTETER SPIKE_IN
sp|P31949|S10AB_HUMAN ISSPTETER -8.63 2 515.26 1 y 8 916.42 6767000.00 ISSPTETER SPIKE_IN
sp|P31949|S10AB_HUMAN ISSPTETER -8.63 2 515.26 1 y 7 829.39 3382000.00 ISSPTETER SPIKE_IN
sp|P31949|S10AB_HUMAN ISSPTETER -8.63 2 515.26 1 y 6 742.36 3798000.00 ISSPTETER SPIKE_IN
sp|P31949|S10AB_HUMAN DGYNYTLSK 11.1 2 530.75 1 y 6 725.38 1117000.00 DGYNYTLSK SPIKE_IN
sp|P31949|S10AB_HUMAN DGYNYTLSK 11.1 2 530.75 1 y 5 611.34 601200.00 DGYNYTLSK SPIKE_IN
sp|P31949|S10AB_HUMAN DGYNYTLSK 11.1 2 530.75 1 y 4 448.28 537800.00 DGYNYTLSK SPIKE_IN
sp|P31949|S10AB_HUMAN DGYNYTLSK 11.1 2 534.76 1 y 6 733.40 1117000.00 DGYNYTLSK SPIKE_IN
sp|P31949|S10AB_HUMAN DGYNYTLSK 11.1 2 534.76 1 y 5 619.35 601200.00 DGYNYTLSK SPIKE_IN
sp|P31949|S10AB_HUMAN DGYNYTLSK 11.1 2 534.76 1 y 4 456.29 537800.00 DGYNYTLSK SPIKE_IN
sp|P31949|S10AB_HUMAN DPGVLDR -4.05 2 386.20 1 y 5 559.32 29260.00 DPGVLDR SPIKE_IN
sp|P31949|S10AB_HUMAN DPGVLDR -4.05 2 386.20 1 y 4 502.30 5170.00 DPGVLDR SPIKE_IN
sp|P31949|S10AB_HUMAN DPGVLDR -4.05 2 386.20 1 y 3 403.23 9090.00 DPGVLDR SPIKE_IN
sp|P31949|S10AB_HUMAN DPGVLDR -4.05 2 391.21 1 y 5 569.33 29260.00 DPGVLDR SPIKE_IN
sp|P31949|S10AB_HUMAN DPGVLDR -4.05 2 391.21 1 y 4 512.31 5170.00 DPGVLDR SPIKE_IN
sp|P31949|S10AB_HUMAN DPGVLDR -4.05 2 391.21 1 y 3 413.24 9090.00 DPGVLDR SPIKE_IN
sp|P36952|SPB5_HUMAN IIELPFQNK 58.65 2 551.32 1 y 6 746.42 903400.00 IIELPFQNK SPIKE_IN
sp|P36952|SPB5_HUMAN IIELPFQNK 58.65 2 551.32 1 y 5 633.34 1793000.00 IIELPFQNK SPIKE_IN
sp|P36952|SPB5_HUMAN IIELPFQNK 58.65 2 555.33 1 y 6 754.43 903400.00 IIELPFQNK SPIKE_IN
sp|P36952|SPB5_HUMAN IIELPFQNK 58.65 2 555.33 1 y 5 641.35 1793000.00 IIELPFQNK SPIKE_IN
sp|P39687|AN32A_HUMAN ELVLDNSR 3.51 2 473.25 1 y 6 703.37 20500.00 ELVLDNSR SPIKE_IN
sp|P39687|AN32A_HUMAN ELVLDNSR 3.51 2 473.25 1 y 5 604.30 27810.00 ELVLDNSR SPIKE_IN
sp|P39687|AN32A_HUMAN ELVLDNSR 3.51 2 473.25 1 y 4 491.22 13890.00 ELVLDNSR SPIKE_IN
sp|P39687|AN32A_HUMAN ELVLDNSR 3.51 2 478.26 1 y 6 713.38 20500.00 ELVLDNSR SPIKE_IN
sp|P39687|AN32A_HUMAN ELVLDNSR 3.51 2 478.26 1 y 5 614.31 27810.00 ELVLDNSR SPIKE_IN
sp|P39687|AN32A_HUMAN ELVLDNSR 3.51 2 478.26 1 y 4 501.23 13890.00 ELVLDNSR SPIKE_IN
sp|P39687|AN32A_HUMAN CPNLTHLNLSGNK 25.69 3 489.92 1 y 7 745.42 468400.00 C[+57]PNLTHLNLSGNK SPIKE_IN
sp|P39687|AN32A_HUMAN CPNLTHLNLSGNK 25.69 3 489.92 1 y 6 632.34 478000.00 C[+57]PNLTHLNLSGNK SPIKE_IN
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sp|P39687|AN32A_HUMAN CPNLTHLNLSGNK 25.69 3 489.92 1 y 4 405.21 284700.00 C[+57]PNLTHLNLSGNK SPIKE_IN
sp|P39687|AN32A_HUMAN CPNLTHLNLSGNK 25.69 3 492.59 1 y 7 753.43 468400.00 C[+57]PNLTHLNLSGNK SPIKE_IN
sp|P39687|AN32A_HUMAN CPNLTHLNLSGNK 25.69 3 492.59 1 y 6 640.35 478000.00 C[+57]PNLTHLNLSGNK SPIKE_IN
sp|P39687|AN32A_HUMAN CPNLTHLNLSGNK 25.69 3 492.59 1 y 4 413.22 284700.00 C[+57]PNLTHLNLSGNK SPIKE_IN
sp|P55011|S12A2_HUMAN VELPGTAVPSVPEDAAPASR 46.04 2 982.01 1 y 13 1295.66 995200.00 VELPGTAVPSVPEDAAPASR SPIKE_IN
sp|P55011|S12A2_HUMAN VELPGTAVPSVPEDAAPASR 46.04 2 982.01 1 y 12 1196.59 7980000.00 VELPGTAVPSVPEDAAPASR SPIKE_IN
sp|P55011|S12A2_HUMAN VELPGTAVPSVPEDAAPASR 46.04 2 982.01 1 y 9 913.44 1397000.00 VELPGTAVPSVPEDAAPASR SPIKE_IN
sp|P55011|S12A2_HUMAN VELPGTAVPSVPEDAAPASR 46.04 2 987.01 1 y 13 1305.67 995200.00 VELPGTAVPSVPEDAAPASR SPIKE_IN
sp|P55011|S12A2_HUMAN VELPGTAVPSVPEDAAPASR 46.04 2 987.01 1 y 12 1206.60 7980000.00 VELPGTAVPSVPEDAAPASR SPIKE_IN
sp|P55011|S12A2_HUMAN VELPGTAVPSVPEDAAPASR 46.04 2 987.01 1 y 9 923.45 1397000.00 VELPGTAVPSVPEDAAPASR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 2 687.84 1 y 9 993.51 515000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 2 687.84 1 y 8 922.47 1686000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 2 687.84 1 y 6 726.35 522600.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 2 692.85 1 y 9 1003.52 515000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 2 692.85 1 y 8 932.48 1686000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 2 692.85 1 y 6 736.36 522600.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 3 458.90 1 y 8 922.47 3103000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 3 458.90 1 y 6 726.35 3745000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 3 458.90 1 y 5 589.29 2648000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 3 462.23 1 y 8 932.48 3103000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 3 462.23 1 y 6 736.36 3745000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN AFYAPVHADDLR 30.67 3 462.23 1 y 5 599.30 2648000.00 AFYAPVHADDLR SPIKE_IN
sp|P55011|S12A2_HUMAN EGLDISHLQGQEELLSSQEK 60.03 3 747.37 1 y 7 804.45 247300.00 EGLDISHLQGQEELLSSQEK SPIKE_IN
sp|P55011|S12A2_HUMAN EGLDISHLQGQEELLSSQEK 60.03 3 747.37 1 y 6 691.36 382500.00 EGLDISHLQGQEELLSSQEK SPIKE_IN
sp|P55011|S12A2_HUMAN EGLDISHLQGQEELLSSQEK 60.03 3 747.37 1 y 5 578.28 462100.00 EGLDISHLQGQEELLSSQEK SPIKE_IN
sp|P55011|S12A2_HUMAN EGLDISHLQGQEELLSSQEK 60.03 3 750.04 1 y 7 812.46 247300.00 EGLDISHLQGQEELLSSQEK SPIKE_IN
sp|P55011|S12A2_HUMAN EGLDISHLQGQEELLSSQEK 60.03 3 750.04 1 y 6 699.38 382500.00 EGLDISHLQGQEELLSSQEK SPIKE_IN
sp|P55011|S12A2_HUMAN EGLDISHLQGQEELLSSQEK 60.03 3 750.04 1 y 5 586.29 462100.00 EGLDISHLQGQEELLSSQEK SPIKE_IN
sp|P55011|S12A2_HUMAN ITDNELELYK 38.06 2 619.32 1 y 9 1124.55 20950.00 ITDNELELYK SPIKE_IN
sp|P55011|S12A2_HUMAN ITDNELELYK 38.06 2 619.32 1 y 8 1023.50 20530.00 ITDNELELYK SPIKE_IN
sp|P55011|S12A2_HUMAN ITDNELELYK 38.06 2 619.32 1 y 2 310.18 7514.00 ITDNELELYK SPIKE_IN
sp|P55011|S12A2_HUMAN ITDNELELYK 38.06 2 623.33 1 y 9 1132.56 20950.00 ITDNELELYK SPIKE_IN
sp|P55011|S12A2_HUMAN ITDNELELYK 38.06 2 623.33 1 y 8 1031.51 20530.00 ITDNELELYK SPIKE_IN
sp|P55011|S12A2_HUMAN ITDNELELYK 38.06 2 623.33 1 y 2 318.19 7514.00 ITDNELELYK SPIKE_IN
sp|P62330|ARF6_HUMAN FNVWDVGGQDK 53.03 2 632.80 1 y 9 1003.48 144000.00 FNVWDVGGQDK SPIKE_IN
sp|P62330|ARF6_HUMAN FNVWDVGGQDK 53.03 2 632.80 1 y 8 904.42 326500.00 FNVWDVGGQDK SPIKE_IN
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sp|P62330|ARF6_HUMAN FNVWDVGGQDK 53.03 2 632.80 1 y 7 718.34 145300.00 FNVWDVGGQDK SPIKE_IN
sp|P62330|ARF6_HUMAN FNVWDVGGQDK 53.03 2 636.81 1 y 9 1011.50 144000.00 FNVWDVGGQDK SPIKE_IN
sp|P62330|ARF6_HUMAN FNVWDVGGQDK 53.03 2 636.81 1 y 8 912.43 326500.00 FNVWDVGGQDK SPIKE_IN
sp|P62330|ARF6_HUMAN FNVWDVGGQDK 53.03 2 636.81 1 y 7 726.35 145300.00 FNVWDVGGQDK SPIKE_IN
sp|P80188|NGAL_HUMAN SYPGLTSYLVR 63.13 2 628.34 1 y 9 1005.57 189900.00 SYPGLTSYLVR SPIKE_IN
sp|P80188|NGAL_HUMAN SYPGLTSYLVR 63.13 2 628.34 1 y 8 908.52 30110.00 SYPGLTSYLVR SPIKE_IN
sp|P80188|NGAL_HUMAN SYPGLTSYLVR 63.13 2 633.34 1 y 9 1015.58 189900.00 SYPGLTSYLVR SPIKE_IN
sp|P80188|NGAL_HUMAN SYPGLTSYLVR 63.13 2 633.34 1 y 8 918.53 30110.00 SYPGLTSYLVR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 2 975.52 1 y 12 1333.75 4050.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 2 975.52 1 y 11 1220.66 43880.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 2 975.52 1 y 9 994.57 23530.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 2 980.52 1 y 12 1343.76 4050.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 2 980.52 1 y 11 1230.67 43880.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 2 980.52 1 y 9 1004.58 23530.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 3 650.68 1 y 9 994.57 789600.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 3 650.68 1 y 8 897.52 420900.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 3 650.68 1 y 7 840.49 200600.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 3 654.02 1 y 9 1004.58 789600.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 3 654.02 1 y 8 907.52 420900.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN LENYPIPEPGPNEVLLR 75.82 3 654.02 1 y 7 850.50 200600.00 LENYPIPEPGPNEVLLR SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 2 791.92 1 y 12 1226.64 141.40 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 2 791.92 1 y 11 1127.57 238.10 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 2 791.92 1 y 10 1014.49 250.20 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 2 795.92 1 y 12 1234.65 141.40 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 2 795.92 1 y 11 1135.58 238.10 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 2 795.92 1 y 10 1022.50 250.20 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 3 528.28 1 y 8 820.40 21700.00 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 3 528.28 1 y 7 691.36 31990.00 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 3 528.28 1 y 6 620.32 21030.00 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 3 530.95 1 y 8 828.42 21700.00 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 3 530.95 1 y 7 699.38 31990.00 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN KPMVLGHEASGTVEK -9.53 3 530.95 1 y 6 628.34 21030.00 KPMVLGHEASGTVEK SPIKE_IN
sp|Q00796|DHSO_HUMAN LPDNVTFEEGALIEPLSVGIHACR 99.39 3 879.78 1 y 12 1351.72 11340.00 LPDNVTFEEGALIEPLSVGIHAC[+57]R SPIKE_IN
sp|Q00796|DHSO_HUMAN LPDNVTFEEGALIEPLSVGIHACR 99.39 3 879.78 1 y 11 1238.63 21290.00 LPDNVTFEEGALIEPLSVGIHAC[+57]R SPIKE_IN
sp|Q00796|DHSO_HUMAN LPDNVTFEEGALIEPLSVGIHACR 99.39 3 879.78 1 y 10 1109.59 53780.00 LPDNVTFEEGALIEPLSVGIHAC[+57]R SPIKE_IN
sp|Q00796|DHSO_HUMAN LPDNVTFEEGALIEPLSVGIHACR 99.39 3 883.12 1 y 12 1361.72 11340.00 LPDNVTFEEGALIEPLSVGIHAC[+57]R SPIKE_IN
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sp|Q00796|DHSO_HUMAN LPDNVTFEEGALIEPLSVGIHACR 99.39 3 883.12 1 y 11 1248.64 21290.00 LPDNVTFEEGALIEPLSVGIHAC[+57]R SPIKE_IN
sp|Q00796|DHSO_HUMAN LPDNVTFEEGALIEPLSVGIHACR 99.39 3 883.12 1 y 10 1119.60 53780.00 LPDNVTFEEGALIEPLSVGIHAC[+57]R SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 2 795.42 1 y 9 961.53 3408.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 2 795.42 1 y 8 862.46 1728.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 2 795.42 1 y 7 763.39 1828.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 2 800.42 1 y 9 971.54 3408.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 2 800.42 1 y 8 872.47 1728.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 2 800.42 1 y 7 773.40 1828.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 3 530.62 1 y 4 434.24 31840.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 3 530.62 1 b 8 728.38 18620.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 3 530.62 1 b 11 1043.52 19460.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 3 533.95 1 y 4 444.24 31840.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 3 533.95 1 b 8 728.38 18620.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN AMGAAQVVVTDLSATR 64.42 3 533.95 1 b 11 1043.52 19460.00 AMGAAQVVVTDLSATR SPIKE_IN
sp|Q00796|DHSO_HUMAN EIGADLVLQISK 75.03 2 643.37 1 y 10 1043.61 487300.00 EIGADLVLQISK SPIKE_IN
sp|Q00796|DHSO_HUMAN EIGADLVLQISK 75.03 2 643.37 1 y 6 687.44 239300.00 EIGADLVLQISK SPIKE_IN
sp|Q00796|DHSO_HUMAN EIGADLVLQISK 75.03 2 643.37 1 y 5 588.37 367800.00 EIGADLVLQISK SPIKE_IN
sp|Q00796|DHSO_HUMAN EIGADLVLQISK 75.03 2 647.38 1 y 10 1051.62 487300.00 EIGADLVLQISK SPIKE_IN
sp|Q00796|DHSO_HUMAN EIGADLVLQISK 75.03 2 647.38 1 y 6 695.45 239300.00 EIGADLVLQISK SPIKE_IN
sp|Q00796|DHSO_HUMAN EIGADLVLQISK 75.03 2 647.38 1 y 5 596.39 367800.00 EIGADLVLQISK SPIKE_IN
sp|Q01105|SET_HUMAN VEVTEFEDIK 44.68 2 604.81 1 y 8 980.49 1824000.00 VEVTEFEDIK SPIKE_IN
sp|Q01105|SET_HUMAN VEVTEFEDIK 44.68 2 604.81 1 y 7 881.43 1900000.00 VEVTEFEDIK SPIKE_IN
sp|Q01105|SET_HUMAN VEVTEFEDIK 44.68 2 604.81 1 y 5 651.33 751300.00 VEVTEFEDIK SPIKE_IN
sp|Q01105|SET_HUMAN VEVTEFEDIK 44.68 2 608.81 1 y 8 988.51 1824000.00 VEVTEFEDIK SPIKE_IN
sp|Q01105|SET_HUMAN VEVTEFEDIK 44.68 2 608.81 1 y 7 889.44 1900000.00 VEVTEFEDIK SPIKE_IN
sp|Q01105|SET_HUMAN VEVTEFEDIK 44.68 2 608.81 1 y 5 659.35 751300.00 VEVTEFEDIK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 920.91 1 y 10 1302.56 887.10 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 920.91 1 y 9 1155.50 638.00 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 920.91 1 y 6 797.38 2297.00 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 920.91 1 y 4 537.27 1042.00 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 924.91 1 y 10 1310.58 887.10 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 924.91 1 y 9 1163.51 638.00 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 924.91 1 y 6 805.40 2297.00 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN IDFYFDENPYFENK 93.03 2 924.91 1 y 4 545.28 1042.00 IDFYFDENPYFENK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 2 723.83 1 y 10 1033.48 570.50 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 2 723.83 1 y 9 920.40 872.70 EFHLNESGDPSSK SPIKE_IN
Supplementary table 3 contd.
 
!! 161!
 
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 2 723.83 1 y 4 418.23 1670.00 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 2 727.84 1 y 10 1041.49 570.50 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 2 727.84 1 y 9 928.41 872.70 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 2 727.84 1 y 4 426.24 1670.00 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 3 482.89 1 y 6 590.28 845500.00 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 3 482.89 1 y 4 418.23 2314000.00 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 3 482.89 1 y 3 321.18 649300.00 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 3 485.56 1 y 6 598.29 845500.00 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 3 485.56 1 y 4 426.24 2314000.00 EFHLNESGDPSSK SPIKE_IN
sp|Q01105|SET_HUMAN EFHLNESGDPSSK 2.16 3 485.56 1 y 3 329.19 649300.00 EFHLNESGDPSSK SPIKE_IN
sp|Q15124|PGM5_HUMAN VPVYETPAGWR 40.31 2 637.83 1 y 9 1078.53 41600.00 VPVYETPAGWR SPIKE_IN
sp|Q15124|PGM5_HUMAN VPVYETPAGWR 40.31 2 637.83 1 y 8 979.46 95580.00 VPVYETPAGWR SPIKE_IN
sp|Q15124|PGM5_HUMAN VPVYETPAGWR 40.31 2 637.83 1 y 7 816.40 56490.00 VPVYETPAGWR SPIKE_IN
sp|Q15124|PGM5_HUMAN VPVYETPAGWR 40.31 2 642.83 1 y 9 1088.54 41600.00 VPVYETPAGWR SPIKE_IN
sp|Q15124|PGM5_HUMAN VPVYETPAGWR 40.31 2 642.83 1 y 8 989.47 95580.00 VPVYETPAGWR SPIKE_IN
sp|Q15124|PGM5_HUMAN VPVYETPAGWR 40.31 2 642.83 1 y 7 826.41 56490.00 VPVYETPAGWR SPIKE_IN
sp|Q15181|IPYR_HUMAN AAPFSLEYR 44.4 2 527.27 1 y 7 911.46 3517000.00 AAPFSLEYR SPIKE_IN
sp|Q15181|IPYR_HUMAN AAPFSLEYR 44.4 2 527.27 1 y 6 814.41 9705000.00 AAPFSLEYR SPIKE_IN
sp|Q15181|IPYR_HUMAN AAPFSLEYR 44.4 2 527.27 1 y 5 667.34 7233000.00 AAPFSLEYR SPIKE_IN
sp|Q15181|IPYR_HUMAN AAPFSLEYR 44.4 2 532.28 1 y 7 921.47 3517000.00 AAPFSLEYR SPIKE_IN
sp|Q15181|IPYR_HUMAN AAPFSLEYR 44.4 2 532.28 1 y 6 824.42 9705000.00 AAPFSLEYR SPIKE_IN
sp|Q15181|IPYR_HUMAN AAPFSLEYR 44.4 2 532.28 1 y 5 677.35 7233000.00 AAPFSLEYR SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 2 932.47 1 y 6 706.38 119300.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 2 932.47 1 y 4 496.24 70420.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 2 932.47 1 b 10 1158.56 62340.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 2 936.47 1 y 6 714.39 119300.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 2 936.47 1 y 4 504.25 70420.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 2 936.47 1 b 10 1158.56 62340.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 3 621.98 1 y 8 934.49 12680.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 3 621.98 1 y 6 706.38 25100.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 3 621.98 1 y 4 496.24 12050.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 3 624.65 1 y 8 942.50 12680.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 3 624.65 1 y 6 714.39 25100.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN GQYISPFHDIPIYADK 71.22 3 624.65 1 y 4 504.25 12050.00 GQYISPFHDIPIYADK SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 2 664.34 1 y 7 829.46 1759000.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 2 664.34 1 y 6 698.42 890200.00 DVFHMVVEVPR SPIKE_IN
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sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 2 664.34 1 y 5 599.35 361600.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 2 669.35 1 y 7 839.47 1759000.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 2 669.35 1 y 6 708.43 890200.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 2 669.35 1 y 5 609.36 361600.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 3 443.23 1 y 7 829.46 38500.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 3 443.23 1 y 5 599.35 18900.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 3 443.23 1 y 4 500.28 27460.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 3 446.57 1 y 7 839.47 38500.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 3 446.57 1 y 5 609.36 18900.00 DVFHMVVEVPR SPIKE_IN
sp|Q15181|IPYR_HUMAN DVFHMVVEVPR 70.25 3 446.57 1 y 4 510.29 27460.00 DVFHMVVEVPR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 650.65 1 b 2 324.15 24450.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 650.65 1 y 8 897.42 16190.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 650.65 1 y 7 782.39 14870.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 650.65 1 y 5 574.29 13250.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 653.98 1 b 2 324.15 24450.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 653.98 1 y 8 907.43 16190.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 653.98 1 y 7 792.40 14870.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN HWILPQDYDHAQAEAR 31.7 3 653.98 1 y 5 584.30 13250.00 HWILPQDYDHAQAEAR SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 485.26 1 y 7 806.44 5000.00 YIFDNVAK SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 485.26 1 y 6 693.36 377300.00 YIFDNVAK SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 485.26 1 y 5 546.29 28990.00 YIFDNVAK SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 485.26 1 y 4 431.26 3038.00 YIFDNVAK SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 489.26 1 y 7 814.45 5000.00 YIFDNVAK SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 489.26 1 y 6 701.37 377300.00 YIFDNVAK SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 489.26 1 y 5 554.30 28990.00 YIFDNVAK SPIKE_IN
sp|Q15293|RCN1_HUMAN YIFDNVAK 28.66 2 489.26 1 y 4 439.28 3038.00 YIFDNVAK SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 850.92 1 y 10 1151.58 894500.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 850.92 1 y 9 1052.52 4557000.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 850.92 1 y 8 905.45 2730000.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 850.92 1 y 7 834.41 4932000.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 855.92 1 y 10 1161.59 894500.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 855.92 1 y 9 1062.52 4557000.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 855.92 1 y 8 915.46 2730000.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN EGVYTVFAPTNEAFR 71.94 2 855.92 1 y 7 844.42 4932000.00 EGVYTVFAPTNEAFR SPIKE_IN
sp|Q15582|BGH3_HUMAN LTLLAPLNSVFK 109.84 2 658.40 1 y 10 1101.67 962500.00 LTLLAPLNSVFK SPIKE_IN
sp|Q15582|BGH3_HUMAN LTLLAPLNSVFK 109.84 2 658.40 1 y 9 988.58 1978000.00 LTLLAPLNSVFK SPIKE_IN
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sp|Q15582|BGH3_HUMAN LTLLAPLNSVFK 109.84 2 658.40 1 y 8 875.50 5871000.00 LTLLAPLNSVFK SPIKE_IN
sp|Q15582|BGH3_HUMAN LTLLAPLNSVFK 109.84 2 662.41 1 y 10 1109.68 962500.00 LTLLAPLNSVFK SPIKE_IN
sp|Q15582|BGH3_HUMAN LTLLAPLNSVFK 109.84 2 662.41 1 y 9 996.60 1978000.00 LTLLAPLNSVFK SPIKE_IN
sp|Q15582|BGH3_HUMAN LTLLAPLNSVFK 109.84 2 662.41 1 y 8 883.51 5871000.00 LTLLAPLNSVFK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN VALAGLLGFGLGK 109.43 2 608.38 1 y 9 861.52 7713.00 VALAGLLGFGLGK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN VALAGLLGFGLGK 109.43 2 608.38 1 y 7 691.41 3708.00 VALAGLLGFGLGK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN VALAGLLGFGLGK 109.43 2 608.38 1 y 6 578.33 3376.00 VALAGLLGFGLGK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN VALAGLLGFGLGK 109.43 2 612.38 1 y 9 869.53 7713.00 VALAGLLGFGLGK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN VALAGLLGFGLGK 109.43 2 612.38 1 y 7 699.43 3708.00 VALAGLLGFGLGK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN VALAGLLGFGLGK 109.43 2 612.38 1 y 6 586.34 3376.00 VALAGLLGFGLGK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 332.50 1 y 4 428.25 392900.00 DAHFPPPSK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 332.50 1 y 3 331.20 68930.00 DAHFPPPSK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 332.50 1 b 4 471.20 184200.00 DAHFPPPSK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 332.50 1 b 5 568.25 487700.00 DAHFPPPSK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 335.17 1 y 4 436.26 392900.00 DAHFPPPSK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 335.17 1 y 3 339.21 68930.00 DAHFPPPSK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 335.17 1 b 4 471.20 184200.00 DAHFPPPSK SPIKE_IN
sp|Q56VL3|OCAD2_HUMAN DAHFPPPSK -16.28 3 335.17 1 b 5 568.25 487700.00 DAHFPPPSK SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GLYWVAPLNTDGR 71.93 2 731.38 1 y 9 942.50 71970.00 GLYWVAPLNTDGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GLYWVAPLNTDGR 71.93 2 731.38 1 y 8 843.43 244600.00 GLYWVAPLNTDGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GLYWVAPLNTDGR 71.93 2 736.38 1 y 9 952.51 71970.00 GLYWVAPLNTDGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GLYWVAPLNTDGR 71.93 2 736.38 1 y 8 853.44 244600.00 GLYWVAPLNTDGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GFSYLYGAWGR 71.9 2 638.81 1 y 7 822.43 33300.00 GFSYLYGAWGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GFSYLYGAWGR 71.9 2 638.81 1 y 6 709.34 98950.00 GFSYLYGAWGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GFSYLYGAWGR 71.9 2 638.81 1 y 5 546.28 76040.00 GFSYLYGAWGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GFSYLYGAWGR 71.9 2 643.81 1 y 7 832.43 33300.00 GFSYLYGAWGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GFSYLYGAWGR 71.9 2 643.81 1 y 6 719.35 98950.00 GFSYLYGAWGR SPIKE_IN
sp|Q6UX06|OLFM4_HUMAN GFSYLYGAWGR 71.9 2 643.81 1 y 5 556.29 76040.00 GFSYLYGAWGR SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN TLPIGQNFPIR 60.42 2 628.36 1 y 9 1041.58 5443000.00 TLPIGQNFPIR SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN TLPIGQNFPIR 60.42 2 628.36 1 y 8 944.53 3437000.00 TLPIGQNFPIR SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN TLPIGQNFPIR 60.42 2 628.36 1 y 7 831.45 6764000.00 TLPIGQNFPIR SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN TLPIGQNFPIR 60.42 2 633.37 1 y 9 1051.59 5443000.00 TLPIGQNFPIR SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN TLPIGQNFPIR 60.42 2 633.37 1 y 8 954.54 3437000.00 TLPIGQNFPIR SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN TLPIGQNFPIR 60.42 2 633.37 1 y 7 841.46 6764000.00 TLPIGQNFPIR SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN STHYQQYQPVVTLQK 26.92 3 607.32 1 y 7 784.49 389200.00 STHYQQYQPVVTLQK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN STHYQQYQPVVTLQK 26.92 3 607.32 1 y 5 588.37 90510.00 STHYQQYQPVVTLQK SPIKE_IN
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sp|Q8WUJ3|K1199_HUMAN STHYQQYQPVVTLQK 26.92 3 607.32 1 y 4 489.30 78260.00 STHYQQYQPVVTLQK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN STHYQQYQPVVTLQK 26.92 3 609.99 1 y 7 792.51 389200.00 STHYQQYQPVVTLQK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN STHYQQYQPVVTLQK 26.92 3 609.99 1 y 5 596.39 90510.00 STHYQQYQPVVTLQK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN STHYQQYQPVVTLQK 26.92 3 609.99 1 y 4 497.32 78260.00 STHYQQYQPVVTLQK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN IFQVVPIPVVK 80.03 2 619.90 1 y 7 751.51 5630.00 IFQVVPIPVVK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN IFQVVPIPVVK 80.03 2 619.90 1 y 6 652.44 10820.00 IFQVVPIPVVK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN IFQVVPIPVVK 80.03 2 619.90 1 y 4 442.30 18970.00 IFQVVPIPVVK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN IFQVVPIPVVK 80.03 2 623.90 1 y 7 759.52 5630.00 IFQVVPIPVVK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN IFQVVPIPVVK 80.03 2 623.90 1 y 6 660.45 10820.00 IFQVVPIPVVK SPIKE_IN
sp|Q8WUJ3|K1199_HUMAN IFQVVPIPVVK 80.03 2 623.90 1 y 4 450.32 18970.00 IFQVVPIPVVK SPIKE_IN
sp|Q92688|AN32B_HUMAN ELVLDNCK 4.86 2 495.75 1 y 6 748.37 1554000.00 ELVLDNC[+57]K SPIKE_IN
sp|Q92688|AN32B_HUMAN ELVLDNCK 4.86 2 495.75 1 y 5 649.30 2750000.00 ELVLDNC[+57]K SPIKE_IN
sp|Q92688|AN32B_HUMAN ELVLDNCK 4.86 2 495.75 1 y 4 536.21 1829000.00 ELVLDNC[+57]K SPIKE_IN
sp|Q92688|AN32B_HUMAN ELVLDNCK 4.86 2 499.76 1 y 6 756.38 1554000.00 ELVLDNC[+57]K SPIKE_IN
sp|Q92688|AN32B_HUMAN ELVLDNCK 4.86 2 499.76 1 y 5 657.31 2750000.00 ELVLDNC[+57]K SPIKE_IN
sp|Q92688|AN32B_HUMAN ELVLDNCK 4.86 2 499.76 1 y 4 544.23 1829000.00 ELVLDNC[+57]K SPIKE_IN
sp|Q92688|AN32B_HUMAN LPNLTHLNLSGNK 47.19 3 474.27 1 y 7 745.42 1126000.00 LPNLTHLNLSGNK SPIKE_IN
sp|Q92688|AN32B_HUMAN LPNLTHLNLSGNK 47.19 3 474.27 1 y 6 632.34 1174000.00 LPNLTHLNLSGNK SPIKE_IN
sp|Q92688|AN32B_HUMAN LPNLTHLNLSGNK 47.19 3 474.27 1 y 4 405.21 625000.00 LPNLTHLNLSGNK SPIKE_IN
sp|Q92688|AN32B_HUMAN LPNLTHLNLSGNK 47.19 3 476.94 1 y 7 753.43 1126000.00 LPNLTHLNLSGNK SPIKE_IN
sp|Q92688|AN32B_HUMAN LPNLTHLNLSGNK 47.19 3 476.94 1 y 6 640.35 1174000.00 LPNLTHLNLSGNK SPIKE_IN
sp|Q92688|AN32B_HUMAN LPNLTHLNLSGNK 47.19 3 476.94 1 y 4 413.22 625000.00 LPNLTHLNLSGNK SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 728.39 1 y 10 989.52 31220.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 728.39 1 y 9 861.46 218700.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 728.39 1 y 7 707.38 21780.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 728.39 1 y 5 553.31 22490.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 733.39 1 y 10 999.52 31220.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 733.39 1 y 9 871.47 218700.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 733.39 1 y 7 717.39 21780.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN LGAPQQPGPGPPPSR 5.05 2 733.39 1 y 5 563.32 22490.00 LGAPQQPGPGPPPSR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN EAEYFELPELVR 90.7 2 747.88 1 y 8 1002.56 307900.00 EAEYFELPELVR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN EAEYFELPELVR 90.7 2 747.88 1 y 7 855.49 436000.00 EAEYFELPELVR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN EAEYFELPELVR 90.7 2 747.88 1 y 6 726.45 306500.00 EAEYFELPELVR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN EAEYFELPELVR 90.7 2 752.88 1 y 8 1012.57 307900.00 EAEYFELPELVR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN EAEYFELPELVR 90.7 2 752.88 1 y 7 865.50 436000.00 EAEYFELPELVR SPIKE_IN
sp|Q96CX2|KCD12_HUMAN EAEYFELPELVR 90.7 2 752.88 1 y 6 736.46 306500.00 EAEYFELPELVR SPIKE_IN
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sp|Q96CX2|KCD12_HUMAN FNFLEQAFDK 82.1 2 629.81 1 y 8 997.50 71810.00 FNFLEQAFDK SPIKE_IN
sp|Q96CX2|KCD12_HUMAN FNFLEQAFDK 82.1 2 629.81 1 y 7 850.43 53120.00 FNFLEQAFDK SPIKE_IN
sp|Q96CX2|KCD12_HUMAN FNFLEQAFDK 82.1 2 629.81 1 y 6 737.35 60780.00 FNFLEQAFDK SPIKE_IN
sp|Q96CX2|KCD12_HUMAN FNFLEQAFDK 82.1 2 633.82 1 y 8 1005.51 71810.00 FNFLEQAFDK SPIKE_IN
sp|Q96CX2|KCD12_HUMAN FNFLEQAFDK 82.1 2 633.82 1 y 7 858.44 53120.00 FNFLEQAFDK SPIKE_IN
sp|Q96CX2|KCD12_HUMAN FNFLEQAFDK 82.1 2 633.82 1 y 6 745.36 60780.00 FNFLEQAFDK SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN SNCYGYFR 21.01 2 533.72 1 y 6 865.37 1812000.00 SNC[+57]YGYFR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN SNCYGYFR 21.01 2 533.72 1 y 5 705.34 1645000.00 SNC[+57]YGYFR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN SNCYGYFR 21.01 2 533.72 1 y 4 542.27 2266000.00 SNC[+57]YGYFR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN SNCYGYFR 21.01 2 538.73 1 y 6 875.37 1812000.00 SNC[+57]YGYFR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN SNCYGYFR 21.01 2 538.73 1 y 5 715.34 1645000.00 SNC[+57]YGYFR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN SNCYGYFR 21.01 2 538.73 1 y 4 552.28 2266000.00 SNC[+57]YGYFR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN EASTIAEYISGYQR 65.67 2 794.39 1 y 9 1086.52 2749000.00 EASTIAEYISGYQR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN EASTIAEYISGYQR 65.67 2 794.39 1 y 7 886.44 905700.00 EASTIAEYISGYQR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN EASTIAEYISGYQR 65.67 2 794.39 1 y 5 610.29 397900.00 EASTIAEYISGYQR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN EASTIAEYISGYQR 65.67 2 799.39 1 y 9 1096.53 2749000.00 EASTIAEYISGYQR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN EASTIAEYISGYQR 65.67 2 799.39 1 y 7 896.45 905700.00 EASTIAEYISGYQR SPIKE_IN
sp|Q9BYZ8|REG4_HUMAN EASTIAEYISGYQR 65.67 2 799.39 1 y 5 620.30 397900.00 EASTIAEYISGYQR SPIKE_IN
sp|Q9C002|NMES1_HUMAN LITINQQWKPIEELQNVQR 79.06 3 784.10 1 y 10 1225.65 272300.00 LITINQQWKPIEELQNVQR SPIKE_IN
sp|Q9C002|NMES1_HUMAN LITINQQWKPIEELQNVQR 79.06 3 784.10 1 y 7 886.47 202400.00 LITINQQWKPIEELQNVQR SPIKE_IN
sp|Q9C002|NMES1_HUMAN LITINQQWKPIEELQNVQR 79.06 3 787.44 1 y 10 1235.66 272300.00 LITINQQWKPIEELQNVQR SPIKE_IN
sp|Q9C002|NMES1_HUMAN LITINQQWKPIEELQNVQR 79.06 3 787.44 1 y 7 896.48 202400.00 LITINQQWKPIEELQNVQR SPIKE_IN
sp|Q9C002|NMES1_HUMAN TDVILDR 3.9 2 416.23 1 y 6 730.41 9723.00 TDVILDR SPIKE_IN
sp|Q9C002|NMES1_HUMAN TDVILDR 3.9 2 416.23 1 y 5 615.38 271500.00 TDVILDR SPIKE_IN
sp|Q9C002|NMES1_HUMAN TDVILDR 3.9 2 421.24 1 y 6 740.42 9723.00 TDVILDR SPIKE_IN
sp|Q9C002|NMES1_HUMAN TDVILDR 3.9 2 421.24 1 y 5 625.39 271500.00 TDVILDR SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN NVTGHYISPFHDIPLK 53.66 3 613.32 1 y 10 1166.66 297900.00 NVTGHYISPFHDIPLK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN NVTGHYISPFHDIPLK 53.66 3 613.32 1 y 9 1053.57 418600.00 NVTGHYISPFHDIPLK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN NVTGHYISPFHDIPLK 53.66 3 613.32 1 y 8 966.54 252600.00 NVTGHYISPFHDIPLK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN NVTGHYISPFHDIPLK 53.66 3 616.00 1 y 10 1174.67 297900.00 NVTGHYISPFHDIPLK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN NVTGHYISPFHDIPLK 53.66 3 616.00 1 y 9 1061.59 418600.00 NVTGHYISPFHDIPLK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN NVTGHYISPFHDIPLK 53.66 3 616.00 1 y 8 974.55 252600.00 NVTGHYISPFHDIPLK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN LIAINANDPEASK 21.8 2 678.36 1 y 11 1129.55 1482000.00 LIAINANDPEASK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN LIAINANDPEASK 21.8 2 678.36 1 y 9 945.43 2066000.00 LIAINANDPEASK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN LIAINANDPEASK 21.8 2 678.36 1 y 5 531.28 3690000.00 LIAINANDPEASK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN LIAINANDPEASK 21.8 2 682.37 1 y 11 1137.56 1482000.00 LIAINANDPEASK SPIKE_IN
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sp|Q9H2U2|IPYR2_HUMAN LIAINANDPEASK 21.8 2 682.37 1 y 9 953.44 2066000.00 LIAINANDPEASK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN LIAINANDPEASK 21.8 2 682.37 1 y 5 539.29 3690000.00 LIAINANDPEASK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN AFALEVIK 54.38 2 445.77 1 y 7 819.50 174.90 AFALEVIK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN AFALEVIK 54.38 2 445.77 1 y 6 672.43 1540.00 AFALEVIK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN AFALEVIK 54.38 2 445.77 1 y 5 601.39 435.20 AFALEVIK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN AFALEVIK 54.38 2 449.78 1 y 7 827.51 174.90 AFALEVIK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN AFALEVIK 54.38 2 449.78 1 y 6 680.44 1540.00 AFALEVIK SPIKE_IN
sp|Q9H2U2|IPYR2_HUMAN AFALEVIK 54.38 2 449.78 1 y 5 609.41 435.20 AFALEVIK SPIKE_IN
sp|Q9UKY7|CDV3_HUMAN SLDNFFAK 45.12 2 471.24 1 y 6 741.36 2035000.00 SLDNFFAK SPIKE_IN
sp|Q9UKY7|CDV3_HUMAN SLDNFFAK 45.12 2 471.24 1 y 5 626.33 139900.00 SLDNFFAK SPIKE_IN
sp|Q9UKY7|CDV3_HUMAN SLDNFFAK 45.12 2 471.24 1 y 4 512.29 53090.00 SLDNFFAK SPIKE_IN
sp|Q9UKY7|CDV3_HUMAN SLDNFFAK 45.12 2 475.25 1 y 6 749.37 2035000.00 SLDNFFAK SPIKE_IN
sp|Q9UKY7|CDV3_HUMAN SLDNFFAK 45.12 2 475.25 1 y 5 634.34 139900.00 SLDNFFAK SPIKE_IN
sp|Q9UKY7|CDV3_HUMAN SLDNFFAK 45.12 2 475.25 1 y 4 520.30 53090.00 SLDNFFAK SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 GALQNIIPASTGAAK 44.65 2 706.40 1 y 11 1042.59 971600.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 GALQNIIPASTGAAK 44.65 2 706.40 1 y 10 928.55 750800.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 GALQNIIPASTGAAK 44.65 2 706.40 1 y 9 815.46 5160000.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 GALQNIIPASTGAAK 44.65 2 710.41 1 y 11 1050.60 971600.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 GALQNIIPASTGAAK 44.65 2 710.41 1 y 10 936.56 750800.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 GALQNIIPASTGAAK 44.65 2 710.41 1 y 9 823.48 5160000.00 GALQNIIPASTGAAK SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 LISWYDNEFGYSNR 72.02 2 882.40 1 y 9 1101.46 177100.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 LISWYDNEFGYSNR 72.02 2 882.40 1 y 8 986.43 79510.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 LISWYDNEFGYSNR 72.02 2 882.40 1 y 6 743.35 152300.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 LISWYDNEFGYSNR 72.02 2 887.41 1 y 9 1111.47 177100.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 LISWYDNEFGYSNR 72.02 2 887.41 1 y 8 996.44 79510.00 LISWYDNEFGYSNR SPIKE_IN
sp|P04406|G3P_HUMAN_mtd2 LISWYDNEFGYSNR 72.02 2 887.41 1 y 6 753.36 152300.00 LISWYDNEFGYSNR SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 HLEINPDHSIIETLR 50.57 3 596.32 1 y 7 831.49 1195000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 HLEINPDHSIIETLR 50.57 3 596.32 1 y 6 744.46 531500.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 HLEINPDHSIIETLR 50.57 3 596.32 1 y 5 631.38 624000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 HLEINPDHSIIETLR 50.57 3 599.66 1 y 7 841.50 1195000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 HLEINPDHSIIETLR 50.57 3 599.66 1 y 6 754.47 531500.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 HLEINPDHSIIETLR 50.57 3 599.66 1 y 5 641.39 624000.00 HLEINPDHSIIETLR SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 DQVANSAFVER 9.64 2 618.30 1 y 9 992.52 461800.00 DQVANSAFVER SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 DQVANSAFVER 9.64 2 618.30 1 y 8 893.45 775100.00 DQVANSAFVER SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 DQVANSAFVER 9.64 2 623.31 1 y 9 1002.52 461800.00 DQVANSAFVER SPIKE_IN
sp|P07900|HS90A_HUMAN_mtd2 DQVANSAFVER 9.64 2 623.31 1 y 8 903.46 775100.00 DQVANSAFVER SPIKE_IN
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Supplementary table 4. Peptides identified with a false discovery rate 
(FDR)  below 1% and a Cscore greater than 10 (SpectroDive output file). 
Supplementary table 5. MSstats Input File (Method 1) 
Supplementary table 6. MSstats Input File (Method 2) 
(Tables were not added due to file size. They would be made available in the electronic 
version of the thesis and also through the supplementary links to the manuscript). 
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6 Conclusions and future perspectives 
In the first part of this study, we report novel findings from an untargeted 
quantitative proteomic study on a large cohort of precancerous colorectal tissues. 
Whereas most proteomic studies on colorectal tumors have targeted advanced stage 
lesions, we focused on the precancerous lesions. This involved a comprehensive 
exploration of the proteome of colorectal adenomas and adjacent normal mucosa 
samples using iTRAQ 8plex chemical labelling and shotgun mass spectrometry. We 
achieved an appreciable depth in our coverage of the proteome of colorectal tissues 
and we identified a large set of proteins whose expression was dysregulated in 
colorectal adenomas compared to samples of the normal mucosa. Furthermore, 
alterations in key enzymes of the polyol pathway were observed to be peculiar to the 
precancerous neoplasms. This finding poses further questions on the involvement of 
the polyol pathway in glucose metabolism, during tumorigenesis. Up-regulated SORD 
expression and activity in adenomas would enhance the production of fructose. 
Fructose is also several times more effective than glucose in promoting intracellular 
non-enzymatic glycation. Advanced glycation end products have been proven to 
contribute to vascular complications in diabetes and aging. Whether these fructose-
driven metabolic events play a role in the development of adenomas is unclear, but an 
increase in the expression of KHK, the enzyme that catalyzes the transformation of 
fructose to fructose-1-P, downstream from the polyol pathway was clearly apparent in 
the few adenomas we studied. There is a dearth of information associating the polyol 
pathway and non-enzymatic glycation to tumorigenesis.  
Our preliminary data on the abundance of polyol pathway metabolites (glucose 
and sorbitol) in colorectal tissues revealed interesting findings that deserve additional 
investigations. Adenomas exhibited dramatically reduced concentrations of glucose, 
the initial substrate in the polyol pathway. Sorbitol level was insignificantly decreased in 
adenomas and also fructose showed slightly lower levels in adenomas. Advanced 
cancer cells consume glucose at a much higher rate than normal cells, and much of 
their intracellular energy (ATP) is generated by aerobic glycolysis rather than through 
oxidative phosphorylation of glucose in the mitochondria (i.e. the Warburg effect). 
Increased aerobic glycolysis facilitates ATP generation via the conversion of pyruvate 
to lactate. Hence higher levels of intracellular lactate are often associated with cancer 
cells unlike normal cells.  The relative concentration of lactate in the adenomas we 
tested was significantly greater than those found in matched samples of normal 
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mucosa, suggesting that the Warburg effect is already evident in precancerous 
colorectal lesions. Studies involving metabolic flux analysis to monitor the fate of 
isotopic tracers in in vitro and in vivo systems would provide further insight into the 
biological roles of this pathway in tumorigenesis. More specifically, tracking the fate of 
glucose breakdown with isotope-labelled metabolites is crucial to understand the 
connection between glucose metabolism and metabolites of the polyol pathway.  
The verification of candidate biomarkers for the early diagnosis of colorectal 
carcinogenesis remains a major challenge due to the lack of techniques for the 
sensitive, reproducible quantification of multiple proteins over large cohorts of samples. 
The early detection of colorectal cancer, at the adenoma or early adenocarcninoma 
stage, remains the best way to curb the high incidence and hence mortality of the 
disease.  
Most of the candidate protein markers verified in the second part of this work 
were previously reported in a quantitative (iTRAQ 8plex) shotgun discovery study on 
human colorectal precancerous tissues. We describe the high-throughput development 
and optimization of reproducible selected reaction monitoring assays for 40 human 
proteins using heavy isotope-labelled peptides. The sample preparation and analytical 
protocols were optimized to ensure reproducibility and analytical precision of 
measurements. Our integrated SRM workflow combined software tools for SRM assay 
development (Skyline), automated peak group identification (mProphet in SpectroDive) 
and protein significance analysis (MSstats). We applied these assays to detect 28 
proteins in 72 human colorectal tissues (19 adenoma and paired normal mucosa; 17 
adenocarcinoma and paired normal mucosa). Furthermore, we show that these SRM 
assays permit reproducible quantification of candidate biomarker proteins by profiling 
25 putative biomarker targets over 78 colorectal samples, including six technical 
duplicates. We effected sample randomization and blocking strategies to achieve 
reproducible quantification with minimal biological and technical variability. In addition 
to this, differences in the expression of 25 proteins were validated in precancerous 
(adenomas) and cancerous (adenocarcinomas) lesions respectively, compared to the 
normal mucosa. We confirmed the significant (fold change > 1.2, adjusted P value < 
0.02) over expression of ten proteins (SORD, SPB5, ANXA3, REG4, S10AB, NUCL, 
NGAL, LDHA, G6PD, AN32A) in precancerous as well as in cancerous neoplasms of 
the colorectum. These protein changes are unambiguously indicative of protein 
abundance variations that could be detectable phenotypes for early stage tumors. 
There is need for further clinical verification studies to monitor the abundance of these 
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candidate markers in the plasma of colorectal patients. This would define their 
suitability for use in non-invasive diagnostic tests for colorectal tumorigenesis. We have 
initiated plans to monitor a selected number of tumor markers in plasma samples from 
colorectal cancer patients. We aim to apply our established SRM assays to detect and 
quantify these proteins in human plasma. 
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7 Abbreviations 
GI Gastrointestinal tract 
CRC Colorectal Cancer 
ACF Aberrant Crypt Foci 
APC Adenomatous Polyposis Coli 
TVA Tubulovillous 
FAP Familial Adenomatous Polyposis 
HNPCC Hereditary Nonpolyposis Colon Cancer 
TNM Tumor, Node, Metastasis 
BMI Body Mass Index 
DCBE Double-Contrast Barium Enema 
FOBT Faecal Occult Blood Test  
FIT Faecal Immunochemical Test  
MIN Microsatellite Instability  
CIN Chromosomal Instability 
MMR Mismatch Repair 
2DE Two-dimensional Gel Electrophoresis 
MS Mass Spectrometry 
iTRAQ Isobaric Tag for Relative and Absolute Quantification 
iCAT Isotope-Coded Affinity Tags 
QQQ Triple quadrupole 
RT Retention time 
SORD Sorbitol dehydrogenase 
ATP Adenosine Triphosphate 
m/z Mass-to-charge Ratio 
MS1 First MS phase 
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MS2 Second MS phase 
SILAC Stable Isotope Labelling by Amino Acids in Cell Culture 
OGE Off Gel Electrophoresis 
SRM Selected Reaction Monitoring 
PRM Parallel Reaction Monitoring 
ELISA Enzyme-linked Immunosorbent Assay 
LC-MSMS Liquid chromatography-tandem mass spectrometry 
FDR False Discovery Rate 
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8 Appendix 
8.1 Appendix I.  
Sorbitol Dehydrogenase Overexpression and
Other Aspects of Dysregulated Protein
Expression in Human Precancerous Colorectal
Neoplasms: A Quantitative Proteomics Study*□S
Anuli Uzozie‡, Paolo Nanni§, Teresa Staiano¶, Jonas Grossmann§,
Simon Barkow-Oesterreicher§, Jerry W. Shay!, Amit Tiwari‡, Federico Buffoli¶,
Endre Laczko§, and Giancarlo Marra‡**
Colorectal adenomas are cancer precursor lesions of the
large bowel. A multitude of genomic and epigenomic
changes have been documented in these preinvasive le-
sions, but their impact on the protein effectors of biolog-
ical function has not been comprehensively explored. Us-
ing shotgun quantitative MS, we exhaustively investigated
the proteome of 30 colorectal adenomas and paired sam-
ples of normal mucosa. Total protein extracts were pre-
pared from these tissues (prospectively collected during
colonoscopy) and from normal (HCEC) and cancerous
(SW480, SW620, Caco2, HT29, CX1) colon epithelial cell
lines. Peptides were labeled with isobaric tags (iTRAQ
8-plex), separated via OFFGEL electrophoresis, and ana-
lyzed by means of LC-MS/MS. Nonredundant protein fam-
ilies (4325 in tissues, 2017 in cell lines) were identified and
quantified. Principal component analysis of the results
clearly distinguished adenomas from normal mucosal
samples and cancer cell lines from HCEC cells. Two hun-
dred and twelve proteins displayed significant adenoma-
related expression changes (q-value < 0.02, mean fold
change versus normal mucosa !1.4), which correlated
(r " 0.74) with similar changes previously identified by our
group at the transcriptome level. Fifty-one (!25%) pro-
teins displayed directionally similar expression changes in
colorectal cancer cells (versus HCEC cells) and were
therefore attributed to the epithelial component of adeno-
mas. Although benign, adenomas already exhibited can-
cer-associated proteomic changes: 69 (91%) of the 76
protein up-regulations identified in these lesions have al-
ready been reported in cancers. One of the most striking
changes involved sorbitol dehydrogenase, a key enzyme
in the polyol pathway. Validation studies revealed dramat-
ically increased sorbitol dehydrogenase concentrations and
activity in adenomas and cancer cell lines, along with impor-
tant changes in the expression of other enzymes in the same
(AKR1B1) and related (KHK) pathways. Dysregulated polyol
metabolism might represent a novel facet of metabolome
remodeling associated with tumorigenesis. Molecular &
Cellular Proteomics 13: 10.1074/mcp.M113.035105, 1198–
1218, 2014.
Colorectal cancer ranks third among the world’s high-inci-
dence cancers and is a leading cause of cancer-related death
among older adults (1, 2). In the United States alone, projec-
tions for 2013 include 102,480 new cases and 50,830 deaths
(2). Cancerogenesis in the large bowel begins with the trans-
formation of the epithelial cell lining of the gut. Molecular
alterations, mainly involving the WNT signaling pathway,
render these cells hyperproliferative, and they form benign
adenomatous tumors. The neoplasms are initially noninvasive
(3, 4), and the vast majority remain that way. But as genetic
and epigenetic anomalies continue to accumulate, the tumor
cells’ capacity for invasion and destruction of surrounding
tissues increases. At some point, this process drives certain
adenomas into the realm of frank malignancy, transforming
them into adenocarcinomas.
Early diagnosis of colorectal tumors has been greatly facil-
itated by screening methods based on fecal analysis or
colonoscopy, but both approaches have limitations (5–9).
Better understanding of the molecular mechanisms underly-
ing large bowel tumorigenesis could improve our chances of
detecting these lesions in the adenomatous or localized ad-
enocarcinomatous stage, when the chances of successful
treatment are greater. Promising results for the detection and
validation of potential cancer biomarkers are emerging from
proteomic studies of cancer development (10). Relative to
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older gel-electrophoresis-based approaches, shotgun pro-
teomics methods, particularly those that include pre-MS
OFFGEL electrophoretic peptide fractionation (11), enhance the
sensitivity, robustness, and reproducibility of these studies (12)
and expand the proteome coverage to include proteins that are
less abundantly expressed (13–16). Furthermore, with the aid of
isobaric-tag peptide-labeling strategies, MS can also be used
for the relative quantification of protein expression levels within
a series of multiple human tissue samples (12, 17–19).
Thus far, only a few MS-based proteomics studies have
examined human colorectal adenomas (reviewed in Refs. 9
and 20). We therefore decided to explore the proteome of a
relatively large series of these precancerous lesions (each with
a paired sample of normal colon mucosa) using quantitative
shotgun MS with the widely used iTRAQ1 peptide labeling tech-
nique (21, 22) and OFFGEL fractionation. Adenoma-related pro-
tein expression variations specific to the epithelial compart-
ments of these lesions were identified with a novel approach,
which involved comparing the human tissue proteome with that
of colon epithelial cell lines. The results of these studies revealed
several protein expression changes previously documented
only in advanced colorectal cancers. They also disclosed sev-
eral novel changes with potentially important roles in early-stage
large bowel tumorigenesis, including the marked up-regulation
of a key enzyme in the polyol pathway.
EXPERIMENTAL PROCEDURES
Human Tissue Samples and Cell Lines—Human colorectal tissues
were prospectively collected from patients undergoing colonoscopy
in the Istituti Ospitalieri of Cremona, Italy. Approval was obtained from
the local ethics committee, and tissues were used in accordance with
the Declaration of Helsinki. Each donor provided written informed
consent to sample collection, data analysis, and publication of the
findings. Progressive numbers were assigned to each patient to protect
human confidentiality. The series comprised 30 colorectal adenomas,
each with a paired sample of normal mucosa from the same colon
segment, !2 cm from the lesion. Tissues were collected endoscopi-
cally, promptly frozen in liquid nitrogen, and stored at "80 °C.
Five colorectal cancer cell lines (HT29, Caco2, CX1, SW480, and
SW620) were obtained from the Zurich Cancer Network’s Cell Line
Repository. All had been recently purchased from the American Tis-
sue Culture Collection (Teddington, UK) and were certified as myco-
plasma infection free. We cultured Caco2 and CX1 cells in Dulbecco’s
modified Eagle’s medium; HT29 cells in McCoy’s medium; and
SW480 and SW620 cells in RPMI 1640 medium supplemented with
10% fetal bovine serum, L-glutamine, and 1% penicillin-streptomycin
(Sigma, St. Louis, MO). The recently established line of immortalized
human colon epithelial cells (HCEC) was obtained from J. W. Shay
and grown as described elsewhere (23).
Protein Extraction from Tissues and Cell Lines—For MS studies,
frozen tissue samples were quickly weighed and homogenized on ice
(1 min of grinding, 1 min on ice, 1 min of grinding) in a Wheaton glass
borosilicate grinder containing a solution of 100 mM triethylammo-
nium bicarbonate (Sigma, St Louis, MO), 1X Complete EDTA-free
Protease Inhibitor Mixture (Roche, Mannheim, Germany), 1 M urea, 5
mM !-glycerophosphate disodium salt hydrate, 1 mM sodium or-
thovanadate, and 5 mM sodium fluoride (Sigma). The efficiency of cell
lysis was microscopically confirmed. The homogenates were then son-
icated with a Bioruptor (Diagenode, Denville, NJ) (high power, five
10-s/10-s on/off cycles) and centrifuged (16,000g for 5 min at 4 °C). The
supernatant containing the proteins was collected and stored at
"80 °C.
Cells (grown to !80% confluence in 15-cm2 dishes) were washed
in PBS, covered with 250 "l of the buffer used for tissue sample
homogenization (see above), detached from the dish with a cell
scraper, and homogenized (25 passages through a 25-gauge needle).
The efficiency of cell lysis was microscopically confirmed. Sonication
and centrifugation were repeated as described above, and the protein
concentration was determined via Bradford assay. Prior to MS analysis,
a 5-"g sample of each protein extract was subjected to one-dimen-
sional gel electrophoresis on a 12% bisacrylamide gel to assess protein
integrity and extraction protocol reproducibility. The entire proteomic
workflow, from tissue/cell processing to statistical analysis, is summa-
rized in Fig. 1 and described in detail in the next five subsections.
For sorbitol dehydrogenase (SORD) assays (see below), !80%
confluent cells were washed in PBS and covered with a solution
consisting of 100 mM triethanolamine (Sigma) and 1X Complete
EDTA-free Protease Inhibitor Mixture (Roche). (A simple buffer was
used to reduce the risk of introducing anti-enzymatic substances into
our extract.) Cells were then scraped and homogenized with 25
passages through a 25-gauge needle. Tissue samples were weighed
and homogenized in a Wheaton glass borosilicate grinder containing
the buffer described above. After centrifugation (16,000 g, 4 °C, 5
min), the supernatant was aliquoted and stored at "80 °C. Protein
concentration was measured via Bradford assay.
Protein Digestion and iTRAQ 8-plex Labeling—iTRAQ 8-plex ex-
periments were performed to analyze tissue extracts (10 experiments)
and cell-line extracts (1 experiment) (Fig. 1). Labeling efficiency and
relative quantitation accuracy were assessed with the aid of two
reference protein extract mixtures: one for tissue samples (pooled
extracts from three normal tissues and three adenomas) and one for
cell lines (pooled aliquots of each of the six cell line extracts). Fifty
micrograms of protein per sample were used for each iTRAQ channel.
Tryptic digestion (10% w/w, sequencing-grade modified trypsin, Pro-
mega, Madison, WI) and iTRAQ 8-plex labeling (AB Sciex, Framing-
ham, MA) were performed according to the manufacturers’ instruc-
tions (2.5-h incubation of samples with iTRAQ labels). For tissue
experiments, two iTRAQ labels, 113 and 114, were chosen for the
reference mixture, and labels 115/116, 117/118, and 119/121 were
used for the three pairs of normal/adenomatous tissues included in
each experiment. For the cell line experiment, labels 113 and 114
were used for the reference mixture, and labels 115–121 represented
HCEC, HT29, Caco2, CX1, SW480, and SW620 cells, respectively
(Fig. 1). After iTRAQ labeling, the samples (for each experiment) were
combined, desalted on 500-mg SepPak C18 columns (Millipore, Bil-
lerica, MA), dried in a SpeedVac concentrator (Thermo Scientific), and
subjected to peptide fractionation.
OFFGEL Electrophoresis—Peptide fractionation was performed
according to the manufacturer’s protocols with an Agilent 3100
OFFGEL fractionator and 12-well OFFGEL kit (both from Agilent
Technologies, Santa Clara, CA). Briefly, samples were resolubilized in
1.8 ml of 1X OFFGEL peptide stock solution containing carrier am-
pholytes (pH range 3–10), loaded into the wells (150 "l per well), and
focused until 20 kV/h was reached with a maximum current of 50 "A.
For each experiment, 12 fractions were collected. A 15-"l aliquot of
each fraction was acidified with 1.5 "l of a 50% acetonitrile/1%
1 The abbreviations used are: iTRAQ, isobaric tags for relative and
absolute quantification; HCEC, human colon epithelial cell; FDR, false
discovery rate; GO, Gene Ontology; INHAT, inhibitor of acetyltrans-
ferases; MS/MS, tandem mass spectrometry; PSM, peptide spectra
match; emPAI, exponentially modified protein abundance index; SORD,
sorbitol dehydrogenase; TBST, Tris-buffered saline with Tween 20.
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trifluoroacetic acid solution, desalted using ZipTip C18 (Millipore,
Billerica, MA), dried, resolubilized in 15 !l of a 0.1% formic acid/3%
acetonitrile solution, and analyzed with MS.
Liquid Chromatography and Mass Spectrometry—Peptide samples
(4 !l) were analyzed on an LTQ-Orbitrap Velos mass spectrometer
(Thermo Fischer Scientific, Bremen, Germany) coupled to a nano-
HPLC system (Eksigent Technologies, Dublin, CA). The solvent com-
positions were 0.2% formic acid and 1% acetonitrile for channel A
and 0.2% formic acid and 80% acetonitrile for channel B. Peptides
were loaded onto an in-house-made tip column (75 !m ! 80 mm)
packed with reverse-phase C18 material (AQ, 3 !m, 200 Å, Bischoff
GmbH, Leonberg, Germany) and eluted (flow rate, 250 nL/min; sol-
vent B gradient: from 3% to 30% in 62 min, from 30% to 45% in 70
min, and from 45% to 97% in 75 min).
Full-scan MS spectra (300–1700m/z) were acquired at a resolution
setting of 30,000 at 400 m/z after accumulation to a target value of
1 ! 106. For the eight most intense signals per cycle above a thresh-
old of 1000, both collision-induced dissociation and higher-energy
collisional dissociation spectra were acquired in a data-dependent
manner (Fig. 1). Collision-induced dissociation scans were recorded
in the ion trap (settings: normalized collision energy, 35; maximum
injection time, 50 ms; automatic gain control, 1 ! 104 ions). For the
higher-energy collisional dissociation scans, spectra were recorded
at a resolution setting of 7500 at 400m/z (normalized collision energy,
52; maximum injection time, 125 ms; automatic gain control, 5 ! 104
ions). Charge state screening was enabled, and singly charged states
were rejected. Precursor masses previously selected for MS/MS were
excluded from further selection for 60 s, and the exclusion window
was set at 10 ppm. The maximum number of entries in the exclusion
list was set at 500. All samples were analyzed in duplicate, and
precursors selected in the first run were excluded from fragmentation
in the second run. The exclusion list was set on a time window of 4
min and a mass width of 10 ppm. Spectra were acquired using
internal lock mass calibration on m/z 429.088735 and 445.120025.
Peak List Generation and Database Search—As depicted in Fig. 1,
Mascot Distiller 2.4.3.3 (Matrix Science, Boston, MA) was used to
generate Mascot generic format peak lists. De-isotoping and peak
picking were not performed between 112.5 and 121.5 m/z (the range
containing iTRAQ reporter ions), and the higher-energy collisional
dissociation and collision-induced dissociation spectra were merged
by summing. For each of the 11 experiments, the corresponding 24
Mascot generic format peak lists were concatenated and searched,
with the aid of Mascot Server 2.3.02 (Matrix Science), against a
forward UniProtKB/Swiss-Prot database for human proteins concat-
enated to a reversed decoyed FASTA database. The concatenated
database contained a total of 147,438 proteins with accessions in
Gene Ontology–compatible format and 260 common MS contami-
nants (NCBI taxonomy I.D. 9606, released December 13, 2011).
Methylthio (C), iTRAQ 8-plex labeling at the N terminus and lysine
were set as fixed modifications, and variable modifications consisted
of methionine oxidation and iTRAQ 8-plex labeling of tyrosine. We
used the iTRAQ 8-plex-vs114 (Applied Biosystems Zug, Switzerland)
quantitation method. The isotope and impurity correction factors
used for each iTRAQ label were those provided by the manufacturer.
Precursor and fragment tolerances were set at 10 ppm and 0.8 Da,
respectively. The enzyme specificity was set to trypsin with an allow-
ance of up to one missed cleavage. Using Mascot internal export
scripts, we transformed Mascot DAT files into XML files and parsed
them with in-house scripts so that peptide sequences, scores, and
intensities of the individual reporter ion channels were reported. Con-
fidently identified and quantified peptides were selected with the
following filters: rank 1 (best spectra assignment); ion score, " 15;
and presence of iTRAQ intensity values for reporter channels 113 and
114.
Quantification of Relative Protein Abundance—(These steps are
described in the boxes of the lower half of Fig. 1.) Peptide reporter
channel intensities were summed for each protein individually using
R-scripts. Ratios were built from summed channels (113/114 to 121/
114) for all proteins identified in each iTRAQ experiment. False dis-
covery rates (FDRs) (24) were determined at the spectrum, peptide,
and protein levels. The results of individual experiments were then
merged into one matrix, which was used for statistical analysis in R
and Perseus (Version 1.2.7.4). All proteins identified with the same
peptide(s) were grouped into families, each of which was identified by
a unique protein family number. Ratios of the intensity of each ion
channel to that of 114 were converted to base 2 logarithmic values
and normalized respectively on the median (which was set at 0),
resulting in ratios that followed a Gaussian distribution. Proteins
identified on the basis of the same peptide(s) shared the same family
number and were represented once in our statistical analysis. The
paired t test was used to compare the expression of a given protein
in each adenoma and that found in the corresponding sample of
normal mucosa. To correct for multiple comparisons, the FDR was
controlled with the Benjamini–Hochberg procedure. The average pro-
tein-expression fold change in adenomas, relative to the normal mu-
cosa, was then calculated. For this, median normalized ratios for all
proteins in each paired adenoma–normal mucosa sample were de-
convoluted of the reference standard effects (114) to compute the
adenoma versus normal mucosa ratio per protein (deconvoluted fold
change, (116/114)/(115/114) # (116/115)) and the mean fold change
per protein in all tissue pairs. The Mascot emPAI values for all proteins
were included in XML exports for each experiment. Thereafter, the
mean Mascot emPAI value was calculated for all proteins.
Functional Annotation of Proteins—Gene Ontology (GO) annota-
tions and GO terms for proteins in the UniProt/Swiss-Prot database
were sourced from the European Bioinformatics Institute. The Scaf-
fold program (Version 3) was used to identify the cellular localizations
and biological processes most represented in lists of proteins quan-
tified in tissues and cell lines. The topGO Bioconductor software
package in R was used to identify and screen for GO biological
process categories displaying enrichment for proteins that were dif-
ferentially regulated in adenomas (versus normal mucosa) (25). First,
we prepared a “universe” comprising all the proteins quantified in our
study, each matched to GO terms and annotations. This served as the
“background.” The “foreground” consisted of the list of significantly
dysregulated proteins. The most significant GO terms were scored
with the Eliminating Genes (elim) method (25).
Western Blotting—Proteins were separated on a 10% SDS-poly-
acrylamide gel and transferred to a hydrophobic polyvinylidene diflu-
oride membrane (GE Healthcare, Amersham Biosciences Hybond-P
PVDF membrane, Pittsburgh, PA) according to standard protocols
(26). After 1 h of blocking with 5% nonfat dry milk in TBS with 1%
Tween 20 (milk–TBST), membranes were incubated overnight with the
primary antibody (anti-SORD (HPA040260, Sigma); anti-aldose re-
ductase, AKR1B1 (GTX113381, GeneTex, Irvine, CA); anti-keto-
hexokinase, KHK (GTX109591, GeneTex)) diluted 1:1000 in milk–TBST
and washed once with milk–TBST (20 min) and twice with TBST (20
min). After 1 h of incubation in horseradish-peroxidase-conjugated sec-
ondary antibody (anti-rabbit IgG, GE Healthcare) diluted 1:5000 in milk–
TBST, membranes were washed once with milk (20 min) and twice with
TBST (20 min). Enhanced chemiluminescence (Amersham Biosciences,
catalog no. RPN2106) was used to detect immunoreactive proteins.
Immunostaining of Cells and Tissues—HT29 and HCEC cells were
seeded (3 ! 105 per well) on 22-mm ! 22-mm cover slips in six-well
plates and grown under standard conditions until cells reached 70%
to 80% confluence. Cells were then washed twice with PBS and fixed
in ethanol:methanol solution (50:50) for 10 min at room temperature.
Fixed cells were permeabilized (10 min with 0.25% Triton X-100),
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blocked (30 min in 10% goat serum (X0907, Dako, Glostrup, Den-
mark)), and incubated with primary antibody (rabbit polyclonal anti-
SORD, HPA040260, Sigma, 1:100) for 18 h at 4 °C. After three washes
with PBS, the cells were incubated for 1 h with secondary antibody
conjugated to polymer-HRP anti-rabbit (Dako, EnVision! System-
HRP, catalog no. K4010). They were then washed three times in PBS
and incubated for 15 min in the substrate-chromogen 3,3-diamino-
benzidine tetrahydrochloride (Dako, EnVision! System-HRP, catalog
no. K4010). Cells were washed quickly with PBS and mounted on
slides (EUKITT, O. Kindler, GmbH, Freiburg, Germany) for light mi-
croscopy (Leica Microsystems GmbH, Wetzlar, Germany). Images
were examined and recorded with Leica Application Suite (V3.3.0)
software.
SORD immunohistochemistry was performed as previously de-
scribed (27). Tissue sections (normal colon and ileum, colorectal
adenomas, and adenocarcinomas) were incubated for 24 h at 4 °C
with primary antibody (rabbit polyclonal anti-SORD, HPA040261,
Sigma) at a 1:100 dilution.
Measurement of SORD Activity—Total protein was extracted from
cell lines and tissues as described above. SORD catalyzes the revers-
ible conversion of D-sorbitol to D-fructose, with !-NADH as a cofactor.
D-fructose" !-NADH¢O¡
SORD
D-sorbitol" !-NAD
(Eq. 1)
SORD activity was quantified via continuous spectrophotometric
rate measurement of the !-NAD formation rate (temperature 25 °C,
pH 7.6, A340, light path of 1 cm) in a Cary 50 Scan UV-visible
spectrophotometer using the Cary Kinetics Application (both from
Varian Inc., Palo Alto, CA) (28). The final reagent concentrations in a
1-ml cuvette were as follows: 78.33 mM triethonolamine, 183 mM
D-fructose, 0.21 mM !-NADH, 0.033% (w/v) BSA. The absorbance
reading was recorded when the enzyme was added. One unit of
enzyme activity was defined as the amount of enzyme required per
minute to convert 1.0 #M D-fructose to D-sorbitol at pH 7.6 at 25 °C.
A mixture of reagents plus recombinant SORD was used as the
positive control; negative controls consisted of the same reagent
mixture with no recombinant SORD, with recombinant SORD but no
D-fructose, or with recombinant SORD but no !-NADH.
Extraction and Quantification of Intracellular Metabolites by Tar-
geted Gas Chromatography Coupled with MS—Frozen tissue (50 to
100 mg) was homogenized in 250 #l of ice-cold 80% methanol using
a glass borosilicate grinder from Wheaton (Rockdale, UK). The homo-
genate wasmicroscopically examined to ensure that it was cell free, and
then it was transferred to Eppendorf vials and left on ice for 15 min to
ensure efficient protein precipitation. After centrifugation (15,000g for 3
min at 0 °C), the supernatant was snap-frozen and stored at "80 °C,
and the protein content of the pellet was determined via the Bradford
method.
For gas chromatography coupled with MS (GC-TOF-MS), 10 #l of
supernatant was transferred to a 1.5-ml Eppendorf tube, and internal
standards (13C1-sorbitol,
13C1-fructose, and
13C1-glucose; 1.2 pM of
each) were added. The samples were then dried overnight in a vac-
uum centrifuge (Concentrator 5301, Eppendorf AG, Wesseling-Ber-
zdorf, Germany). Methoxyamine hydrochloride and N-methyl-N-(tri-
methylsilyl)trifluoroecetamide were used as derivatization reagents
(29).
The derivatized metabolites and internal standards were subjected
to GC-TOF-MS (GC 7890A, Agilent Technologies, Santa Clara, CA;
GCT Premier Micromass, Waters, Manchester, UK) with an Rxi-5Sil
MS Integra-Guard column (length, 30 m; internal diameter, 0.25 mm)
and a film thickness of 0.25 #m (Restek, Bellafonte, PA). One micro-
liter of each derivatized sample was injected in splitless mode on a
baffled glass liner and transferred to the capillary column by rapid
heating of the liner from 50 °C to 250 °C at a rate of 12 °C/s. For the
separation of the metabolites, helium was used at a flow rate of 1
ml/min, and after an initial hold time of 2 min, a temperature gradient
from 80 °C to 320 °C (rate# 8 °C/min) was applied. The TOF-MS was
set to acquire centroided standard electron ionization mass spectra
over a range of 50 to 600 m/z at a rate of three spectra per second.
The GC-MS transfer line was heated to 280 °C. Dynamic range en-
hancement was activated. C6ClF5 was used as lock mass compound.
The MassLynx and QuanLynx programs (Waters, UK) were used to
review and analyze the acquired data. The absolute concentrations of
D-sorbitol, $ and ! D-fructose, and $ and ! D-glucose were calculated
on the basis of the ratio of the intensity of specific fragments originating
from the unlabeled compound to that of the added labeled analog
(internal standard). These concentrations were used to estimate intra-
cellular levels per milligram of tissue (adenoma versus normal mucosa).
The relative concentration of lactate was estimated from the ratio of the
intensity of specific fragments originating from the unlabeled compound
to that of the added 13C1-sorbitol (internal standard).
RESULTS
Proteomic Analysis of Human Colorectal Tissues and Colon
Cell Lines—We used a quantitative-MS-based discovery
strategy to explore the proteome of human colorectal tissues
and colon cell lines (normal and neoplastic). The characteris-
tics of the precancerous colorectal lesions are listed in Table
I. Protein extracts from these tumors and their paired samples
of normal mucosa (60 samples total) were analyzed using
iTRAQ LC-MS/MS and the workflow described in Fig. 1. The
inclusion of two reference sample mixes allowed us to control
for technical variability across the 10 experiments on tissue
samples, as the reference sample was analyzed twice in each
experiment. OFFGEL electrophoresis was used to obtain
highly reproducible, pI-based, in-solution separation of
pooled iTRAQ-labeled peptides. Furthermore, for relative
quantification of proteins using iTRAQ reporter ions, we ad-
opted a stringent FDR for peptide spectra matches (PSMs),
and high-confidence peptides for protein quantification were
selected only if the reporter ions (113 and 114) were quantified
in the reference sample mix (iTRAQ reporter channels 113 and
114). The dataset generated with this approach was large and
complex, but we developed a simplified analytical method
that allowed us to work with and merge the large data files
generated after MS/MS (Fig. 1). High-resolution MS/MS spec-
tra acquired on the LTQ-Orbitrap Velos spectrometer after
duplicate analysis of OFFGEL tissue sample fractions pro-
duced a total of 240 raw files (10 experiments, 120 fractions,
2 replicates). A total of 37,184 (FDR # 0.9%) unique tryptic
peptides were confidently identified and quantified from
285,929 unique PSMs (FDR # 0.2%) (Table II, supplemental
Table S1). Ten thousand four hundred and fifty-two proteins
(FDR # 1.5%) were assembled from the quantified peptides.
Proteins that were indistinguishable in MS/MS (i.e. two or
more proteins identified on the basis of the same peptide
sequence; see “Experimental Procedures” for details) were
represented as a single family. The result was a total of 4325
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nonredundant protein families, two-thirds (2865, 66%) of
which were relatively quantified in at least 9 normal mucosa–
adenoma pairs, and 1072 (25%) in all 30 pairs (Table II,
supplemental Table S1).
To verify the efficiency of iTRAQ protein labeling, we re-
peated the database search with methylthio (C) set as a fixed
modification and iTRAQ 8-plex (N-term), iTRAQ 8-plex (K),
iTRAQ 8-plex (Y), and oxidation (M) set as variable modifica-
tions. (All other search parameters were unchanged.) The
assigned PSMs were filtered, as described in “Experimental
Procedures,” and the average iTRAQ labeling efficiency
achieved in each of the 10 tissue experiments was 96%
(supplemental Table S2). To ascertain the efficacy of including
a standard sample mix as a reference for normalization, we
compared combined Gaussian plots of log2-protein ratios of
normal mucosa or adenoma samples with the respective ref-
erence channel per experiment (e.g. 115/114 versus 113/114
for normal tissues, 116/114 versus 113/114 for adenomas;
see Fig. 1). The ratios displayed normal distributions in all
channels. For the reference channel (113/114), log2-ratios
were largely centered on 0, whereas the distribution of ade-
noma and normal channel log2-ratios was broader and not
always centered at 0 (data not shown).
Sample complexity is a common problem in the analysis of
proteomic data from human colorectal tissues. It stems in part
from contamination of the epithelial cell proteome by proteins
from stromal cells (which were inevitably present in our spec-
imens, even though the endoscopic tissue sampling proce-
dure we used yielded superficial specimens with consistently
high epithelial contents). Microdissection can be utilized to
TABLE I
Characteristics of the precancerous colorectal lesions included in the study
Patient
number Age Sex
Colon
segment
involved
Maximum
lesion
diameter (mm)
Paris
classificationa
Pit pattern
classificationb
Microscopic
appearance
Highest degree
of dysplasia
in the lesionc
Number of
lesions at study
colonoscopyd
Number of
previously
excised lesions
1 77 M S 25 IIa!IIc IIIs-IIIL TA LGD 1 0
2 73 F A 25 IIa!IIc IIIs-IIIL TA LGD 1 2
3 59 M T 30 IIa!IIc IIIs!IIIL TA LGD 1 0
4 73 F R 50 Is IV VA LGD 1 0
5 74 M R 40 Is IV VA HGD 2 1
6 77 M C 25 IIa IIIL VA LGD 1 0
7 80 M A 40 IIa IIIL TVA LGD 1 1
8 82 M A 15 IIa IIIL VA LGD 2 0
9 73 F S 20 Ip IV TVA LGD 1 0
10 70 F C 25 IIa IIIL TVA LGD 2 0
11 63 M A 45 Is IIIL-IV TVA LGD 0 0
12 68 M A 30 IIa!Is IIIL-IV TVA HGD 0 0
13 60 M D 30 Is IV-Vi TVA HGD 0 0
14 55 M C 25 IIa!Is IIIL-IV SSA LGD 0 0
15 70 M A 15 Is IV TVA LGD 7 0
16 85 F S 25 Is!IIa IV TA LGD 1 1
17 66 M A 30 IIa IIIL TA HGD 2 0
18 72 M A 30 Is IV TVA HGD 2 0
19 71 M S 30 IIa IIIL TVA LGD 2 0
20 59 M R 60 Is IV-Vi TVA HGD 1 0
21 78 M A 50 Is IV-Vi TA LGD 1 0
22 75 M R 25 Is IV-Vn TVA HGD 6 0
23 73 F D 25 Is IV TA LGD 1 0
24 69 F R 90 Is!IIa IV TVA LGD 1 0
25 75 M T 18 IIa IIIL TA LGD 1 0
26 61 M A 40 Is!IIa IV TVA LGD 20 0
27 76 M S 30 Is IV-Vi TA HGD 1 0
28 78 F R 60 IIa!Is IV TVA LGD 1 1
29 89 M R 30 Is IV TA LGD 3 0
30 75 M A 50 Is IV-Vn TVA HGD/cancer 7 0
Abbreviations: M, male; F, female; C, cecum; A, ascending colon; T, transverse colon; D, descending colon; S, sigmoid colon; R, rectum;
TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma; SSA, sessile serrated adenoma; LGD, low-grade dysplasia; HGD,
high-grade dysplasia.
a Macroscopic appearance of neoplastic lesions was classified according to the Paris Endoscopic Classification of Superficial Neoplastic
Lesions (Gastrointest. Endosc. 2003;58(Suppl.):S3–S27).
b Morphological analysis of colon crypt patterns according to the Kudo classification (82).
c Low-grade versus high-grade dysplasia as defined by the World Health Organization classification of tumors of the digestive system at the
editorial and consensus conference in Lyon, France, November 6–9, 1999.
d This number includes the lesion included in our proteomic study.
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isolate subpopulations of cells, but it can diminish the quantity
and quality of the proteins, rendering them suboptimal for
some types of proteomic analysis. To avoid this problem, we
adopted a novel strategy for preliminary identification of the
proteomic alterations that were most likely to involve the
epithelial-cell component of the adenomas. The proteomic
profiles of the colon tissues were compared with those of six
colon epithelial cell lines (five colon cancer cell lines plus
Tissue or cells
protein extract
peptides
iTRAQ 8plex labeling
OFFGEL electrophoresis
(OGE)
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Raw data converted to 
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against UniProt / 
SwissProt database
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FIG. 1. Project design and iTRAQ 8-plex labeling scheme. Sample preparation for shotgun MS/MS and important steps in the analysis of
proteomic data for the detection of dysregulated proteins in adenomas and colon cancer cell lines. For each experiment on tissue samples,
iTRAQ tags were assigned to a duplicate reference (two identical pools of normal and adenoma samples: 113 and 114, respectively), normal
tissues (115, 117, 119) and corresponding adenomas (116, 118, 121). The same pattern was repeated in all 10 experiments. In cell line
experiments, two identical pools, each comprising all six cell lines, were used as references (113 and 114), and each of the remaining six tags
was used to label a single cell line. The data analysis flow chart depicted in this figure is described in “Experimental Procedures.”
Proteomic Profiling of Colorectal Adenomas
Molecular & Cellular Proteomics 13.5 1203
 
!! 179!
 
HCEC cells, to our knowledge the only well-characterized line
established from normal colorectal epithelium (23)). Changes
in expression levels observed in adenomas (i.e. up-regulation
or down-regulation with respect to normal mucosal levels)
were presumed to be epithelial-cell-specific if similar changes
were found in the colon cancer cell lines (relative to HCEC
cells). After OFFGEL fractionation, duplicate MS analysis of
iTRAQ-labeled peptides (24 fractions) from the six cell lines
was performed in an LTQ-Orbitrap Velos mass spectrometer,
and 11,266 peptides (FDR! 0.5%) were confidently identified
and quantified from 27,922 unique PSMs (FDR! 0.4%) (Table
II, supplemental Table S3). A total of 2017 nonredundant
protein families (FDR ! 1.1%) were identified and relatively
quantified in cell lines; 1957 (97%) were present in all six cell
lines (Table II). In the iTRAQ experiment with cell lines, the
peptide labeling efficiency was 95% (supplemental Table S2).
Relative Quantification of the Proteomes of Colorectal Tis-
sues and Cell Lines—The concentration range for proteins
expressed in human tissues spans 10 orders of magnitude.
We chose not to deplete our protein samples of high-abun-
dance proteins (e.g. albumin, IgG), because with the number
of tissue samples being analyzed, additional sample prepara-
tion steps were considered potential sources of confounding
variability (30). As an alternative, each of the 10 pooled
iTRAQ-labeled samples (10 experiments) was separated into
12 fractions based on the isoelectric point of peptides, reduc-
ing the complexity of our protein matrix and limiting the risk of
bias toward the more abundant proteins.
The expression levels of the 4325 nonredundant protein
families we were able to relatively quantify in colorectal tis-
sues spanned 4 orders of magnitude, as deduced from the
protein Mascot emPAI value (used as a proxy for the emPAI
value (31) to estimate protein concentrations) (Fig. 2A). Thirty
percent (1304/4325) of these families were relatively quanti-
fied on the basis of more than one unique peptide. At the top
of this list were the large proteins AHNAK, DYNC1H1, DSP,
and FCGBP (Fig. 2B). In colon epithelial cell lines, 1174 of the
2017 protein families were relatively quantified with more than
one unique peptide.
Gene Ontology Annotation in Scaffold was used to identify
the subcellular localizations of these protein families and the
biological processes they were involved in. The GO categories
represented in the tissue and cell line proteomes were fairly
similar. In the cell line proteome, however, the categories
generally contained fewer proteins, as the total number of
proteins detected in these cells was less than that in the
tissues (Fig. 2C). Cytoplasmic and organelle- or membrane-
associated proteins were the most highly represented cate-
gories in our extracts, but nuclear proteins were also readily
identified, which indicates that our protein extraction proce-
dure was not strongly biased toward a few cell compartments.
The most highly represented biological processes in the tis-
sue proteome were metabolic or biosynthetic processes,
whereas cell component organization and developmental pro-
cesses predominated in the cell line proteome (Fig. 2D). Stro-
mal contamination was probably responsible for the in-
creased representation of immune system processes in the
tissue proteome (relative to that of the cell lines).
Log2-expression levels of the protein families identified in all
tissues (n ! 1072) and cell lines (n ! 1957) (Table II) were
subjected to principal component analysis, which easily dis-
tinguished the adenomas from the normal mucosa samples
(Fig. 3A) and the five colon cancer cell lines from the immor-
talized normal colon epithelial cell line HCEC (Fig. 3B). The
cancer cell lines were also segregated into three distinct
groups reflecting their patient origins (Fig. 3B). When principal
component analysis was performed on the expression inten-
sity values of the 1496 nonredundant proteins expressed and
quantified in all tissues and cell lines (i.e. those representing
the intersection of the tissue (n ! 10,452) and cell line (n !
5056) protein sets reported in Table II), colon cancer cell lines
clustered with adenomas, whereas HCEC cells were closer to
the normal mucosa samples (Fig. 3C).
As a quality control measure, data for the 60 tissue samples
(1072 protein families) were subjected to hierarchical cluster-
ing analysis. As shown in supplemental Fig. S1, three main
clusters emerged: one consisting almost exclusively of normal
mucosa samples, a second containing mainly adenomas, and
a third that included both tissue types. The 18 samples in the
third cluster (nine adenoma–normal mucosa pairs) formed
three subclusters, which corresponded to 3 of the 10 exper-
iments for which trypsin digestion, iTRAQ labeling, and LC-
MS/MS were performed on the same day. These findings
were suggestive of an experimental bias. Indeed, when these
18 potentially substandard samples were included in subse-
quent statistical analyses, they diminished the stringency of
our threshold and increased the error margin for false identi-
fication. We therefore excluded these samples from the anal-
yses described in the following section.
Proteins Displaying Dysregulated Expression in Colorectal
Adenomas and Colon Cell Lines—To identify proteins with
significantly altered expression in adenomas (relative to nor-
mal mucosa), we analyzed data on the proteins quantified in
TABLE II
Summary of proteomics data
Tissues
(n ! 60)
Cell lines
(n ! 6)
Total FDR (%) Total FDR (%)
Peptide spectra
matches
285,929 0.2 27,922 0.4
Peptides 37,184 0.9 11,266 0.5
Proteinsa 10,452 1.5 5056 1.1
Proteinsb 4325 - 2017 -
Proteinsc 1072 - 1957 -
a Total number of proteins quantified in the 10 tissue experiments
and the single experiment with cell lines.
b Nonredundant protein families quantified in our dataset.
c Nonredundant protein families quantified in all 60 tissues or in all
six cell lines.
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the remaining 21 tissue pairs. The experimentally derived
protein fold-change threshold defining differential expression
was based on comparison of the distributions of average
intensity log2 ratios in the reference standard (113 versus 114,
seven experiments) and in patient samples (adenoma versus
normal, seven experiments). The average ratios in the refer-
ence sample were centered on 1 (i.e. log2 0). Average fold-
change ratios for the tissue samples displayed wider variance
(supplemental Fig. S2). Seventeen percent of the log2 ratios
for the tissue samples exceeded !0.5 log2 scale (indicating a
linear fold change ! !1.4), as opposed to only 5% of those
for the reference samples. For each protein, a paired t test
was used to compare the intensity ratios in normal and ade-
nomatous samples (i.e. normal/114; adenoma/114). After
adjustment for multiple comparison (Benjamini–Hochberg
method), we selected a stringent q value cutoff of "0.02.
The 212 proteins that satisfied this criterion and presented
a mean expression fold change of !1.4 (log2 0.5) or greater
were classified as significantly dysregulated in adenomas.
They included 76 with up-regulated expression and 136 with
down-regulated expression in the tumor samples (Table III).
When protein abundance iTRAQ ratios for these 212 proteins
FIG. 2. Protein coverage with iTRAQ shotgun analysis in colorectal tissues. A, analysis of Mascot emPAI values (used as a proxy for
emPAI values) revealed a dynamic range of protein abundance in tissues that spanned 4 orders of magnitude (y-axis) and corresponded with
known abundance estimates for various proteins in these tissues. The high/moderate-abundance proteins (e.g. ACTB, FABP5, CHGA) and
low-abundance protein (e.g. POLR3A) relatively quantified in our samples are highlighted relative to their mean Mascot emPAI value. B,
distribution of reported abundance ranges for the proteins with at least one unique peptide identified in tissues, and the high-molecular-weight
proteins with the greatest number of unique peptides identified. Subcellular localizations of the proteins identified in colorectal tissues and cell
lines (C) and biological processes in which these proteins are involved (D). This analysis was performed using Scaffold and Gene Ontology
annotations (see “Experimental Procedures”).
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FIG. 3. Principal component analysis of protein expression. Three-dimensional principal component analysis score plot of log2 protein
expression intensity values for (A) tissues (normal mucosa, black; adenomas, red), (B) cell lines (HCEC, cyan; colon cancer cell lines, green), and
(C) both. The first three principal components (PCs) account for 40%, 82%, and 36% of the total variance in the tissue, cell line, and tissue ! cell
line sets, respectively. PC1, the main direction of spread in the three groupings, reflects intergroup variance based on tissue or cell line type (i.e.
normal/immortalized versus tumorous). Cell lines derived from the same patient: *SW480 and SW620 cells; ˆHT29 and CX1 cells.
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TABLE III
Proteins displaying differential expression in adenomas versus normal mucosa
UniProt accession numbera Gene name q value
Average fold
change (log2)
P12429 ANXA3 0.00000001 1.44
Q9UN36 NDRG2 0.00000001 !0.79
P00918 CA2 0.00000003 !2.26
P23946 CMA1 0.00000005 !1.38
P00488 F13A1 0.00000005 !1.30
Q9UBR2 CTSZ 0.00000016 !1.23
P10645 CHGA 0.00000016 !1.82
O60844 ZG16 0.00000024 !2.02
P17174 GOT1 0.00000045 !0.61
P31949 S100A11 0.00000062 1.49
P00338b; P07195 LDHA; LDHB 0.00000068 0.62
O60701 UGDH 0.00000104 !0.70
P55011 SLC12A2 0.00000115 0.85
O95571 ETHE1 0.00000120 !0.74
Q01105 SET 0.00000230 0.72
Q16851 UGP2 0.00000275 !0.53
Q00796 SORD 0.00000275 0.62
P20231; Q15661 TPSB2; TPSAB1 0.00000275 !1.51
Q15181; Q9H2U2b PPA1; PPA2 0.00000421 0.64
Q9H3G5 CPVL 0.00000467 !0.69
P01282 VIP 0.00000722 !1.10
P07339 CTSD 0.00000856 !0.71
P19338 NCL 0.00000934 0.50
Q6UWP2 DHRS11 0.00001070 !1.20
P04066 FUCA1 0.00001240 !1.32
Q53EL6 PDCD4 0.00001270 !0.51
P07585 DCN 0.00001580 !1.36
P02511 CRYAB 0.00002720 !1.19
Q96CX2 KCTD12 0.00003590 !0.70
Q05707; P08123 COL14A1 0.00004020 !1.21
P51884 LUM 0.00004160 !0.96
Q15063 POSTN 0.00004240 !2.10
P21397 MAOA 0.00004240 !0.63
O00748 CES2 0.00004610 !0.88
Q56VL3 OCIAD2 0.00004960 0.95
Q9BYZ8 REG4 0.00004960 0.98
P55008 AIF1 0.00005650 !0.75
P50224; P50225 SULT1A3; SULT1A1 0.00005760 !0.63
O14773 TPP1 0.00006430 !0.52
Q16853 AOC3 0.00006650 !1.16
P53634 CTSC 0.00006940 !0.58
O95881 TXNDC12 0.00006940 0.55
O75795 UGT2B17 0.00006940 !1.57
O00391 QSOX1 0.00006940 !0.70
Q99538 LGMN 0.00006940 !0.63
P12111 COL6A3 0.00006990 !0.74
P80188 LCN2 0.00006990 1.32
P12956b XRCC6 0.00007190 0.53
Q6NZI2 PTRF 0.00007860 !0.76
P09382 LGALS1 0.00007880 !0.84
P25815 S100P 0.00008020 3.38
Q15118 PDK1 0.00008120 !0.90
O75380 NDUFS6 0.00008650 !0.63
Q9HAW8 UGT1A10 0.00009090 !0.95
P01042 KNG1 0.00009660 !0.74
O75356 ENTPD5 0.00012385 !0.54
Q15293 RCN1 0.00012867 0.61
P17931 LGALS3 0.00013151 !0.62
P36952 SERPINB5 0.00013151 1.31
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TABLE III—continued
UniProt accession numbera Gene name q value
Average fold
change (log2)
P09211b GSTP1 0.00014809 0.55
P20774 OGN 0.00015467 !1.52
Q8NBJ4 GOLM1 0.00015467 !0.51
Q16563 SYPL1 0.00015568 1.16
P04229; P13761; Q30134; Q9TQE0; Q9GIY3;
Q29974; P04440; P79483
HLA-DRB1; HLA-DRB1; HLA-DRB1; HLA-DRB1;
HLA-DRB1; HLA-DRB1; HLA-DPB1; HLA-DRB3
0.00015568 !0.81
P35555 FBN1 0.00017230 !0.74
Q9H4M9; Q9NZN4; Q9H223 EHD1; EHD2; EHD4 0.00017230 !0.56
O00754 MAN2B1 0.00017278 !0.65
B4DR31 DPYSL2 0.00018023 !0.55
P06703b S100A6 0.00018025 1.18
P19801 ABP1 0.00022289 !0.50
P20042 EIF2S2 0.00022417 0.68
P51858 HDGF 0.00024151 0.56
P49959b MRE11A 0.00024174 0.64
O00299b; Q9Y696 CLIC1; CLIC4 0.00024726 0.67
P61604b HSPE1 0.00024977 0.52
O43252; O95340 PAPSS1; PAPSS2 0.00027464 !0.57
Q12765 SCRN1 0.00029349 !0.64
Q9HB40 SCPEP1 0.00030328 !0.87
P48556 PSMD8 0.00032019 0.56
O60547 GMDS 0.00034711 0.58
Q9Y6R7 FCGBP 0.00035167 !0.73
P61626 LYZ 0.00036558 0.74
Q9Y224 C14orf166 0.00038868 0.52
P01765; P01764 (Ig heavy chain V-III region TIL; Ig heavy chain V-III
region VH26)
0.00038868 !0.69
Q9NVP1 DDX18 0.00038996 0.67
P80365 HSD11B2 0.00039413 !0.68
P39687; Q92688 ANP32A; ANP32B 0.00039654 0.56
Q86WA6 BPHL 0.00046215 0.52
P24298 GPT 0.00047338 !0.56
Q12874 SF3A3 0.00052166 0.50
P04899; Q14344; P63092 GNAI2; GNA13; GNAS 0.00062192 !0.51
Q15124 PGM5 0.00068593 !0.68
Q9HAW7; Q9HAW9; O60656 UGT1A7; UGT1A8; UGT1A9 0.00071202 !0.87
P19224 UGT1A6 0.00071202 !0.87
P06748 NPM1 0.00071508 0.81
Q9NUV9 GIMAP4 0.00071508 !0.89
P18283b GPX2 0.00071508 0.54
P13688 CEACAM1 0.00072482 !1.06
P01591 IGJ 0.00084082 !1.10
P19823 ITIH2 0.00085565 !0.71
P01774; P01776; P01779 (Ig heavy chain V-III region POM; Ig heavy chain V-III
region WAS; Ig heavy chain V-III region TUR)
0.00085565 !0.79
P27695b APEX1 0.00086971 0.54
Q9C002 NMES1 0.00087016 !0.91
Q96F85 CNRIP1 0.00088956 !1.27
Q9BPX5 ARPC5L 0.00095098 0.67
P62263 RPS14 0.00095182 0.52
Q9BY32 ITPA 0.00095634 0.51
P01625 (Ig kappa chain V-IV region Len) 0.00097041 !0.61
Q15582 TGFBI 0.00097041 0.90
Q07021b C1QBP 0.00101874 0.76
P00738 HP 0.00102030 !0.61
O15143 ARPC1B 0.00103757 !0.50
Q03154 ACY1 0.00108571 0.60
Q9HCB6 SPON1 0.00115609 !0.89
Q96HE7 ERO1L 0.00119027 0.50
P08575 PTPRC 0.00119950 !0.52
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TABLE III—continued
UniProt accession numbera Gene name q value
Average fold
change (log2)
Q9Y266 NUDC 0.00152358 0.56
P63313; P62328 TMSB10; TMSB4X 0.00159602 0.98
Q96SQ9 CYP2S1 0.00162405 0.84
Q71U36 TUBA1A 0.00162405 0.54
P00915 CA1 0.00163258 !1.18
P04844 RPN2 0.00165748 0.55
P09669 COX6C 0.00171230 !0.61
P21980 TGM2 0.00174251 !0.55
P00325 ADH1B 0.00175658 !1.18
O14745 SLC9A3R1 0.00175658 !0.51
Q9H8H3 METTL7A 0.00179938 !0.50
P61009 SPCS3 0.00186488 !0.69
Q15746; O15264; Q16539 MYLK; MAPK13; MAPK14 0.00186488 !0.53
P01876; P01877; Q92973 IGHA1; IGHA2; TNPO1 0.00191760 !1.01
P12109 COL6A1 0.00194792 !0.67
Q9BX66 SORBS1 0.00205902 !0.64
E9PGJ9 CC2D1A 0.00213982 !0.53
P49006 MARCKSL1 0.00233532 0.51
Q01524 DEFA6 0.00233532 1.60
P01620 (Ig kappa chain V-III region SIE) 0.00238585 !0.56
P36873 PPP1CC 0.00240171 0.58
Q07507 DPT 0.00240576 !1.28
P37840 SNCA 0.00261720 !0.57
P00326; P07327 ADH1C; ADH1A 0.00271753 !1.17
P22105 TNXB 0.00271753 !0.51
O95299 NDUFA10 0.00272901 !0.84
Q9NRP0 OSTC 0.00275806 0.76
P10082 PYY 0.00282902 !1.59
P21810 BGN 0.00283401 !0.66
Q8IV08 PLD3 0.00295758 !0.74
P01857; P01859; P01860; P01861 IGHG1; IGHG2; IGHG3; IGHG4 0.00343621 !0.57
P62330 ARF6 0.00343645 0.84
Q03135 CAV1 0.00346186 !0.71
P22309; P35503; P22310; P35504 UGT1A1; UGT1A3; UGT1A4; UGT1A5 0.00349148 !0.87
Q9NSU2 TREX1 0.00349148 !0.76
Q9UKY7 CDV3 0.00355684 0.79
Q7Z4V5 HDGFRP2 0.00360855 0.65
P07357 C8A 0.00372327 !0.62
Q99757 TXN2 0.00377179 !0.73
P13686 ACP5 0.00385765 !0.80
Q8WWA0 ITLN1 0.00392858 !1.30
P62861 FAU 0.00395014 0.51
P57737 CORO7 0.00401004 !0.83
P10606 COX5B 0.00412793 !0.71
Q9Y259 CHKB 0.00420774 !0.59
Q9Y2J8 PADI2 0.00435864 !0.50
O94919 ENDOD1 0.00451988 !0.80
B9A064; P0CG05; A0M8Q6 IGLL5; IGLC2; IGLC7 0.00451988 !0.56
P20039 HLA-DRB1 0.00459324 !0.82
P63167b; Q96FJ2 DYNLL1; DYNLL2 0.00468484 0.63
Q9UNN8 PROCR 0.00480932 !0.78
P07099 EPHX1 0.00486543 !0.54
P32322 PYCR1 0.00495977 0.55
Q9P0J0 NDUFA13 0.00534323 !0.60
E7EUF8; E9PFN5 EPB41L3; GSTK1 0.00539222 !0.95
O75531 BANF1 0.00560405 0.73
P26447 S100A4 0.00562754 !0.53
Q9NVJ2 ARL8B 0.00562754 0.50
Q8N752 CSNK1A1 0.00562754 0.52
P40616 ARL1 0.00583778 0.60
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were plotted on a heat map, adenomas and normal mucosa
samples formed two distinct clusters (Fig. 4A). As shown in
Fig. 4B, tissue expression levels for the 212 dysregulated
proteins showed good correlation (r ! 0.74, p " 0.001, 95%
confidence interval ! 0.67–0.79) with those of mRNAs for the
same genes (measured by our group in another set of colo-
rectal adenomas) (26).
Table IV lists the biological processes that were overrepre-
sented in this set of proteins. At the top of this list was
xenobiotic metabolism, a process already linked with ade-
noma formation on the basis of enrichment studies of tran-
scriptomic datasets conducted by our group (32). Three of the
dysregulated proteins involved in this process (CYP2S1,
NQO1, and GSTP1) displayed up-regulated expression in ad-
enomas, but most were characterized by tumor-related
down-regulation (ADH1B, ADH1C/ADH1A, UGT1A9/UGT1A6,
UGT1A1/UGT1A4/UGT1A3/UGT1A5, UGT1A7/UGT1A8, UGDH,
MAOA, SULT1A3/SULT1A1, PAPSS1/PAPSS2, UGP2). Net-
work-building analysis revealed that all these proteins were
linked by subnetworks controlled by cancer-associated tran-
scription factors, such as SP1 or, less frequently, MYC,
HIF1A, or TP53 (supplemental Fig. S3). As noted in Table IV,
a very similar picture emerged when GO enrichment was also
analyzed in a larger set of 621 dysregulated proteins selected
with less stringent criteria (q value cutoff ! 0.2; average log2
fold change " #0.5).
The expression levels of 111 (52%) of the 212 proteins that
were differentially expressed in adenomas were also quanti-
fied in cell lines (those shown in bold in Table III and referred
to hereinafter as the “epithelial cell signature” proteins). Al-
most half (n ! 51, 46%) showed directionally similar tumor-
related dysregulation in both analyses. Because cell line stud-
TABLE III—continued
UniProt accession numbera Gene name q value
Average fold
change (log2)
Q96GA7 SDSL 0.00583778 $0.82
P01275 GCG 0.00607808 $1.33
P15289 ARSA 0.00633336 $0.57
O75521 ECI2 0.00635218 $0.60
P62158b CALM1; CALM2; CALM3 0.00657472 0.67
P49821 NDUFV1 0.00669319 $0.66
Q15746–5 MYLK 0.00678109 $0.51
Q96BM9 ARL8A 0.00686655 0.54
Q6UX06 OLFM4 0.00696505 1.14
P10153 RNASE2 0.00724902 $0.50
P19075b TSPAN8 0.00837908 0.59
Q8WU39 PACAP 0.00837978 $0.56
P21953 BCKDHB 0.00837978 0.54
O76041 NEBL 0.00837978 0.71
Q9H4G4 GLIPR2 0.00849532 $1.10
P01766; P01767; P01768 (Ig heavy chain V-III region BRO; Ig heavy chain V-III
region BUT; Ig heavy chain V-III region CAM)
0.00895132 $0.61
Q9NR56; Q5VZF2 MBNL1; MBNL2 0.00996176 0.55
P27105 STOM 0.01083127 $0.51
P05387 RPLP2 0.01100903 0.62
Q96AB3 ISOC2 0.01164408 $0.51
O43294 TGFB1I1 0.01198321 $0.57
Q08752 PPID 0.01211602 0.55
Q96DG6 CMBL 0.01289211 $0.51
P61619 SEC61A1 0.01375705 0.59
P56381; Q5VTU8 ATP5E; ATP5EP2 0.01440856 $0.52
P14174b MIF 0.01488262 0.51
P12110 COL6A2 0.01526347 $0.53
Q14956 GPNMB 0.01546825 $0.63
P46952 HAAO 0.01570996 $0.53
Q86VN1 VPS36 0.01610077 0.67
Q96S52 PIGS 0.01626862 $0.61
P15559b NQO1 0.01626862 0.56
O60575 SPINK4 0.01810104 0.77
P55735 SEC13 0.01827155 0.59
P02452 COL1A1 0.01933726 $1.32
P00403 MT-CO2 0.02012815 $0.62
a Two or more accession numbers: proteins from the same family or isoforms from the same gene. Boldface numbers indicate “epithelial cell
signature” proteins (see text).
b Designated candidate cancer biomarkers in the Human Protein Atlas database.
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ies were conducted with only one noncancerous line, these
findings obviously require further validation. They suggest,
however, that these 51 proteins are indeed expressed in the
epithelial cells of normal colorectal tissues and that their ex-
pression is dysregulated in the epithelial cells of adenomas.
Up-regulation of SORD Expression and Activity in Colorec-
tal Adenomas and Cancer Cell Lines—Sorbitol dehydrogen-
ase, a key enzyme in the polyol pathway, was one of the most
significantly up-regulated proteins in our colorectal adenomas
(based on q values) (Table III). Because its increased expres-
sion could have metabolic consequences with potential ef-
fects on tumorigenesis, we performed Western blotting and
immunostaining studies to validate this finding. The reliability
of the anti-SORD antibody we had chosen was first tested on
protein extracts from the six colorectal epithelial cell lines (Fig.
5A). The tumor-related log2 fold changes detected with West-
ern blotting were substantially greater than those documented
with iTRAQ (2 to 6 versus 0.4 to 1, respectively) (Fig. 5B),
which was not surprising, as iTRAQ has been reported to
underestimate protein abundance (33). However, the relative
quantities of SORD found with the two methods were fully
consistent. As for the 21 adenomas, the elevated SORD ex-
pression documented in these tumors by iTRAQ (Fig. 5C)
showed good correlation with the increased SORD mRNA
levels we had previously found in 42 other lesions of this type
(26) (Fig. 5D). Western blot analysis of four randomly se-
lected adenoma–normal mucosa pairs from the present se-
ries revealed obvious up-regulation of SORD expression in
all four tumors, although the magnitude of the increase
varied (Fig. 5E).
SORD activity was then assayed (see “Experimental Proce-
dures”) to see how it corresponded with the enzyme expres-
sion levels reported above. As shown in Fig. 5F, the results of
cell line assays were fully consistent with the Western blotting
data: SORD activity was seven times higher in HT29 than in
HCEC cells, and more limited up-regulation was found in
SW480. High correlation between enzyme activity and protein
level was also documented for three randomly selected
adenoma–normal mucosa pairs (Fig. 5F).
MS and Western blotting findings were further validated
with immunostaining studies, as shown in Fig. 6. Cytoplasmic
SORD staining was evident in the colon cancer cell line HT29
but was weaker or even absent in normal epithelial HCEC
cells (Figs. 6A and 6B). As for colorectal tissues, SORD cyto-
plasmic expression was limited to the bottom of the normal
epithelial crypts (Figs. 6C, 6D, and 6E), but its expression was
markedly increased in adenomatous and cancerous glands
(Figs. 6F–6I). These findings suggest that SORD is likely to be
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FIG. 4. Analysis of the 212 proteins displaying significant tumor-
related dysregulation. A, hierarchical clustering of iTRAQ abun-
dance ratios (normal versus 114, adenoma versus 114) for the
212 proteins displaying significant adenoma-related dysregulation
grouped tissue samples into two discrete clusters: adenoma (A) and
normal (N). B, Pearson’s correlation test comparing average fold
changes (at least !0.5 log2) for the 212 proteins (red, up-regulated;
blue, down-regulated) in the tissue series with average log2 fold
changes for the corresponding mRNAs measured in another set of
adenoma/normal mucosal samples.
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expressed in proliferating cells, although it was largely absent
in HCECs, which undergo regular proliferation in vitro. Fur-
thermore, nuclear localization of SORD was noted in some
adenomatous crypts (supplemental Figs. S4A and S4C), and
the cells in question were almost always negative for the
well-known proliferation marker Ki-67 (supplemental Figs.
S4B and S4D). This mutually exclusive staining pattern was
also observed in normal crypts of the ileum, where SORD,
interestingly, appeared to be expressed in the nuclei of puta-
tive stem cells (supplemental Figs. S4E and S4F).
Polyol Pathway Enzyme Expression and Metabolite Levels
in Cell Lines and Tissues—We then examined the state of the
polyol pathway (supplemental Fig. S5A) in colorectal cell lines
and tissues. As shown in supplemental Fig. S5B, immunoblot
studies revealed decreased AKR1B1 expression in HT29 (ver-
sus HCEC cells) and adenomas (versus corresponding normal
mucosal samples), whereas SORD expression and that of
KHK were up-regulated in tumor cells and tissues. As for the
metabolites (supplemental Fig. S5C), D-glucose levels were
significantly decreased in adenomas. Less dramatic changes
were observed in the levels of D-sorbitol and D-fructose, which
both showed a tendency to decrease in tumor tissues.
DISCUSSION
Although a number of proteomic studies have compara-
tively analyzed different types of colorectal tissues, precan-
cerous lesions have been considered in only three (21, 34, 35),
and in two of these (21, 34), the number of adenomas ana-
lyzed was very small (!4). The study by Lam et al. (35) is the
only one that compared protein expression in a relatively large
number (n ! 20) of paired adenoma and normal mucosa
samples. They used two-dimensional gel electrophoresis to
resolve over 1000 proteins in the two tissue groups, and those
displaying differential expression were then analyzed with
MALDI-TOF/TOF-MS. MS/MS validation pinpointed four pro-
teins (ANXA3, S100A11, EIF-5A1, and S100P) whose expres-
sion in adenomas was significantly increased. Using MS with
iTRAQ 8-plex peptide labeling and OFFGEL fractionation al-
lowed us to quantitatively compare protein expression in 30
colorectal adenomas and paired samples of normal mucosa
and investigate low-abundance proteins that cannot be eval-
uated with proteomics based on two-dimensional gel electro-
phoresis. All in all, 4325 nonredundant protein families were
quantified in our colorectal tissues (25% of which were iden-
tified in all 60 samples) (Table II), and the 212 proteins we
flagged as significantly dysregulated in adenomas included
three of the four proteins identified by Lam et al. (up-regula-
tion of the fourth, EIF-5A1, failed to meet our stringent crite-
rion for significance) (Table III).
The cell types in which these proteomic changes occur is of
obvious interest, as colorectal cancer arises from the epithe-
lial component of the colorectal mucosa. Although our find-
ings are preliminary and will naturally require validation in
future studies, 51 of the 212 proteins listed in Table III were
“epithelial cell signature” proteins and showed directionally
similar expression changes in colon cancer cell lines versus
HCEC. It therefore seems likely that their dysregulated ex-
pression in adenomas is a feature of neoplastic transforma-
tion of colorectal epithelial cells. However, epithelial–stromal
cell interactions can also play important roles in tumorigenesis
(20). Our approach also allowed us to identify 101 proteins
displaying adenoma-related dysregulation that were probably
TABLE IV
Gene Ontology (GO) biological processes enriched in the set of 212 proteins whose expression displayed adenoma-related dysregulation (see
Table III)
GO I.D. GO term Annotateda Significantb
Up in
adenomas
Down in
adenomas
Expectedc
elim p
valued
GO:0006805 Xenobiotic metabolic processe 64 21 3 18 2.8 1.70E-09
GO:0006958 Complement activation, classical pathwaye 74 17 0 17 3.24 1.10E-08
GO:0051552 Flavone metabolic processe 5 5 0 5 0.22 1.50E-07
GO:0052696 Flavonoid glucuronidatione 5 5 0 5 0.22 1.50E-07
GO:0052697 Xenobiotic glucuronidatione 5 5 0 5 0.22 1.50E-07
GO:0042573 Retinoic acid metabolic processe 9 6 0 6 0.39 5.00E-07
GO:0045087 Innate immune responsef 249 33 4 29 10.91 7.80E-07
GO:0031295 T-cell costimulationf 34 10 0 10 1.49 1.10E-06
GO:0030199 Collagen fibril organizatione 8 5 0 5 0.35 7.80E-06
GO:0001501 Skeletal system development 54 11 1 10 2.37 1.60E-05
GO:0070208 Protein heterotrimerizatione 5 4 0 4 0.22 1.70E-05
GO:0050852 T-cell receptor signaling pathwayf 48 10 0 10 2.1 3.20E-05
a Proteins in TopGO Background list.
b 212 dysregulated proteins of Table III.
c Number of significant proteins expected to map to the GO term if the significant proteins are randomly distributed over all GO terms.
d p value from the Eliminating Genes method (25). Only processes with an elim p value " 1.0E-04 are shown.
e Processes that were also among the top 12 processes displaying enrichment in a larger set of 621 dysregulated proteins selected with less
stringent criteria (q value ! 0.2; average log2 fold change " #0.5; see “Results” section for details).
f Processes that shared a common GO ancestor (immune system process) with the process displaying the most significant enrichment in
the larger set.
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of stromal-cell origin, as they were not expressed in any of the
six epithelial cell lines we examined (Table III). These proteins
were mainly involved in immune-related processes (immune
response, complement activation, T-cell co-stimulation), which
are usually not represented in colon epithelial cell lines. Their
expression changes are likely to have important effects on the
microenvironment of an epithelial-cell tumor.
Our search for potential biomarkers of early-stage colorec-
tal tumorigenesis focused exclusively on the 76 proteins
whose expression was significantly up-regulated in adeno-
mas. According to the Human Protein Atlas database (36), 69
(91%) of these have cancer-related features, and 16 of the 69
are already classified as candidate cancer biomarkers (Table
III). The Human Protein Atlas database contains information
on protein expression in normal and cancer tissues, but not in
those regarded as precancerous. The overlap between our
findings and those of the Human Protein Atlas suggest that
most protein expression changes identified thus far in colo-
rectal adenocarcinomas are probably already detectable in
the benign precursors of these lesions. Supplemental Fig. S6
shows the expression profiles of the 10 proteins that were
most markedly up-regulated in adenomas. This group in-
cluded two of the four proteins identified by Lam et al. (35)
as significantly overexpressed in adenomas. Annexin A3
(ANXA3), for example, is at the top of our list (based on q
values) (Table III). An angiogenic factor that induces VEGF
production via the HIF-1 pathway (37), ANXA3 belongs to a
family of calcium-dependent, phospholipid-binding proteins
involved in diverse biological processes, including signal
transduction, inflammatory responses, membrane organiza-
tion, and the regulation of cellular growth (38, 39). Dysregu-
lated ANXA expression is also a common feature of colorectal
cancer (39), and most other cancers as well (40). S100A11
expression was also increased in these tumors, which is
consistent with earlier reports (41). The cytosolic S100 pro-
teins interact directly with peptides on the N-terminal domain
of annexins (38, 42), and like the annexins, they also have
diverse intracellular and extracellular functional roles (43).
Among the other top 10 proteins displaying adenoma-re-
lated up-regulation were LDHA and LDHB. Their expression
levels were not measured separately, but LDHA is presumably
responsible for the increased expression observed in our
adenomas. LDHB expression is in most cases epigenetically
silenced in colon cancer cells (44, 45), whereas LDHA is
overexpressed, and its activity is maintained via the onco-
genic tyrosine kinase FGFR1 (46). LDHA is a key player in the
reversible conversion of pyruvate to lactate during aerobic
glycolysis, a typical feature of cancer cell metabolism first
described by Warburg (47). The sodium- and potassium-cou-
pled chloride cotransporter SLC12A2 is expressed on the
basolateral membrane of the normal colon epithelium, where
its recruitment and activation are regulated by calcium and
cAMP. Loss of SLC12A2 leads to impaired chloride secretion
in the intestine (48, 49), but to our knowledge, there are no
published data linking this protein to colon cancer. The fifth
markedly overexpressed protein was SET, one of the five
proteins that make up the inhibitor of acetyltranferases
(INHAT) complex. Two other INHAT components, APEX1 and
ANP32A/ANP32B, were also up-regulated in adenomas (al-
beit to a lesser extent than SET) (Table III). These changes are
noteworthy because INHAT binds directly to histones, pre-
venting their acetylation by histone acetyl transferases (50–
52), and loss of histone acetylation is a crucial step in gene
silencing (53, 54). Thus far, INHAT’s role in cancer has not
been widely investigated, but overexpression of the complex
components has been observed in serous epithelial ovarian
cancer (55). The up-regulated expression of PPA1/PPA2 in
our adenomas might play various roles in colorectal tumori-
genesis, as these proteins are key players in the synthesis of
fatty acids, nucleotides, amino acids, and other essential
molecules (56). The phosphoprotein nucleolin, an essential
protein for proliferating cells (57), appears to regulate several
steps in the biogenesis of ribosomes, including transcription,
ribosome assembly, and the processing of precursor ribo-
somal RNA (58–60), all of which might be instrumental in
adenoma growth. As for OCIAD2, strong immunoreactivity for
this protein has been reported in early-stage adenocarcino-
mas of the lung and in ovarian cancers (61–63), but there are
no published data linking it to colorectal tumorigenesis. In
contrast, the secreted protein REG4, which promotes mitosis
and enhances the motility and invasiveness of colon cancer
cells, is strongly expressed in these cells and in the serum of
patients with colorectal cancer (64–66).
The final protein characterized by marked adenoma-related
up-regulation was SORD, a key enzyme in the polyol meta-
bolic pathway. It was selected for validation studies because
although aberrant polyol pathway activity has been implicated
in diabetic complications (67–70) and myocardial ischemia
FIG. 5. Significantly up-regulated SORD expression and activity in colorectal cell lines and adenomas. A, tumor-related up-regulation
of sorbitol dehydrogenase (SORD) in colon cancer cell lines was confirmed with Western blotting. The SORD dysregulation trend was identical
to that observed with iTRAQ-based MS/MS, although when immunoblot results were quantified (B), the log2 fold changes were more than five
times greater than those documented in the iTRAQ study. C, SORD protein expression (iTRAQ analysis) in 21 normal mucosa–adenoma tissue
pairs. D, SORD mRNA expression in 42 other normal mucosa–adenoma pairs from a previous study by our group (26). Error bars indicate the
means and 95% confidence intervals. E, Western blots showing tumor-related up-regulation of SORD expression in four randomly selected
adenoma (A)/normal mucosa (N) tissue pairs of the 21 shown in panel C (see Table I for sample descriptions). F, SORD activity also displayed
tumor-related up-regulation in cell lines (HT29 and SW480 versus HCEC cells) and tissues (adenomas versus normal mucosa). Columns show
mean enzyme activity measured in at least two replicates; error bars indicate standard deviations from means. The Western blot beneath the
graph shows SORD levels measured in the extracts used for the enzyme activity assays.
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(71), the role of SORD in tumorigenesis was completely un-
known. During the execution of this study, however, up-reg-
ulated SORD expression was reported in prostate cancer (72)
and in colorectal adenomas (21), and these findings strength-
ened our resolve to characterize this phenomenon in colorec-
tal tumorigenesis.
Up-regulated SORD expression and activity in adenomas
(Fig. 5) would enhance the production of fructose (see sche-
A B
C D E
F G
H I
FIG. 6. Anti-SORD immunostaining of colorectal cell lines and tissues. Consistent with proteomic data, SORD expression was (A) negligible
or absent in HCECs but (B) clearly expressed in the cytoplasm of HT29 cells. C, in normal colorectal mucosa, SORD expression was limited to the
lower portion of the epithelial crypts, where stem cells and highly proliferating cells are located. Higher magnification views show staining at (D) the
base versus (E) the mouth of colonic crypts. F,G, its expression wasmarkedly increased in adenomatous glands (red arrowheads) relative to normal
crypts (green arrowheads). Panels H and I show abundant expression of SORD in a large adenoma and in a cancer, respectively.
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matic of supplemental Fig. S5A), thereby increasing the gen-
eration of triose sugars and diacylglycerol (intermediates in
the glycolytic and lipid signaling pathways, respectively).
Fructose is also several times more effective than glucose in
promoting intracellular non-enzymatic glycation (73–75), and
advanced glycation end products may contribute to the vas-
cular complications of diabetes and other pathologic condi-
tions (67, 76–78). Whether these fructose-driven metabolic
events play a role in the development of adenomas is unclear,
but the polyol pathway was very active in the adenomatous
cells we examined. This activity was also reflected in the
concomitant increase of the expression of KHK (supplemental
Fig. S5B), the enzyme that catalyzes the transformation of
fructose to fructose-1-P, downstream from the polyol
pathway.
The effects of these enzymatic changes on sorbitol and
fructose concentrations in adenomas need to be investigated
in larger tissue series, but our preliminary data suggest that
the levels of both are slightly decreased in these lesions
(supplemental Fig. S5C). In contrast, our adenomas exhibited
dramatically reduced concentrations of glucose, the initial
substrate in the polyol pathway (supplemental Fig. S5C). Ad-
enoma-related dysregulation was also noted in the expression
of AKR1B1, the enzyme that converts glucose to sorbitol
(supplemental Fig. S5B). Exploitation of the polyol pathway to
divert carbon from glucose to other energy intermediates
might provide adenomatous cells with a selective advantage
over normal cells. This pathway might prove to be another
means of tumor-related glucose consumption in addition to
the well-known glycolytic and pentose phosphate pathways
(supplemental Fig. S5A). Advanced cancer cells consume
glucose at a much higher rate than normal cells, and much of
their energy is generated by aerobic glycolysis rather than by
oxidative phosphorylation of glucose in the mitochondria (i.e.
the Warburg effect) (79). The predominantly glycolytic pheno-
type of cancer cells results in low glucose levels and high
concentrations of lactate (47, 80, 81). The relative concentra-
tions of lactate in the three adenomas we tested were signif-
icantly greater than those found in matched samples of nor-
mal mucosa (supplemental Fig. S5C), indicating that the
Warburg effect is already evident in precancerous colorectal
lesions. Studies involving metabolic flux analysis to monitor
the fate of isotopic tracers in in vitro and in vivo systems would
provide further insight into the biological roles of the polyol
pathway in tumorigenesis. Further information on selected
PSMs, peptides, and corresponding assembled proteins can
be found in supplemental Tables S1 (tissues) and S3 (cell
lines). Supplemental Figs. S7 through S17 show spectra for
the proteins identified with a single peptide (listed in supple-
mental Tables S1 and S3).
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